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Persistent infection of the cervix with high risk (HR) types of Human Papilloma 
Virus (HPV) (HR-HPV) can result in precancerous lesions and cancers. However, 
most HPV infections can be cleared naturally by the immune response without 
causing disease. Although genetic variations have long been considered as the main 
explanation for individual heterogeneity in cancer susceptibility, the underlying 
mechanisms remain unclear.  
In this project, a panel of routinely taken clinical samples was assessed for 32 
rationally selected SNPs with allele frequency related to disease outcome using the 
Taqman® OpenArray® system. The panel incorporated 475 HR-HPV negative, 
cytologically-normal cervical samples, 413 HR-HPV positive cervical high grade 
squamous intraepithelial lesion (HSIL) cases and 62 HR-HPV positive cervical 
cancers. Two SNPs, rs2234671 and rs2623047, were found with significant 
differences between HR-HPV negative, cytologically-normal samples and HR-HPV 
positive cervical HSIL cases. In the validation step, these two SNPs were further 
genotyped in the same set of samples using TaqMan® SNP genotyping assay and/or 
LightSNiP assay and in additional samples including 83 HR-HPV positive, 
cytologically-normal cervical samples, 21 HR-HPV positive cervical cancer cases, 
129 HR-HPV positive vulval intraepithelial neoplasia cases and 23 HR-HPV positive 
vulval cancer cases. Statistical analysis was then performed based on pooled and 
re-grouped genotyping data of the above-mentioned samples under different genetic 
models so as to evaluate the associations with different stages in the disease process. 
After validation, SULF1 rs2623047 revealed a strong significant association with the 
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susceptibility to HR-HPV infection but not with the development of high-grade 
squamous intraepithelial lesion and the progression to cervical cancer. CXCR1 
rs2234671, by contrast, was associated with the progression of HR-HPV-related 
cancers and the minor allele CXCR1 827C was significantly enriched in HPV16 
positive cancers.  
CXCR1 is a receptor for the chemokine CXCL8/IL-8 and CXCR1 rs2234671 leads 
to a serine to threonine change in an extracellular loop of the receptor. Functionally, 
the CXCR1 827C allele was shown to enhance cell motility in response to IL-8 
stimulation in a chemotaxis assay with transiently transfected fibroblasts (HEK293 
cells) and also in a wound healing assay with stably transduced cervical cancer 
(CaSki) cells. In addition, significantly increased cell proliferation 
upon IL-8 treatment was observed in two cervical cancer derived cell lines, CaSki 
and SiHa, transduced with CXCR1-827C allele, but not in their CXCR1 827G 
transduced counterparts.  
These findings suggest that SULF1 rs2623047 and CXCR1 rs2234671 may be 
genetic risk factors for HR-HPV-related cervical disease and CXCR1 rs2234671 
might affect HR-HPV-related cancer susceptibility by functionally altering 
IL-8-CXCR1 signalling. This information has potential for use in the risk 
stratification of HR-HPV infected women and may also suggest new therapeutic 







Human papillomavirus (HPV) is the most common viral infection in the reproductive 
tract. Most people will get HPV at least once in their lifetime. To date, over 200 
different HPV types have been identified. Among these 200 HPV types, at least 14 
are classified as high risk HPV (HR-HPV) types because persistent infection with 
them is necessary for the development of cervical cancer. Although HR-HPV 
infections are quite prevalent in the population, most of the time they can be cleared 
by our body's defence systems without any kind of treatment. Only a small number 
of women will have persistent infection and even fewer will develop cervical cancer. 
Evidence shows that genetic factors contribute greatly to the increased cancer risk in 
HR-HPV infected women, but very few of these genetic factors have been identified 
and the underlying mechanisms remain unclear.  
Therefore, this project aimed to find genetic factors that are associated with 
HR-HPV-related cervical disease and to explain the mechanisms by which they may 
contribute to the disease risk. Single nucleotide polymorphism (SNP) was selected as 
the main focus for this project because it is the most common type of genetic 
difference in whole populations and has frequently been linked to diseases. In the 
discovery phase, 32 carefully selected SNPs have been tested in a panel of routinely 
taken clinical cervical samples consisting of 475 HR-HPV negative, abnormal 
cells-free controls and 475 cases with HR-HPV infections and high-grade 
abnormalities in their cervix. By comparing the differences between the controls and 
cases in the genetic make-up of each SNP tested, two novel SNPs, CXCR1 
rs2234671 and SULF1 rs2623047 were found to be associated with the risk of 
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HR-HPV-related cervical disease. After validating the results in the discovery phase 
using other genotyping methods and testing the two SNPs in additional samples 
reflecting different stages of the HR-HPV-related cervical disease, SULF1 
rs2623047 was found to be associated with the acquisition of the HPV infection 
whilst CXCR1 rs2234671 was linked to the development of cervical cancer in the 
presence of a common HR-HPV type, HPV16.  
The CXCR1 rs2234671 leads to a structural change in the cell surface molecule 
CXCR1, which is a receptor for a protein called IL-8. CXCR1 can regulate a wide 
range of cell functions in the presence of IL-8, such as cell movement and cell 
growth. In subsequent functional experiments, the serine to threonine change in 
CXCR1 rs2234671 was found to increase cell movement and growth of HPV16 
positive cervical cancer cells in response to IL-8. These findings provided possible 
functional explanations for the observed association with high grade cervical disease. 
Overall, my data reveal two novel SNPs that are associated with different transition 
states of the natural history of HR-HPV-related cervical disease. Of the two SNPs, 
CXCR1 rs2234671 was found to affect the development of cervical cancer by 
changing cell functions mediated by CXCR1 in response to IL-8. These findings 
provide novel insights into the roles of SNPs in the pathogenesis of HR-HPV-related 
disease. The associations still need to be further verified in a larger sample set. Once 
verified, these SNPs may be used as biomarkers, aiding in the advancement of 
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1.1 Human papillomavirus (HPV) infection  
1.1.1 Basic structure of human papillomavirus  
HPVs are a group of small, non-enveloped circular double-stranded 
deoxyribonucleic acid (DNA) viruses belonging to the papillomavirus family, which 
infect cutaneous or mucosal epithelium. The human papillomavirus family is split 
into 5 recognised genera (alpha, beta, gamma, mu and nu) and a group of 
unclassified types depending upon their genetic sequence homology (see Figure 1). 
The prototypical structure of HPV consists of a genome of about 8 kilobase pairs (kb) 
and a symmetrical icosahedral capsid. The HPV genome contains three functional 
regions: the long control region, the early coding region and the late coding region. 
The eight known primary viral protiens of HPV, including the six early proteins (E1, 
E2, E4, E5, E6 and E7) and the two late proteins (L1 and L2), are encoded by the 




Figure 1 Phylogenetic tree of HPVs 
The figure shows the phylogeny of fully sequenced HPVs in the NCBI taxonomy database 
(released at 07/08/2017) with all alpha genus HPVs in Red, beta genus HPV in orange , 
gamma genus HPVs in green, mu and nu genus HPVs in grey and other unclassified HPVs in 
blue. The figure was generated on the basis of Papillomaviridae subtree (NCBI Taxonomy 
ID: 151340) using online tool phyloT and Interactive Tree Of Life(iTOL) v3(Letunic and Bork, 
2016). 
 
L1 and L2 are the structural proteins forming the capsid of the virus. The major 





to the host cells while the minor capsid protein L2 was reported to be necessary for 
the genome encapsidation and endosomal escape (Horvath et al., 2010; Xue et al., 
2012c). E1 and E2 play essential roles in the initiation of viral replication. By serving 
as a loader through protein-protein interactions, E2 recruits E1 to the viral repliaction 
origin. The helicase domain of E1 then unwinds double-stranded DNA and faciliates 
the replication. Besides, E2 can also act as a tethering factor for the maintaince of the 
viral genome and controls viral transcription in a dose dependent manner (McBride, 
2013). The most commonly investigated E4 is actually a fusion protein E1^E4, 
which was shown to be important for the amplification of the viral genome as well as 
the assembly and release of virus (Doorbar, 2013). Unlike the previously mentioned 
viral proteins, E5 is not a universal protein for all HPV types and is present mainly in 
alpha genus HPV types. Several subgroups of E5 exist and the alpha group E5, 
which contains a relatively conserved sequence, was shown to be oncogenic (Müller 
et al., 2015). E6 and E7 proteins are the two most widely investigated viral proteins 
among all the primary viral proteins. They are oncoproteins in certain HPV types and 
faciliate tumourigenesis though a wide variety of mechanisms, of which the most 
well-characterized include E6 induced degradation of the tumour suppressor protein 
p53 and E7 induced degradation of retinoblastoma protein (Xue et al., 2012c). Apart 
from these primary viral proteins, functional isoforms of the primary viral proteins 
and fusion proteins were also shown to be present in specific HPV types (Graham, 
2010). The long control region does not encode any viral proteins, instead, it exerts 
regulatory functions on viral replication and transcription (Xue et al., 2012a).  
24 
 
1.1.2 Classification of HPVs 
The major capsid protein L1 open reading frame (ORF) sequence was found to be 
the most conserved region within the papillomavirus genome. Therefore, L1 has been 
chosen as the basis for taxonomy. According to the consensus criteria, a novel HPV 
type could be identified if its genetic sequence of L1 shares no more than 90% 
nucleotide sequence identity with all other known HPV types (De Villiers et al., 
2004). To date, over 200 types of HPV have been identified and numbered based on 
this criteria (Van Doorslaer et al., 2013). HPV types that share more than 70% but 
less than 90% nucleotide sequence identity within the L1 ORF could be grouped 
together as a species. And an order higher, HPV types that share between 60% to 70% 
homology of the L1 ORF sequence could be classified as a genus. All the recorded 
HPV types in the current National Centre for Biotechnology Information (NCBI) 
taxonomy database are shown in Figure 1. 
At least 14 mucosal HPV types in the alpha genus are consensually classified as high 
risk (oncogenic) types due to their causal associations with cervical cancer, including 
HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Certain HPV 
types from the beta and gamma genera, such as HPV5, HPV8 and HPV60, have 
recently attracted more attention since they were found to act as “accomplices” in 
non-melanoma skin cancer and head and neck cancers (Agalliu et al., 2016; Paradisi 
et al., 2011). In contrast, mu and nu genera have only been observed in cutaneous 
infections and have not been associated with malignant diseases (Tommasino, 2014). 
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1.1.3 Prevalence of HPV infection  
HPVs are the most common viral infection in the genital tract. According to a newly 
released report from National Centre for Health Statistics in the USA, the prevalence 
of genital HPV in American adults aged 15-59 years were 45.2% and 39.9 % in men 
and women respectively during 2013-2014. The corresponding data for HR-HPV 
types were 25.1% and 20.4% (McQuillan et al., 2017). In the UK, HPV was 
observed in 10.3% of women with normal cervical cytology. In women with 
abnormal cervical cytology, HPV16 and HPV18, the two most common high 
risk-HPV (HR-HPV) types, were shown to account for nearly 60% of high-grade 
cervical intraepithelial lesions and 79% of cervical cancers (Bruni et al., 2017).  
Taking advantage of the self-assembly feature of the major capsid protein L1, 
virus-like particle based prophylactic vaccines have been developed and 
commercialized to prevent cervical HPV infection. Currently, three HPV vaccines 
are available on the market, which are Cervarix, Gardasil® and Gardasil®9 
respectively. Cervarix is designed to protect against the two most common HR-HPV 
types HPV16 and HPV18. Although initially targeting only two HR-HPV types, a 
cross-protection was observed for Cervarix against HPV31, HPV33 and HPV45 
(Cuschieri et al., 2016; Paavonen et al., 2009). Apart from HPV16 and HPV18, 
Gardasil® also protects against HPV6 and HPV11, which cause genital warts. And on 
the basis of Gardasil®, Gardasil®9 offers extra protection against HPV31, HPV33, 
HPV45, HPV52 and HPV58. With the widespread introduction of the vaccines, 
prevalence of HR-HPVs in countries and areas with high vaccine uptake started to 
exhibit significant changes. As an example, Scotland commenced national HPV 
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immunisation programme in 2008 and has maintained relatively high vaccination 
coverage in the applicable populations during these years. A recent study from 
Scotland showed a significant decline of the prevalence of HPV16 and HPV18 in 
fully vaccinated women in comparison with their unvaccinated counterparts. Besides, 
cross protection against several other HR-HPV types and herd protection have also 
been reported (Cameron et al., 2016). As vaccination continues to gain ground 
worldwide, it is expected to see more changes in HPV type prevalence in the near 
future.  
1.1.4 Life cycle of HPV and pathogenesis 
HPVs display tropism towards multi-layered stratified squamous epithelium (see 
Figure 2 for a schematic diagram of the HPV life cycle). Normally, the life cycle 
starts with the infection of dividing basal cells. Through microwounds present in the 
stratified epithelium, HPV reaches to the basal lamina and enters the target cells with 
the assistance from various extracellular matrix and cell surface molecules. Among 
these molecules, heparan sulfate proteoglycans (HSPGs) were considered to be the 
primary attachment factors for many HPV types (Aksoy et al., 2017). After 
internalization into basal cells, the capsid of the virus is disassembled in acidic 
endocytic vesicles. Chaperoned by L2, the viral genome then egresses from 
endosomes, traffics through the trans-Golgi network and finally reaches nucleus 
(DiGiuseppe et al., 2017). At the early stage of infection, the viral genome is 
amplified slowly along with the cell cycle and is subsequently maintained in the 
basal cells as episomes at low copy numbers. E1 and E2 play essential roles in this 
stage, though both are expressed at a relatively low level. Expression of E6 and E7 
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are also observed at this stage but divergence presents between high-risk and 
low-risk HPV types. E6 and E7 of the high-risk HPV types can promote cell 
proliferation within the basal and parabasal layers and results in the development of 
neoplasia (Doorbar et al., 2015). A productive life cycle of the virus continues as 
infected daughter cells of the asymmetrically dividing basal cells leave the basal 
layers and start differentiation. E6 and E7 from both high-risk and low-risk HPV 
types interact with multiple cellular molecules and consequently induce cell cycle 
re-entering of the differentiated cells in the mid and the upper cell layers, which lays 
the foundation for the sharp increase in viral copy number during this phase. 
Expression of other regulatory viral early genes also increases in these cells 
following activation of corresponding promoters and this directly or indirectly 
contributes further to the amplification of viral genomes. To complete the full life 
cycle, the synthetic strategy of the virus switches from early proteins to late proteins 
while the infected cells finally exit cell cycle and migrate to the upper layers of the 
stratified epithelium. By altering the splicing pattern, both L1 and L2 are 
increasingly expressed in the cell cytoplasm and then delivered to the nucleus for 
virus packaging (Doorbar et al., 2015). After a complicated process of encapsidation 
and maturation, infectious virions are released from the infected cells with the aid of 
viral protein E4. This release process disturbs the normal structures of the superficial 




Figure 2 Schematic diagram representing the life cycle of HPV  
HPV viruses reach to the basal layer and enter the target cells through a micro-wound or 
micro-abrasion. The viral life cycle is tightly dependent on the differentiation process of the 
host epithelial cells. Ordered viral gene expression and life cycle events are indicated on the 
right side. HPV infected cells are showing as cells with green nuclei while HPV viruses are 
showing as grey particles. 
 
Intraepithelial lesions caused by HR-HPV types are characterised by increased 
mitotic activity, nuclear atypicality, cellular immaturity and disorganization and 
preferentially occur at the transformation zone of the cervix. In low-grade 
intraepithelial lesions, HR-HPV types go through the above-mentioned productive 
life cycle and ordered viral gene expression remains unaffected. However, in 
high-grade intraepithelial lesions, the productive life cycle is retarded due to the 
deregulation of viral oncoproteins, especially E6 and E7. Deregulated E6 and E7 not 
only promote cell proliferation throughout the epithelium but also predispose cells to 
undergo genomic changes or even malignant transformation (Doorbar et al., 2015).  
Previous studies found that increased levels of E6 and E7 could cause both numerical 
and structural chromosomal aberrations by interacting with various cellular 
components (Graham, 2017; Moody and Laimins, 2010). For example, high risk 
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HPV E7 could cause aberrant centrosome duplication and subsequently lead to the 
development of aneuploidy and chromosome missegregation. The centrosome 
abnormalities have been shown to be mediated through the binding of E7 to γ-tubulin 
or the retinoblastoma family of proteins. In coordination with E7, E6 could induce 
centrosome abnormalities by compromising mitotic checkpoint functions through a 
p53 dependent mechanism (Moody and Laimins, 2010). Also, E6 and E7 could cause 
DNA damage indirectly through the induction of oxidative stress (Marullo et al., 
2015). 
To counteract naturally occurring or exogenous agents-induced DNA damage, cells 
have evolved a complex network of pathways collectively named as DNA damage 
response (DDR). Upon sensing DNA damage, DDR pathways are activated, leading 
to cell cycle arrest, DNA repair and cell death (Hollingworth and Grand, 2015). In 
HPV infection, the major regulators of the DDR pathways, such as ATM (Ataxia 
telangiectasia mutated) and ATR (Ataxia telangiectasia and Rad3-related) kinases, 
are activated and hijacked by HPV to support its genome maintenance and facilitate  
productive viral replication (Anacker and Moody, 2017). Meanwhile, E6 and E7 play 
an important role in countering downstream of the DDR cascades and consequently 
allow accumulation of DNA damage within infected cells. For example, both E6 and 
E7 have been shown to be capable of abrogating p53-dependent cell cycle 
checkpoints (Fischer et al., 2017). E7 has also been reported to interrupt cell cycle 
checkpoints through interactions with histone deacetylases, cyclins and 
cyclin-dependent kinase inhibitors (Moody and Laimins, 2010). Additionally, E6 
could disrupt postmitotic checkpoint through a p53 independent mechanism by 
upregulating cyclin-dependent kinase 1 (Zhang et al., 2015). 
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In conjunction with the abrogation of cell cycle checkpoints, E6 and E7 could disrupt 
normal DNA repair processes and prevent infected cells from undergoing apoptosis 
and senescence. Attenuation of single strand break repair was found to be mediated 
by E6 through its interaction with O (6)-methylguanine-DNA methyltransferase and 
protein XRCC1 (Iftner et al., 2002; Srivenugopal and Ali-Osman, 2002). Base 
excision repair could also be attenuated through the interaction between E6 and 
XRCC1. In addition, both E6 and E7 have been shown to impede double strand 
break repair by impairing homologous recombination pathway (Wallace et al., 2017). 
Furthermore, E6 and E7 could jointly promote the activities of several DNA 
methyltransferases, thereby resulting in epigenetic inactivation of tumour suppressor 
and immune genes (Soto et al., 2017; Wilting and Steenbergen, 2016).  
In certain conditions, the viral genome can be integrated into the cellular genome. 
Evidence showed that integration events could happen at a relatively early stage of 
the neoplasia development, sometimes even before the formation of the low-grade 
lesions (Peitsaro et al., 2002). Disruption of the E2 ORF frequently occurs in the 
integrant whereas the E6 and E7 ORFs usually remain intact. Together with the loss 
of viral episomes, the E2-disrupted integration could cause reduction of regulatory 
E2 proteins within the cells. Since E2 can negatively regulate expression of E6 and 
E7 by occupying the binding sites within the long control region, the reduction of E2 
will weaken transcriptional repression and contribute to deregulation of the two 
oncoproteins. As a consequence, the effects induced by E6 and E7 will be augmented. 
This mechanism is considered to be important for malignant transformation, though 
about 12.5% of cervical cancers can still derive from cells with exclusively episomal 
HR-HPV (Doorbar et al., 2015; Xue et al., 2012b). 
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1.2  HR-HPV-related diseases 
Persistent infection with HR-HPV types, if left undetected and untreated, can 
predispose the host to cancer. Due to the mucosal tropism of the known HR-HPV 
types, HR-HPV-related cancers frequently occur at anogenital areas and in the 
mucosa of the mouth and throat. In a recently published report, HPVs have been 
shown to be linked with nearly all of cervical cancer cases globally. Additionally, 
HR-HPVs are also linked to 88% of anal cancers, 78% of vaginal cancers, 50% of 
penile cancers, 35% of oropharyngeal cancers and 25% of vulval cancers (de Martel 
et al., 2017). 
HR-HPV-related cervical disease is the main focus of this project. Cervical cancer 
ranks as the 4th most common cancer among women worldwide, with incidence rates 
varying across countries and regions (Bruni et al., 2017). In the UK, thanks to the 
launch of the National Health Service (NHS) cervical screening program in the late 
1980s and the introduction of HPV vaccines in 2008, cervical cancer incidence rates 
have fallen by almost a quarter since the early 1990s. However, despite the 
encouraging drop in incidence rates, cervical cancer remains a challenging health 
care problem in the UK. There are still over 3000 new cervical cancer cases being 
diagnosed and approximately 900 deaths being reported each year 1 . It 
is worthwhile to note that more than half of these newly diagnosed cervical patients 
in the UK are younger than 45 years old and the incidence rates peak in woman of 
childbearing age. Because of this feature, the economic burden of cervical cancer is 
large. According to a published report, the estimated average yearly cost for each 
                                                             






cervical cancer patient is about £19,400, including both the personal cost and the 
costs to the NHS and wider society (Salter and Demos, 2014).  
Cervical cancer is manifested by vaginal bleeding, discharge and coital pain. It is 
normally identified through gynaecological screening tests and diagnosed based on 
systemic clinical examinations. Pathologically, cervical cancer is classified as 
squamous cell carcinoma, adenocarcinoma, and other rare cancer types. Squamous 
cell carcinomas are the most common type and constitute around 70%-80% of 
all cervical malignancies (Marth et al., 2017). In this project, all the cervical cancer 
samples tested are squamous cell carcinomas. Clinically, cervical cancer is staged 
using International Federation of Gynaecology and Obstetrics (FIGO) classification 
(see Table 1), which is applicable to all pathological types. 
As can be seen from the FIGO staging, cervical cancer cells can spread to other parts 
of the body. Direct invasion of adjacent tissues and organs is the primary route of 
spread. Lymphatic dissemination occurs less frequently. Haematogenous 
dissemination is even less common and has only been found in about 5% of cervical 
cancer patients (Gallup, 2008). For early-stage patients (up to FIGO IIA), surgery is 
recommended and in certain cases, fertility could be preserved by conisation or 
simple trachelectomy. In more advanced disease, chemoradiotherapy or palliative 
chemotherapy is often applied (Marth et al., 2017). As shown in dataset (ICD-10 C53) 
from ISD Scotland2, the age-standardised overall relative five-year survival rate for 
15-99 year old cervical cancer patients diagnosed in Scotland during 2007-2011 is 
nearly 60.2%. As the stage goes up, the five-year survival rate drops dramatically. 
                                                             
2 Information Services Division (ISD) Scotland is part of NHS National Services Scotland. Statistics 




Table 1 The latest FIGO staging for carcinoma of cervix (Pecorelli, 2009) 
Stages Definition 
I The carcinoma is strictly confined to the cervix (extension to the corpus 
would be disregarded) 
IA Invasive carcinoma which can be diagnosed only by microscopy, with 
deepest invasion ≤5 mm and largest extension ≤7 mm 
IA1 Measured stromal invasion of ≤3.0 mm in depth and extension of ≤7.0 mm 
IA2 Measured stromal invasion of >3.0 mm and not >5.0 mm with an extension 
of not >7.0 mm 
IB Clinically visible lesions limited to the cervix uteri or pre-clinical cancers 
greater than stage IA 
IB1 Clinically visible lesion ≤4.0 cm in greatest dimension 
IB2 Clinically visible lesion >4.0 cm in greatest dimension 
II Cervical carcinoma invades beyond the uterus, but not to the pelvic wall or 
to the lower third of the vagina 
IIA Without parametrial invasion 
IIA1 Clinically visible lesion ≤4.0 cm in greatest dimension 
IIA2 Clinically visible lesion >4.0 cm in greatest dimension 
IIB With obvious parametrial invasion 
III The tumour extends to the pelvic wall and/or involves lower third of the 
vagina and/or causes hydronephrosis or non-functioning kidney 
IIIA Tumour involves lower third of the vagina, with no extension to the pelvic 
wall 
IIIB Extension to the pelvic wall and/or hydronephrosis or non-functioning 
kidney 
IVA The carcinoma has extended beyond the true pelvis or has involved (biopsy 
proven) the mucosa of the bladder or rectum. A bullous edema, as such, 
does not permit a case to be allotted to Stage IV 
IVA Spread of the growth to adjacent organs 
IVB Spread to distant organs 




Benefiting from the effectiveness of the screening tests, nowadays, more and more 
women at risk of developing cervical cancer are identified at the pre-invasive phase, 
a relatively long transition state with dysplastic lesions. In order to describe the 
severity of the cervical dysplasia, the cervical intraepithelial neoplasia (CIN) 
classification system was introduced by Richart (Reich et al., 2015). According to the 
histological diagnosis of the samples obtained by biopsy or surgical excision, CIN is 
classified into three grade levels. Sequentially, CIN grade 1 (CIN1) refers to mild 
dysplasia that is present only in the lower one third thickness of the stratified 
epithelium. CIN grade 2 (CIN2) describes moderate dysplasia that affects the lower 
two thirds of the epithelium. CIN grade 3 (CIN3) defines severe dysplasia that has 
spread to the entire thickness of the epithelium but has not broken through the 
basement membrane (Bruni et al., 2017). Since most CIN1 cases could regress 
naturally without treatment, they are alternatively called low-grade CIN. In contrast, 
CIN2 and CIN3 are grouped together as high grade CIN due to a much lower rate of 
spontaneous regression, though a substantial fraction of CIN2 cases do resolve on 
their own, especially in young women (Castle et al., 2009; Moscicki et al., 2010; 
Motamedi et al., 2015). In lesions caused by squamous cell abnormalities, the 
Bethesda system is often applied to report abnormal cytological findings in cytology 
based screening tests and a two-tiered classification scheme, consisting of low grade 
squamous intraepithelial lesion (LSIL) and high grade squamous intraepithelial 
lesion (HSIL), is utilized. In recent years, in order to unify the cytology and 
histopathology findings and provide a better match for the disease courses, CIN 
grades have been subsumed under the two-tiered classification scheme. According to 
the current World Health Organization (WHO) classification for HPV-associated 
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squamous intraepithelial lesions, CIN1 is subsumed under LSIL (permissive 
infection with low risk of developing into cancer) while CIN2 and CIN3 are 
subsumed under HSIL (persistent infection with high risk of progression to cancer). 
Biomarkers, such as p16INK4a, are recommended to be incorporated in the 
classification of equivocal cases (Reich et al., 2015; Waxman et al., 2012). The 
WHO classification is also applicable to the precancerous lesion in vulva and vagina. 
In this thesis, only the two-tiered WHO terminology was used. 
1.3  Other factors associated with HR-HPV-related cervical 
disease 
Although HR-HPV infections are quite prevalent in the population, only a small 
fraction of infected individuals will have persistent infection and even fewer will 
develop high-grade intraepithelial lesions and cancers (Sheet, 2007). Most HR-HPV 
infections are transient and are cleared naturally by the immune response without 
causing any disease. A previous study showed that 70% of newly infected women 
will be HR-HPV free within one year and as many as 91% will be HR-HPV free 
within two years (Gerberding, 2004). Despite the fact that persistent infection with 
HR-HPV types is the leading risk factor for carcinogenesis, persistent infection with 
HR-HPV types alone is not sufficient to cause cervical cancer. Additional factors, 
other than HR-HPVs, are required for the cancer to develop and progress. Identifying 
and tackling these additional factors are expected to accelerate the control and 




Over the past few decades, many host factors and environmental factors have been 
proposed and actively investigated as co-factors in HR-HPV-related precancerous 
cervical disease and cervical cancer. These include smoking, long-term oral 
contraceptive use, co-infection with other sexually transmitted pathogens (e.g. C. 
trachomatis, N. gonorrhoeae and Herpes simplex virus type 2), sexual activities 
associated with increased HPV acquisition and immunosuppressive conditions (de 
Abreu et al., 2016; Kapeu et al., 2008; Wang et al., 2009b). Among these factors, 
genetic variations have long been considered as key explanations for individual 
differences in disease susceptibility.  
According to two nationwide family-based studies, genetic factors accounted for 
nearly one-fourth of the variation in liability to cervical cancer in the Swedish 
population (Czene et al., 2002; Magnusson et al., 2000) while the contribution of the 
shared environment was quite small (Magnusson et al., 2000). A similar proportion 
(i.e. 24%) was also reported by a recent study based on genome-wide complex trait 
analysis (Chen et al., 2015). Although genetic factors are not as easy to intervene 
with as other factors (e.g. infections and behaviours), studies focusing on genetic 
variations have the potential to enhance our understanding of the disease 
pathogenesis, to improve triage management of the susceptible population, to 
identify biomarkers for early detection of cancer, to predict individual responses 
towards prophylactic vaccinations and treatments, and to facilitate development of 
novel treatments.  
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1.4  Single nucleotide polymorphism and HR-HPV-related 
cervical disease 
1.4.1 Single nucleotide polymorphisms 
Single nucleotide polymorphism (SNP) is the most common type of genetic variation 
among humans. SNP can be defined as a variation at a single base pair location in a 
DNA sequence among individuals (Brookes, 1999). In the human population, the 
vast majority of identified SNPs are biallelic, which means at each locus, only two of 
the four DNA nucleotides are observed. For each biallelic SNP, the nucleotide with a 
frequency above 50% in the studied population is called the major allele while the 
other is called the minor allele. SNPs with a global minor allele frequency (GMAF) 
greater than or equal to 5% are considered as common SNPs and have been centrally 
targeted in previous genomic studies, such as the Phase I and II International 
HapMap Project. According to the public-domain archive dbSNP run by the NCBI in 
the USA, more than 10 million common SNPs have been validated in the human 
genome to date and the number is still increasing (Sherry et al., 2001). In order to 
unify the description of SNPs, dbSNP assigns an accession ID (rs number), a unique 
identifier, to each cluster of submitted SNPs mapped to the same position in the 
genome and routinely performs “rs merge” procedure to reduce the redundancy. 
Currently, the rs number is the most widely used identifier in the SNP research field 
(Sherry et al., 2001). 
SNPs exist throughout the genome. They can be found in the coding region of the 
gene, the non-coding region of the gene as well as intergenic regions. SNPs within 
the coding region of genes can be classified into two groups: synonymous and 
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non-synonymous SNPs. The latter, which alters the amino acid sequence of the 
encoded protein, can be further divided into two subtypes (i.e. missense and 
nonsense SNPs). In general, the genomic distribution of SNPs is not homogenous. 
They occur more frequently in non-coding regions than coding regions (Barreiro et 
al., 2008).  
SNPs are considered to arise from ancient mutation events and have been retained 
during long-term evolution as a consequence of natural selection. Most SNPs do not 
have apparent impact on health or disease and currently have no known functions. 
However, increasing evidence suggests that some SNPs do act functionally in certain 
disease processes. They can affect disease susceptibility, disease outcome or 
treatment response either by modifying gene regulation or by altering the translation 
of encoded proteins. Although this kind of SNPs is frequently observed in the 
regulatory region and the coding region of the gene, they can also be found in other 
parts of the genome. For example, some intergenic SNPs have been shown to be 
capable of regulating the expression of a nearby gene through spatial associations 
(Schierding et al., 2014).  
The importance of functional SNPs has been shown in many common diseases and 
their identification has already led to advances in disease diagnosis and treatment. 
According to a recent keyword search at https://clinicaltrials.gov/3(an online database 
listing 251781 clinical trials in 200 countries), there are at least 395 completed or 
ongoing clinical trials focusing on the clinical applications of disease associated 
SNPs. Many of these trails have been performed to assess the predictive value of 
specific SNPs for disease diagnosis and management. For example, SNP profiles 
                                                             
3 The database is run by the U.S. national institutes of health 
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identifying high-risk individuals have been proposed for breast cancer, venous 
thrombosis and coronary heart disease (Beaney et al., 2017; de Haan et al., 2012; 
Evans et al., 2016). SNP markers can now be tested using automated high-throughput 
methods at relatively low cost. Most advantageously, the SNP profile remains 
unchanged during a person’s lifetime. 
Many functional SNPs have also been used to assess drug efficacy and adverse drug 
responses. Genetic tests for certain polymorphisms have already been implemented 
into clinical practice. For example, multiple functional SNPs have been identified 
within the cytochrome P450 2D6 (CYP2D6) gene and shown to affect the activity 
of the encoded enzyme. Since this enzyme is important for the metabolism of several 
opioids, changed function often causes adverse effects in patients on opioid therapy. 
In some cases, especially in children, overproduction of the metabolite morphine 
could lead to severe respiratory depression and death. Because of these findings, 
CYP2D6 activity score determined by SNP analysis has now become an essential 
determinant of opioid therapy. Genetic testing for CYP2D6 polymorphisms before 
prescribing several types of opioids has been recommended by the Clinical 
Pharmacogenetics Implementation Consortium in their clinical guidelines (Crews et 
al., 2014). Similarly, pre-emptive thiopurine methyltransferase genotype tests have 
been suggested to guide the dosing of thiopurine (Relling et al., 2011). Human 
leukocyte antigen B genotyping has been recommended prior to the prescription of 
abacavir (an anti-HIV drug), carbamazepine (an antiepileptic drug) and allopurinol (a 
gout treatment) (Hershfield et al., 2013; Leckband et al., 2013; Martin et al., 2012).  
Inspired by these findings, it is believed that locating and identifying 
disease-associated functional SNPs will also provide unique opportunities to uncover 
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the mechanisms of HPV-linked carcinogenesis and aid in the advancement of 
diagnostics and therapeutics for HR-HPV associated cervical disease. 
1.4.2 Genetic association studies 
For a given SNP locus, the specific combination of the alleles on the paternal 
chromosome and maternal chromosome of each individual is termed as the genotype. 
Genetic association studies have been widely performed to identify 
disease-associated SNPs through directly comparing the genotype or allele 
frequencies of certain SNPs between subjects with and without a disease phenotype. 
According to their design, genetic association studies can be divided into two kinds: 
family based studies and population based studies. The former is far less popular 
among the researchers due to the difficulty of sample collection and the issues of 
statistical power. In this project, only population based studies were used. 
Case-control design with unrelated individuals is frequently used in population based 
genetic association studies. In some cases, extreme phenotype sampling has been 
employed to increase statistical power. Currently, two main approaches have been 
used to perform population based genetic association studies, which are the 
hypothesis-driven candidate gene approach and genome wide association (GWA) 
studies. Due to advances in genotyping technology, a large number of researchers 
have shifted their research focus from a candidate gene approach to GWA 
approaches and some hold the view that the candidate gene approach should be 
completely replaced by GWA studies. In my opinion, it is improper to simply treat 
the relationship between candidate gene approach and genomic approach as the 
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predecessor and the successor, since they are created and utilized for different 
purposes. 
1.4.2.1 GWA studies 
I will start with the genomic approach since GWA studies can be conducted without 
any prior hypothesis or knowledge and screen the entire genome for possible 
associations between SNPs and the disease being studied. The majority of published 
GWA studies have been performed using SNP genotyping chips, which are 
generated based on tagSNPs (see Figure 3 for a schematic diagram of the summary 
workflow of GWAs). 
For a set of SNP loci that are in close proximity, the sequence of alleles on the same 
chromosome is termed as the haplotype. In our genome, SNPs are not all inherited 
independently following the Mendelian inheritance. Some alleles tend to occur 
together more often than the others. As a consequence, the actual frequency of each 
haplotype usually departs from the expected frequency obtained by simply 
multiplying the allele frequency at each locus under the assumption of independent 
random inheritance. The concept of linkage disequilibrium (LD) therefore has been 
generated to describe the non-random association between SNP alleles at nearby sites 
in the genome and mathematical equations have been proposed to measure the 
difference between observed and expected haplotype frequencies (Reich et al., 2001). 
SNPs in high LD are almost always inherited together. Jointly, these SNPs form a 
unit called the “LD bin”. Testing one SNP gives information about all other SNPs in 
the same LD bin so it is not necessary to test all polymorphisms. The tested SNP is 




Figure 3 Schematic diagram representing the summary workflow of GWAs 
Of note, SNPs in one bin could also be shared by other LD bins. Therefore, the 
tagSNPs used in commercial SNP chips need to be carefully selected to cover the 
whole genome in an efficient way. For this reason, tagSNPs are usually not causal 
SNPs. Once associations have been found between tagSNPs and disease, they cannot 
be interpreted as direct associations with biological function. Instead the association 
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signals are more likely due to unknown causal SNPs within the same bin. 
Additionally, the selection of tagSNPs often relies on data from HapMap projects. As 
a consequence, the majority of chips can actually only cover common variants or 
variants with a GMAF above 1% throughout the entire genome and they may have 
different genomic coverage rate for different ethnic groups due to the various LD 
patterns among ethnicities. 
The above mentioned design strategy and features therefore determine the research 
questions that can be answered by GWA studies. As expected, a large number of 
independent susceptible loci for common diseases have been identified over the last 
decade (Visscher et al., 2017). Many novel common disease-related pathways and 
genes have been recognized through these findings, which has led to predictive, 
diagnostic and therapeutic advances. Additionally, based on the identified loci and 
succeeding complicated summary statistical analyses, we can begin to estimate the 
genetic architecture4 for many complex traits, though it still takes time to include the 
contribution of rare variants and other genetic variations. With an improved 
understanding of the genetic architecture, we could tailor follow-up studies to further 
dissect the causal variant and translate the association signal into biological insights.  
However, it is important to know that GWA study itself is not designed to identify 
and dissect the causal variant. For common diseases contributed by numerous 
variants with low or moderate individual effect size, a substantial increase in the 
sample size is expected to significantly increase the yield of GWA studies. 
                                                             
4 Genetic architecture of a disease indicates the distribution and the interrelationship of allele 
frequencies and effect sizes of all causal variants 
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1.4.2.2 Hypothesis driven candidate gene approach 
Candidate gene approaches were widely used before the era of GWA studies in the 
absence of a clear understanding of the genetic architecture. Unlike GWA studies, 
the purpose of the candidate gene approach is to identify direct associations caused 
by plausible functional variants within pre-selected genes and therefore bridge the 
gap between the genotype to the phenotype (Kwon and Goate, 2000; Zhu and Zhao, 
2007). As a hypothesis driven approach, known biological or functional relevance of 
the pre-selected genes to the disease being studied are necessarily required. 
Additionally, the tested SNPs within the candidate genes need to be carefully 
selected. Usually these SNPs have already been confirmed or predicted to be 
functional so once the associations have been found, it is quite straightforward to 
establish the genotype-phenotype link and offer biological insights.  
The tagSNP strategy has also been applied to the candidate gene approach to cut 
down costs, especially when multiple potentially functional SNPs in complete LD 
are present within the candidate genes. There are also situations in which researchers 
are really interested in certain genes but no known functional or potentially 
functional SNPs have been identified within these genes. In these situations, 
normally two methods will be applied. The first is to scan the entire gene using a 
tagSNP strategy just like a miniature version of a GWA study. The true causal 
variants can be captured when high density SNP genotyping has been performed, 
which is usually quite costly. The second is to choose several pleiotropic SNPs (i.e. 
SNPs that have been shown to be associated with multiple diseases). Since pleiotropy 
is pervasive, pleiotropic SNPs are more likely to be the causal SNPs or in high LD 
with the real causal SNPs.  
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Compared with resource intensive genomic approaches, candidate gene approach 
based studies are much more affordable and accessible to independent laboratories 
and researchers with little or no bioinformatics background. Additionally, benefiting 
from the function centric design, the results obtained from candidate gene based 
association studies are usually more actionable. However, it is important to know 
that the power of the candidate gene approach to detect direct associations is highly 
dependent on the rational selection of candidate genes and SNPs. Currently, for most 
common diseases, our existing knowledge about aetiological mechanisms and 
genetic architecture are still not sufficient to provide prefect predictions. 
Consequently, there is no guarantee that every effort will be rewarded. In addition, 
many results obtained through candidate gene approaches have been criticized for 
poor replicability and lack of further validation or follow-on functional analysis. 
When the sample size of the original study is small or the tested SNPs have not been 
functionally validated, it is necessary to provide functional evidence and complete 
the validation steps before making extensive generalizing conclusions. 
1.4.3 GWA study findings for HR-HPV-related cervical disease 
Over the past 10 years, more than 39000 unique SNP-trait associations have been 
identified through GWA studies. For many diseases, the findings obtained from 
GWA studies have refined our understanding of disease pathogenesis and treatment 
(Visscher et al., 2017). Indeed, the success of GWA study in its first decade is 
undeniable. However, for researchers interested in HR-HPV-related cervical disease, 
it is still too early to celebrate.  
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According to the NHGRI-EBI GWAS Catalog, to date, only 4 susceptible loci have 
been identified for HR-HPV-related disease, which are 4q12 (rs13117307), 17q21.1 
(rs8067378), 6p21.32 (rs4282438, rs9272143, rs73730372, rs3117027 and rs927795) 
and 6p21.33 (rs2516448) (MacArthur et al., 2016). The first two susceptible loci 
were identified in a Chinese population while the last one was found in a Swedish 
population. The only shared susceptible locus between the two populations is 
6p21.32. Together these loci can explain only a small fraction of the estimated 
heritability of cervical cancer (Chen et al., 2015). The details of these loci and 
subsequent studies derived from these findings are discussed in depth in Section 3.1. 
The main explanation for the low yields of these GWA studies is their inadequate 
sample size. A previous study showed that the trait/disease-associated SNPs 
identified through GWA studies generally have moderate effect size (with a median 
odds ratio around 1.3). In highly polygenic common diseases, very few SNPs with an 
odds ratio above 4 have been found (Hindorff et al., 2009). According to a newly 
published authoritative review for GWA studies, under the assumption of a type I 
error rate of 5×10-8 (conventional genome wide significance threshold) and 80% 
power, ~105 samples are required to detect associations caused by SNPs with a 
MAF<10% and an odds ratio of around 1.2. For SNPs with lower MAF frequency 
and smaller effect size, the sample size required would be larger (Visscher et al., 
2017). Unfortunately, none of the published GWA studies in HR-HPV-related 
cervical disease have a sample size above 104, even after pooling the cases from the 
replication sample set with the initial sample set. It is not surprising at all that the one 
performed in Japanese population failed to find any SNPs reaching the significance 
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threshold, since only several hundreds of subjects were genotyped (Miura et al., 
2014). 
Another issue that has hindered the ability to detect associations in published GWA 
studies is the heterogeneity of the cases. In the study performed in a Swedish 
population, the case group includes both carcinoma in situ and invasive cervical 
cancer cases (Chen et al., 2013). In fact, not limited to one or two GWA studies, 
similar grouping strategy has been used widely in association studies for cervical 
cancer. Although this strategy, to a large extent, reduces sampling difficulties, it also 
substantially decreases the power to detect associations. Additionally, as mentioned 
previously, the pathogenesis of cervical cancer consists of three transition states: the 
acquisition of HPV and productive infection, the formation of high-grade cervical 
intraepithelial lesion and the transition from precancerous lesion to cancer. These 
transition states are believed to be driven by different underlying mechanisms. 
Accordingly, the SNPs associated with each transition state could be different. And 
for a given SNP, its role may differ in different transition states. It is entirely 
conceivable that associations related to a specific transition state would be missed 
when cases representing mixed transition states are used. 
Although they are not perfect, current GWA studies still provide important 
information about the genetic architecture and indicate possible directions for the 
future. Based on summary statistics from GWA study results, Chen and colleagues 
estimated that 88.9% of the heritability of cervical cancer is tagged by common 
SNPs (Chen et al., 2015), which  implies that we should be able to obtain more new 
discoveries through GWA studies by using homogeneous samples and by increasing 
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the sample size to an achievable number. It is only a matter of time, and probably 
cost. 
1.4.4 Findings from candidate gene based association studies 
The last two decades have been boom years for candidate gene based association 
studies. Hundreds of studies have been performed and a large number of SNPs 
associated with HR-HPV-related cervical disease have been characterised. In 
recently published studies, SNPs reported to be associated with cervical cancer using 
candidate gene approaches have been thoroughly reviewed (Chen and Gyllensten, 
2015; Martínez-Nava et al., 2016; Mehta et al., 2017; Wang et al., 2015). The 
majority of disease associated SNPs were found within genes/regions involved in 
host defence and oncogenesis, such as tumour protein p53 (TP53), cytochrome P450, 
family 1, subfamily A, polypeptide 1 (CYP1A1), Toll-like receptor 9 (TLR9) , x-ray 
repair complementing defective repair in Chinese hamster cells 1(XRCC1), 
methylene tetrahydrofolate reductase (MTHFR), BRCA1-interacting protein 1 
(BRIP1) and p21, to name but a few (Chen and Gyllensten, 2015; Martínez-Nava et 
al., 2016; Wang et al., 2015).  
With the rapid development of sequencing technology and bioinformatics tools, 
large-scale SNP genotyping has also been utilized in candidate gene based 
association studies. This technique enables researchers to genotype a huge number of 
SNPs within candidate genes simultaneously in large groups of individuals. As a 
consequence, some candidate gene based association studies can also be used to 
indicate new disease related genes based on summary statistics by extending their 
candidate gene list with genes of no known relevance. For example, Wang and 
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colleagues evaluated 7140 tagSNPs from 305 candidate genes, which were 
hypothesized to be involved in DNA repair, viral infection and cell entry, in a 
population-based cohort study. The study found that six genes (i.e. GTF2H4, DUT, 
DMC1, OAS3, IFNG and SULF1) and three regions (i.e. TMC6, TMC8 and 
FLJ35220) were potentially associated with CIN3/cervical cancer. Variants in OAS3, 
SULF1, DUT, and GTF2H4 were associated with HPV persistence whereas IFNG 
and TMC6/TMC8 SNPs were associated with progression to CIN3/cancer (Wang et 
al., 2010). A subsequent study performed by Safaeian and co-workers further 
evaluated 18310 tagSNPs from 1113 candidate genes hypothesized to be involved in 
a wide range of cancers. Two genes, RPS19 and PRDX3 were reported to be 
associated with increased cervical cancer risk and both SNPs (i.e. PRDX3 rs7082598 
and RPS19 rs2305809) were associated with CIN3/cancer and the progression 
(Safaeian et al., 2012). Before the publication of these studies, some of the above 
genes had never been linked to known pathological processes in HPV infection or 
cervical cancer. 
Though findings from candidate gene association studies vastly outnumber those 
obtained from GWA studies, they did not lead to clinical advances as effectively as 
was expected. It is noteworthy that not many of the published associations in 
candidate gene based association studies have been further validated. According to a 
recent review, nearly 90% of the genetic associations reported in studies of cervical 
cancer have been investigated only once (Martínez-Nava et al., 2016). And for those 
associations that have been investigated in more than one study, only few exhibited 
consistency among studies and even fewer have been shown to be 
functionally-relevant. These situations obviously have already deviated from the 
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original purpose of candidate gene based studies: to bridge the knowledge gap 
between genetic association and the underlying biological mechanisms. 
When comparing the results from published GWA studies and candidate gene based 
association studies, only a handful of SNPs within the HLA regions of chromosome 
6 have been picked out by both approaches. None of the non-HLA SNPs identified 
by candidate gene association studies have been shown to be significant in current 
GWA studies (Johanneson et al., 2014). Although a possible explanation for these 
non-overlapping findings is the low mapping resolution for the current GWA studies, 
it is unfair to shift all the blame to GWA studies. It is time to raise the standards for 
reporting associations and recall the original intentions of the candidate gene 
approach. Especially when irrelevant genes and functionally unknown SNPs are 
tested, replication or functional validation of the associations should be included as a 
substantial part of any candidate gene based study. 
1.4.5 Now and the future 
It is clear that the majority of causal SNPs in HR-HPV-related cervical disease are 
still unknown. As a promising tool, GWA studies with a substantial increase in the 
sample size will lead to the discovery of new associations. However, it is hard to 
predict whether this could be happen in the near future. To reach the goal, stable 
funding sources and multi-centre and multi-disciplinary collaboration are necessarily 
required. And the post GWAS analysis will still be quite challenging, especially 
when the aim is to translate GWAS findings into biological insights. During the 
waiting time for future GWAS findings, the candidate gene approach will continue to 
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be a powerful tool for independent laboratories and individual researchers to identify 
novel targets and establish functional links.  
Apart from GWA studies and candidate gene approaches, sequencing based genomic 
study now becomes the third choice for researchers to identify associations. This 
approach has a higher mapping resolution than chip based GWA studies and is 
expected to pick up rare variants missed by GWA studies. Like GWA studies, at the 
moment, this approach is both expensive and resource intensive. Additionally, due to 
an even larger amount of data generated, it will be a real challenge to extract 
association signals from the background noise. In the cervical cancer research field, 
whole genome sequencing (WGS) has not yet been used to identify associations 
of SNPs with disease. The Cancer Genome Atlas (TCGA) Research Network has 
recently published findings from their genomic study based on 228 cervical cancer 
cases but they mainly focused on somatic genomic alterations, rather than SNPs 
(Network, 2017). According to what has been done for other common diseases, 
WGS data could be used as reference panel to impute existing GWAS datasets and 
consequently boost the number of variants assessed and increase the resolution of the 
original GWA studies (Luo et al., 2017; Mitt et al., 2017). It is strongly expected that 
GWAS and WGS jointly will also yield more new associations in HR-HPV-related 
diseases in the future. 
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1.5  Chemokines and chemokine polymorphisms in 
HR-HPV-related cervical disease 
1.5.1 Chemokines and chemokine receptors  
Chemokines are a group of small chemotactic cytokines that capable of inducing 
chemotaxis in nearby responsive cells and altering the immune/inflammation 
responses. To date, about 50 chemokines and 22 cognate chemokine receptors (i.e. 
18 typical chemokine receptors and 4 atypical receptors) have been identified 
(Nagarsheth et al., 2017). According to the location of the first two cysteine residues 
near the N terminus of the chemokine, chemokines can be divided into four groups: 
CC group, CXC group, CX3C group and C group. The CC chemokines contain two 
adjacent cysteine residues while the CXC chemokines have a non-conserved amino 
acid between the two cysteines. CX3CL1 is the only member in the CX3C group and 
is characterized by having three intervening amino acids between the two cysteines. 
The C group has two members and they only have one N terminal cysteine. 
According to their functions, chemokines can also be loosely classified into two 
types: homeostatic and inflammatory chemokines. Homeostatic chemokines are 
constitutively expressed in physiological conditions and participate in basal 
leukocyte trafficking while inflammatory chemokines are predominantly produced in 
pathological conditions and attract leukocyte towards the site of inflammation. The 
majority of chemokines can bind to more than one chemokine receptor and vice 
versa. Together, chemokine and chemokine receptor pairs are involved in a wide 
variety of processes in infectious diseases and cancers (Cardona et al., 2013). 
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1.5.2 Chemokine and chemokine receptors in HR-HPV-related cervical 
disease 
The roles of cytokines have been extensively investigated in HR-HPV-related 
cervical disease (Paradkar et al., 2014). However, unlike other cytokines, the role of 
chemokines in HR-HPV cervical cancer has rarely been investigated. Previous work 
done in our group showed that many chemokines were up-regulated in HR-HPV 
induced high-grade dyskaryosis. Particularly, six chemokines (i.e. CXCL1, CXCL8, 
CXCL10, CXCL12, CCL2 and CCL3) were found to be up-regulated in HR-HPV 
positive high grade cervical disease on both the Luminex® and the proteomic array 
platforms (unpublished data).  
CXCL1 (or called growth-regulated oncogene alpha, GROα) is a potent 
pro-angiogenic chemokine. Sales et al found that CXCL1 released by HeLa cells in 
response to seminal plasma was capable of regulating vascular function in in vitro 
angiogenesis assays (Sales et al., 2012). Serum levels of CXCL1 have been reported 
to be up-regulated as disease progress in patients with cervical cancer (Zhang et al., 
2014). Contrary to CXCL1, CXCL10 (also called interferon-gamma-inducible 
protein 10, IP 10) is an anti-angiogenic chemokine. Yang et al showed that CXCL10 
could down-regulate microvessel density and increase apoptotic rate in an in vivo 
mouse model of cervical cancer (Yang et al., 2009). In cultured condyloma 
acuminatum tissues, Li et al found that CXCL10 could induce apoptosis and reduce 
HPV expression (Li et al., 2009). Furthermore, CXCL10 levels were found to be 
inversely correlated with vascular endothelial growth factor (VEGF) levels in 
patients with cervical cancer (Sato et al., 2007). CXCL8 (also called interleukin 8) 
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plays key role in many physiological and pathological processes. It is of particular 
interest in this project. Details of this chemokine and its receptor CXCR1 and 
CXCR2 are discussed in depth in Section 5.1. CCL2 (also called monocyte 
chemotactic protein 1, MCP1) is a pro-inflammatory chemokine, which is able to 
recruit monocytes, memory T cells and dendritic cells to the site of inflammation. 
Elevated serum CCL2 has been associated with advanced cervical cancer and 
lymphatic metastasis (Lebrecht et al., 2001). The absence of CCL2 expression in 
cervical cancer has been shown to be beneficial (Zijlmans et al., 2006). In a novel 
molecular cascade identified by Schroer et al in cervical cancer, activation of signal 
transducer and activator of transcription 3 (STAT3) led to a strong up-regulation of 
CCL2, which amplified matrix metallopeptidase 9 (MMP-9) expression and 
contributed to the switch from precancerous lesions to malignancy (Schroer et al., 
2011). CXCL12 (also called, stromal cell-derived factor 1, SDF-1) is a homeostatic 
chemokine, which is strongly chemotactic for lymphocytes and highly associated 
with tumorigenesis (Kryczek et al., 2007).  The over-expression of CXCL12 and its 
receptor CCR4 has been correlated with tumour progression in cervical cancer 
(Huang et al., 2013; Wei et al., 2007). In general, the mechanisms by which 
chemokines influence HPV clearance and carcinogenesis are still far from being fully 
elucidated.  
1.5.3 Chemokine polymorphisms in HR-HPV-related cervical disease  
The essential role of chemokine in immune responses and other multiple 
physio-pathological processes makes them ideal candidate genes for genetic 
association studies. Conversely, locating and identifying functional SNPs in these 
55 
 
chemokine genes would help to explain how these genes influence HPV clearance 
and carcinogenesis. However, there are very few reports on variations in chemokine 
genes or chemokine receptor genes in HR-HPV-related cervical diseases. To the best 
of my knowledge, only CCL2 rs1024611, CCR2 rs1799864, CXCL8 rs4703, CCR5 
rs333 (a frame-shift variant) and several variants in CXCL12 have been linked to 
HR-HPV-related cervical diseases to date (Catarinoa et al., 2007; Chatterjee et al., 
2010; Coelho et al., 2005; Ivansson et al., 2007; Maley et al., 2009; Singh et al., 2008; 
Wu et al., 2013a; Wu et al., 2011; Zheng et al., 2006) , which seems incommensurate 
with the boom in studies on genetic polymorphisms. Furthermore, for some of the 
SNPs mentioned above, there is little consensus among existing studies. For example, 
the impacts of CCR2 rs1799864 on the pathogenesis of cervical cancer are still not 
clear. Coelho et al and Ivansson et al reported that the CCR2-64I variant 
(corresponds to the A allele) played a protective role in the development of cervical 
cancer (Coelho et al., 2005; Ivansson et al., 2007), whereas Chatterjee et al suggested 
A allele carriers were at a higher risk of cervical cancer (Chatterjee et al., 
2010),whilst according to the studies conducted by Singh et al and Zheng et al, the 
CCR2-64I variant showed no association with either HPV infection or cervical 
cancer development (Singh et al., 2008; Zheng et al., 2006). The findings are 
contradictory but this might be explained by inadequate sample sizes, ethnic and 
geographic variation. Therefore, studies concerning the role of SNPs in chemokine 
genes or chemokine receptor genes in HR-HPV-related cervical diseases are needed. 
However, as mentioned previously, caution must be taken in regards to 




1.6  Study hypothesis, aim and objectives 
This PhD project was instigated by data from published genetic association studies 
and from the preliminary chemokine profile study in the laboratory of one of my 
supervisors, Prof. Sarah Howie.  
The overarching hypothesis of the project is:  
There are functional SNPs within genes involved in host defence and/or oncogenesis 
that are associated with HR-HPV-related cervical cancer and precancerous cervical 
disease.  
The aim of the project is to identify functional variants in genes/regions of 
confirmed associations and to investigate the mechanisms by which they may 
contribute to HR-HPV-related cervical disease 
The objectives for the project: 
1. Select a proper panel of candidate SNPs for a small scale candidate gene based 
association study through literature mining. 
2. Investigate the associations between selected SNPs with HR-HPV-related cervical 
disease through a custom oligo-microarray. 
3. Validate the genetic associations found in the SNP array in the same set of 
samples and additional samples using other genotyping methods. 
4. Design functional assays to investigate the role of the significant SNPs identified 












































2.1 Ethics statement 
All Samples used in this study were anonymised and routinely taken. Samples used 
in the genetic association study were extracted genomic DNA (gDNA) (where 
available), liquid-based cytology (LBC) cervical samples or formalin-fixed, 
paraffin-embedded (FFPE) sections from biopsies provided by Scottish HPV archive 
and Lothian NRS Bioresource. The provision of extracted DNA samples and 
subsequent research was conducted under the approval held by the NHS Lothian 
NRS Bioresource (East of Scotland REC Ref 15/ES/0094).  
2.2 Materials  
2.2.1 Clinical samples 
A panel of routinely taken clinical samples were tested in the SNP array, which 
incorporated 475 cytologically-normal and HR-HPV negative cases, 413 HR-HPV 
positive HSIL cases and 62 HR-HPV positive cervical squamous cell carcinomas 
(see Section 2.3.2.1 for sample size estimation). The 475 controls were gDNA 
samples obtained directly from Lothian Year 2000 surveillance collection. These 
samples were previously extracted from LBC samples using either the 
QIAamp DNA Mini Kit (Cat#:51306, QIAGEN Ltd., Manchester, UK) or crude 
DNA extraction for unrelated reasons. All the HSIL cases were obtained from HPV 
Surveillance collection, of which 264 were extracted by me from LBC samples using 
MasterPure™ Complete DNA and RNA Purification Kit. The rest of HSIL cases 
were gDNA extracted from FFPE samples. These samples were also previously 
extracted from FFPE samples using QIAamp DNA FFPE Tissue Kit (Cat#:56404, 
QIAGEN Ltd., Manchester, UK) for unrelated reasons. Cervical cancer samples were 
60 
 
all obtained from the Scottish Invasive Cervical Cancers collection and extracted by 
me using GeneRead DNA FFPE Kit. These samples were provided with relevant 
anonymised patient information, including the age at diagnosis, the date on which the 
specimen was received, the date on which the genomic DNA was extracted (when 
applicable), HR-HPV types present5 and histologic disease grade (see Table 2 for 
details). For the cancers, International Federation of Gynaecology and Obstetrics 
(FIGO) stage, TNM category, vital status, survival time after the biopsy were taken, 
date of death and the cause of death were also provided.   
Table 2 Frequency distribution of select characteristics in HR-HPV high-grade 
cases and HR-HPV negative, cytologically-normal controls 
Variables Cases (n=475) Controls (n=475) 
Age, yrs (mean ± SD) 23.88 ±11.57 38.18±11.43 
Source, n (%)   
FFPE 211(44.4%) 0(0%) 
LBC samples 264(55.6%) 475(100%) 
HR-HPV, n (%) 6   
HPV16+ 336(70.7%)  
HPV16- 139(29.3%)  
Histologic gradations, n (%)   
CIN2+ 382(80.4%)  
CIN3 31(6.5%)  
Squamous carcinoma  62(13.1%)  
   
 
In order to investigate the role of significant SNPs in a broader spectrum of 
HPV-related diseases, genotyping results of additional clinical samples were 
included in the statistical analysis of the validation step, including 83 HPV positive, 
cytologically normal LBC samples (average age: 20), 21 HPV positive cervical 
                                                             
5 HR-HPV types, including type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, are of most 
concern in this project. 
6 HPV16 is the biggest causal agent of cervical cancer and is the most widely investigated type.  
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cancer samples (average age: 45.2±12.3), 129 HPV positive vulval intraepithelial 
neoplasia (VIN) samples (average age: 47.5±12.4) and 23 HPV positive vulval 
cancer samples (average age: 56.6±12.2). These additional samples were genotyped 
by Luhan Jiang and Dr Michelle Etherson respectively as part of their Master 
projects in the HPV group. The results were carefully re-inspected by me before 
pooling with the array results. The use of these data was conducted under the 
approval held by the NHS Lothian NRS Bioresource (East of Scotland REC Ref 
15/ES/0094) and National Health Service Greater Glasgow and Clyde (NHSGGC) 
Bio-repository (NHSGGC Bio-repository Ref number 96). 
2.2.2 Reagents and Chemicals  
All chemicals came from Sigma-Aldrich, Poole, UK, unless otherwise stated. All the 
primer/probe sets for the genotyping PCR were purchased from TIB Molbiol, Berlin, 
Germany. GAPDH Primer & Probe set (Cat#: HK-DD-hu-900) was obtained from 
PrimerDesign Ltd, Chandler's Ford, UK. 
Reagents Manufacturer 
Agarose powder Cat#:BIO-41025, Bioline, London, UK 
SYBR®safe DNA gel stain  Cat#:S33102, Invitrogen, Paisley, UK 
GeneRuler 1 kb DNA Ladder Cat#:SM0312, 
ThermoFisher Scientific, Paisley, UK 
Dulbecco's Modified Eagle's 
medium(DMEM) 1X 
Cat#:21969-035, 
ThermoFisher Scientific, Paisley, UK 
GIBCO® Dulbecco's Phosphate-
Buffered Saline (DPBS) 1X  
Cat#:4190-094, 
ThermoFisher Scientific, Paisley, UK 
Gibco® RPMI Medium 1640 1X Cat#:31870-025, 
ThermoFisher Scientific, Paisley, UK 
Fetal Bovine Serum, Qualified, 
Heat Inactivated 
Cat#:10500-064, 
ThermoFisher Scientific, Paisley, UK 
0.05% Trypsin - EDTA (1x) + 
phenol red 
Cat#:25300-054, 




ThermoFisher Scientific, Paisley, UK 
Pen-Step Cat#:15140-122, 
ThermoFisher Scientific, Paisley, UK 
G418 (solution) Cat#:ant-gn-1,  
InvivoGen Europe, Toulouse, France 
Blasticidin (solution) Cat#:ant-bl-1,  
InvivoGen Europe, Toulouse, France 
APC Anti-human CD181 
(CXCR1) 
BioLegend, London, UK 
PE anti-human CD182 
(CXCR2)  
BioLegend, London, UK 
Lipofectamine 2000 Cat#:11668027, 
ThermoFisher Scientific, Paisley, UK 
ProLong® Gold Antifade 
Mountant with DAPI 
Cat#:P36931,  
ThermoFisher Scientific, Paisley, UK 
EDTA solution Cat#:E8008,  
Sigma-Aldrich Company Ltd., Gillingham, UK 
Human TruStain FcX™  Cat#:422301,Biolegend, London, UK 
Recombinant human IL-8 Cat#:208-IL-010/CF,  
R&D Systems, Abingdon, UK 
Opti-MEM I Reduced Serum 
Media 
Cat#:31985062,  
ThermoFisher Scientific, Paisley, UK 
2.2.3 Media, buffers and solutions 
LB medium (Cat#:L3522-1KG, Sigma-Aldrich Company Ltd., Gillingham, 
UK):10g/L Tryptone, 10g/L NaCl and 5g/L Yeast Extract 
LB Broth with agar (Cat#:L3147-1KG, Sigma-Aldrich Company Ltd., Gillingham, 
UK): 15g/L Agar, 10g/L Tryptone,10g/L NaCl and 5g/L Yeast Extract 
2x YT medium (Cat#:Y2377-250G, Sigma-Aldrich Company Ltd., Gillingham, 
UK):16g/L Tryptone, 10 g/L Yeast Extract and 5g/L NaCl 
1x TAE buffer: 40 mM Tris, 20 mM acetic acid and 1 mM EDTA. 
Alkaline lysis Solution I: 50 mM glucose, 25 mM tris-HCl (pH 8.0) and 10 mM 
EDTA (pH 8.0) 
Alkaline lysis Solution II: 0.2 N NaOH and 1% (w/v) SDS 
Alkaline lysis Solution III: 5 M potassium acetate (60.0 ml), glacial acetic acid (11.5 





2.2.4 Kits and enzymes 
Kits 
Kits Manufacturer 
MasterPure™ Complete DNA and 
RNA Purification Kit 
Cat#:MC85200,  
Cambio, Cambridge, UK 
GeneRead DNA FFPE Kit Cat#:180134,  
QIAGEN Ltd., Manchester, UK 
RNeasy Micro Kit Cat#:74004, QIAGEN Ltd., Manchester, UK 
KOD Hot Start DNA Polymerase 
kit  
Cat#:71086-3,  
Merck Millipore, Watford, UK 
QIAprep Spin Miniprep Kit  Cat#:27104, QIAGEN Ltd., Manchester, UK 
LightCycler® FastStart DNA 
Master HybProbe kit  
Cat#:12239272001, 
Roche, Lewes, UK 
QuantiTect Reverse Transcription 
Kit 
Cat#:205311,  
QIAGEN Ltd., Manchester, UK  
PureYield™ Plasmid Midiprep Kit Cat#:A2492, 
Promega UK, Southampton, UK 
Cell Counting Kit-8 (500tests) Cat#:CK04-05 Munich, Germany  
Enzymes:  
XbaI  Cat#:R0145S, New England Biolabs, Hitchin, Herts, UK 
NheI  Cat#:R0131S, New England Biolabs, Hitchin, Herts, UK 
DpnI  Cat#:R0176S, New England Biolabs, Hitchin, Herts, UK 
EcoRV Cat#:R0195S, New England Biolabs, Hitchin, Herts, UK 
Gateway® LR clonase 
II enzyme mixture  








2.2.5 Biological materials 
Plasmids 
All the plasmids used in this project were provided by Professor Jürgen Haas, 
Division of Infection and Pathway Medicine, University of Edinburgh, UK. 
Bacteria 
All the bacteria strains used in this project were provided by Professor Jürgen Haas, 
Division of Infection and Pathway Medicine, University of Edinburgh, UK. 
Cell lines 
Cervical cancer cell lines: HeLa (HPV18 positive) and SiHa (HPV16 positive) cell 
lines were obtained from ATCC (LGC standards, Teddington, UK); the CaSki 
(HPV16 positive) cell line was obtained from Dr Kate Cuschieri, Scottish HPV 
Reference Laboratory, Edinburgh, UK. 
Other cell lines: the human monocytic cell line Mono Mac 6 (MM6) was obtained 
from DSMZ, Braunschwieg Germany; human embryonic kidney cell lines HEK293 
and 293T were provided by Professor Jürgen Haas, Division of Infection and 
Pathway Medicine, University of Edinburgh, UK. 








2.2.6 Equipment and consumables 
Equipment Manufacturer 
LightCycler® Nano Instrument  Roche, Lewes, UK 
Milli-Q® Academic Water 
Purification system 
Merck Millipore, Watford, UK 
Mr. Frosty™ Freezing Container ThermoFisher Scientific, Paisley, UK 
FumeGuard Controller FUMAIR, East Kilbride, UK 
GeneAmp® PCR System 9700 Applied Biosystems, Warrington, UK 
Eppendorf 5415D centrifuge Eppendorf UK Ltd., Stevenage, UK 
Eppendorf Thermomixer® R Dry 
Block Heating and Cooling Shaker 
Eppendorf UK Ltd., Stevenage, UK 
Multitron Standard incubation 
shaker 
Infors HT, Bottmingen, Switzerland 
Raven incubator  LTE Scientific, Greenfield, Oldham, UK 
Eppendorf 5810R centrifuge Eppendorf UK Ltd., Stevenage, UK 
M330 UV-Visible 
Spectrophotometer 
Camspec Limited, Sawston, Cambridge, 
UK 
Sigma 6K15 high speed centrifuge  
with 12256-H angle rotor 
DJB Labcare Ltd, Newport Pagnell, UK 
Eppendorf Eporator® Eppendorf UK Ltd., Stevenage, UK 
U:GENIUS3 UV transilluminator Syngene, Cambridge, UK 
NanoDrop® ND-1000 UV-Vis 
Spectrophotometer 
Nanodrop Technologies, Ringmer, UK 
Applied Biosystems® StepOne™ 
Real-Time PCR System 
ThermoFisher Scientific, Paisley, UK 
BioMAT® 2 Safety Cabinet Contained Air Solutions Ltd, Manchester, 
UK 
Galaxy R+ incubator RS Biotech Laboratory Equipment Ltd., 
Irvine, UK 
QuantStudio 12K Flex Real Time 
PCR System 
Applied Biosystems, Cheshire, UK 
Leica TCS SP5 confocal microscope Leica Microsystems Ltd, Milton 
Keynes, UK 
EVOS™ digital inverted 
microscope 
Advanced Microscopy Group, Bothell, WA 
LSR Fortessa analyser  BD Biosciences, Oxford, UK 
FACSAria II sorter BD Biosciences, Oxford, UK 








Corning® Cell culture flask 
(T25,T75 and T162cm2) 
Sigma-Aldrich, Poole, UK 
Corning® Costar® TC-Treated 
Multiple Well Plates 
(Flat bottom,6,12,24,48 and 96-well) 
Sigma-Aldrich, Poole, UK 
Falcon tube (15,50ml) Corning Ltd, Lakeside, UK 
Corning® tissue-culture treated culture 
dishes (D × H 100 mm × 20 mm) 
Sigma-Aldrich, Poole, UK 
Sterilin™ Standard 90mm Petri Dishes  ThermoFisher Scientific, Paisley, UK 
Corning® Costar® Stripette® serologic
al pipettes (1,5,10,25 and 50ml) 
Sigma-Aldrich, Poole, UK 
Tips (Non-sterile,10,20,200 and 
1000µl) 
Gilson U.K. Dunstable, UK 
Tips (Sterile,10,20,200 and 1000µl) Greiner Bio-One Ltd, Stonehouse, UK 
Microcentrifuge Tubes(0.5,1.5 and 2ml) Eppendorf UK Limited, Stevenage,UK 
Gene Pulser®/MicroPulser™ 
electroporation cuvette 
Cat#:1652082, Bio-Rad Laboratories 
Ltd., Watford, UK 
96-well deep well plate VWR International Ltd 
low profile 96 well PCR plates Cat#:AB0600,  
ThermoFisher Scientific, Paisley, UK 
Nalgene™ PPCO Centrifuge Bottles 
with Sealing Closure 
Cat#:3141-0250  
ThermoFisher Scientific, Paisley, UK 
MicroAmp® Fast Optical 48-Well 
Reaction Plate 
Cat#:4375816 
ThermoFisher Scientific, Paisley, UK 
MicroAmp® 48-Well Optical Adhesive 
Film 
Cat#:4375323 
ThermoFisher Scientific, Paisley, UK 
Low profile PCR tubes, strips of 8 Cat#:AB0771,  
ThermoFisher Scientific, Paisley, UK 
Low Profile Tubes and Flat Caps, strips 
of 8 
Cat#:AB0773,  
ThermoFisher Scientific, Paisley, UK 
8-well chamber slide Cat#: PEZGS0816, Merck Millipore, 
Hertfordshire, UK 
Corning™ Falcon™ Round-Bottom 
Polystyrene Tubes 5ml 
Cat#:352052, Fisher Scientific UK Ltd, 
Loughborough, UK 
Hanging inserts (8.0µm pore, 6.5mm 
diameter) 
Cat#: MCEP24H48, Merck Millipore, 
Hertfordshire, UK 
Falcon™ Cell Strainers, 40μm Nylon  Fisher Scientific Ltd, Loughborough, 
UK 
Rectangular cover glasses, Menzel 
Gläser 24×50 mm 
Cat#:P10143263NR1 
ThermoFisher Scientific, Paisley, UK 
Gloves, NITRILE, S Cat#:112-2371,VWR International Ltd 
Fisherbrand™ Disposable Pipette 
Basins 
Cat#:13-681-500, Fisher Scientific UK 
Ltd, Loughborough, UK 
FastRead 102™ Disposable plastic 
counting slides 
Immune Systems Ltd, Paignton, UK 




2.3. 1 General methods 
2.3.1.1 Preparation of chemically competent Escherichia coli DH10β 
10µl glycerol stock of the Escherichia coli DH10β was streaked onto an 
antibiotic-free lysogeny broth (LB) agar plate and cultured overnight at 37°C in a 
Raven incubator. Single colonies were picked and cultured in 10ml LB medium at 
200rpm, 37°C in a Multitron Standard incubation shaker. The overnight culture was 
inoculated in 2x YT medium (1:200) and the bacterial density was closely monitored 
by measuring optical density (OD) at a wavelength of 600 nm using Camspec M330 
UV-Visible Spectrophotometer. Once the OD600 reached 0.5, bacterial growth was 
halted by swirling the flask vigorously on ice for 15min. DH10β bacteria were 
pelleted by centrifuging 10min at 4000rpm, 4°C using Sigma 6K15 high speed 
centrifuge with 12256-H angle rotor and resuspended in 20ml cold sterile CaCl2 
(100mM). After incubation on ice for 30min, cells were pelleted again by 
centrifuging 10min at 4000rpm, 4°C, resuspended at a concentration of 2×109 
cells/50µl in sterile CaCl2 (100mM) with 15% glycerol and aliquoted in 50µl 
volumes in a dry ice-ethanol bath. The competency of the bacteria was checked by 
transforming one aliquot of the cells with 1pg/µl plasmid vector as described in 
Section 2.3.1.3. Cells with high transformation efficiency (~109cfu/µg) were used for 
the following experiments. 
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2.3.1.2 Preparation of electrocompetent Escherichia coli Stbl3  
Glycerol stock of the Escherichia coli Stbl3 was streaked onto an antibiotic-free LB 
agar plate and cultured overnight at 37°C  as described in Section 2.3.1.1. The 
overnight culture was inoculated in 2x YT medium (1:200) and the bacterial density 
was closely monitored by measuring OD at a wavelength of 600 nm. Once the OD600 
reached 0.5, bacterial growth was halted by swirling the flask vigorously on ice for 
10min. Stbl3 bacteria were pelleted by centrifuging 10min at 6000rpm, 4°C  using 
Sigma 6K15 centrifuge with 12256-H angle rotor and washed twice with cold sterile 
H2O by centrifuging by centrifuging 10min at 6000rpm, 4°C. The bacteria were then 
resuspended at a concentration of 5×109 cells/100µl in 10% Glycerol and aliquoted 
in 100µl  volumes in a dry ice-ethanol bath. The competency of the bacteria was 
checked by transforming with 1pg/µl  plasmid vector as described in Section 2.3.1.4. 
Bacteria with high transformation efficiency (~1011cfu/µg) were used for the 
following experiments. 
2.3.1.3 Transformation of chemically competent Escherichia coli DH10β   
50 µl  of chemically competent DH10β bacteria were taken out of -80°C  and thawed 
on ice. Once thawed completely, 1-2µl  of plasmid DNA was added and incubated on 
ice for 30min, followed by heat shock at 42°C  for 45sec and incubation on ice for 
2min. Then the mixture was recovered with 500µl  antibiotic-free LB medium and 
incubated at 37°C  in an Eppendorf Thermomixer® R Dry Block Heating and 
Cooling Shaker at 800rpm for an hour. After incubation, the mixture was plated 
directly onto a 10cm LB agar plate containing the appropriate antibiotic. The plate 
was then cultured in a Raven incubator at 37°C  overnight. Colonies were picked the 
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next day in appropriate volume of LB medium with the selection antibiotic 
(1.2ml/colony for alkaline lysis and 5ml/colony for QIAprep Spin Miniprep).  
2.3.1.4 Transformation of electrocompetent Escherichia coli Stbl3  
100µl  of electrocompetent Stbl3 were taken out of -80°C  and thawed on ice. Once 
thawed completely, 2µl  of plasmid DNA was added and the mixture was transferred 
to an ice-cold Gene Pulser®/MicroPulser™ electroporation cuvette. The mixture was 
then pulsed in Eppendorf Eporator® at 1.8kV and recovered immediately in 
pre-warmed antibiotic-free LB medium. After incubation at 37°C  in the Eppendorf 
Thermomixer at 800rpm for an hour, the mixture was plated and cultured as 
described in Section 2.3.1.3. 
2.3.1.5 Glycerol stock preparation and storage 
For lab stock maintenance, glycerol stock was always prepared before DNA 
extraction by mixing 300µl  liquid overnight bacterial culture with same volume of 50% 
glycerol. Once made, each glycerol stock was labelled with plasmid name and date, 
and then immediately transferred to a -80°C  freezer for long term storage. 
2.3.1.6 Plasmid DNA extraction  
2.3.1.6.1 Small scale plasmid DNA extraction  
Single bacterial colonies were inoculated into 5ml LB medium with appropriate 
antibiotic within a 15ml Falcon conical tube and cultured overnight at 37°C , 160rpm 
in the Multitron Standard incubation shaker. Next day, glycerol stock was made for 
each sample as described in Section 2.3.1.5 for long term storage. The rest of the 
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culture was centrifuged at 3100G for 5min to pellet the bacteria. Plasmids were then 
extracted using QIAprep Spin Miniprep Kit following the manufacturer's instructions 
2.3.1.6.2 Small scale plasmid DNA extraction using alkaline lysis method 
Single bacterial colonies were inoculated into 1.2ml LB medium with appropriate 
antibiotic within 96 well deep-well plate and cultured overnight at 37°C , 160rpm in 
the Multitron Standard incubation shaker. Next day, 200µl  of culture from each well 
was transferred to a 96 well plate and stored at 4°C  as a short term stock. The rest of 
the culture was centrifuged at 2200G for 10min to pellet the bacteria. 300µl  of 
alkaline lysis solution I was added to each well to resuspend the bacteria, followed 
by 300µl  of alkaline lysis solution II for bacterial lysis and 300µl  ice-cold alkaline 
lysis solution III for neutralization (see Section 2.2.3 for details). Supernatant was 
then collected by centrifuging at 2200G for 30min and mixed with 600µl of 
isopropanol overnight at -20ºC to precipitate the plasmid DNA. On day 3, a DNA 
pellet was obtained by centrifuging at 2200G for 45min, rinsing with 500µl  70% 
ethanol and air-drying. Finally, the pellet was eluted in 35µl ddH2O. 
2.3.1.6.3 Large scale plasmid DNA extraction 
A small volume of a glycerol stock (normally 15-20μl) was inoculated into 200ml 
LB medium with appropriate antibiotic within an Erlenmeyer flask and cultured 
overnight at 37°C , 200rpm in the Multitron Standard incubation shaker. Next day, 
glycerol stock was made for each sample as described in Section 2.3.1.5 for long 
term storage. The rest of the culture was poured into a Nalgene™ PPCO Centrifuge 
bottle (250ml) and centrifuged at 3100G for 5min to pellet the bacteria. Plasmids 
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were then extracted using PureYield™ Plasmid Midiprep Kit 
following the manufacturer's instructions. 
2.3.1.7 Agarose gel electrophoresis  
Agarose gel electrophoresis was performed to separate DNA fragments generated by 
diagnostic restriction enzyme digestion. 1% Agarose gel shows good resolution for 
linear DNA ranging from 500-10000bp and therefore was chosen for this project. 
The 1% agarose gel was made by mixing 1.7g agarose powder with 170ml 
homemade TAE (1x) buffer in a microwavable flask and heating in a microwave 
oven at full power until the agarose powder was completely dissolved. For 
visualization of DNA fragments, 4µl  SYBR®safe DNA gel stain was added after 
cooling down the gel solution to about 50°C . Then, the gel solution was poured into 
a gel tray with a well comb in place. Once completely solidified, the gel was 
transferred to the electrophoresis tank filled with TAE (1x) buffer. After removing 
the comb, 7µl  GeneRuler 1kb DNA Ladder along with each set of DNA digests were 
loaded into wells and run at 100V for 50-70min. Picture of the gel was taken under 
the UV light of the U:GENIUS3 UV transilluminator to visualize the DNA 
fragments. 
2.3.1.8 Cell culture 
2.3.1.8.1 Resuscitation of frozen cell lines 
To retrieve cells for culture, frozen cells were quickly thawed in a 37°C  waterbath 
and pelleted by centrifuging at 190G for 5min. Then, the cells were washed with 
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PBS at 190G for 5min, resuspended in complete growth medium and transferred to 
culture flasks.  
2.3.1.8.2 Cell maintenance 
HeLa and MM6 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 
growth medium plus 10% v/v fetal bovine serum (FBS), 1% L-glutamine, 100μg/ml 
streptomycin and 100U/ml penicillin (37°C, 5% v/v CO2, 100% humidity in a 
Galaxy R+ incubator). HEK293T cells were maintained in DMEM growth medium 
plus 10% FBS, 1% L-glutamine, 100μg/ml streptomycin, 100U/ml penicillin and 
500μg/ml G418. Other cells were all maintained in DMEM plus 10% FBS, 1% 
L-glutamine, 100μg/ml streptomycin and 100U/ml penicillin. Medium was normally 
changed every two days. Once reaching 80%-90% confluence, adherent cells were 
detached with Trypsin-EDTA solution, washed with PBS by centrifuging at 190G for 
5min, resuspended in fresh growth medium and transferred into new flasks with at a 
ratio of 1:5 or seeded as required for experiments. Non-adherent cells were split by 
spinning down at 190G for 5min, washed with PBS and resuspended in fresh growth 
medium with a ratio of 1:8. 
2.3.1.8.3 Cell counting 
Cell numbers were determined using FastRead 102 disposable counting chambers 
following the manufacturer's instructions. Briefly, 9μl aliquoted single cell 
suspension was added into a chamber of the slide. Cell numbers within at least four 
complete 4×4 grids were counted under a light microscope at 10x magnification. 
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Concentration of the cell suspension was calculated as: average cell counts in a 4×4 
grid ×104×sample dilution (if any)/ml. 
2.3.1.8.4 Cryopreservation of cell lines 
Cells were detached from culture flasks and counted as described in Section 
2.3.1.8.3. Then, cells were resuspended at a concentration of 1 x 107 cells/ml in 
ice-cold FBS plus 10% Dimethyl sulfoxide (DMSO). Cell suspension was aliquoted 
in 1.5ml volumes in Nunc® CryoTubes and gradually frozen within Mr. Frosty™ 
Freezing Container at -80°C. Once completely frozen, cells were transferred to a 
liquid nitrogen tank for long-term storage. 
2.3.1.9 DNA extraction  
Genomic DNA was extracted from Cell samples (including LBC samples) and FFPE 
samples using MasterPure™ Complete DNA and RNA Purification Kit and 
GeneRead DNA FFPE Kit respectively following the manufacturer's instructions. 
Purity and concentration of each genomic DNA sample was quantified using a 
NanoDrop® ND-1000 UV-Vis Spectrophotometer based on the absorbance at 
260nm and 280nm. Sample purity was assessed according to the ratio of absorbance 
at 260 nm and 280 nm, which was normally near 1.8. Sample concentration was 
automatically calculated based on the absorbance at 260 nm and displayed in ng/µl .  
2.3.1.10 RNA extraction and cDNA synthesis 
Ribonucleic acid (RNA) was extracted from cell samples using the RNeasy Micro 
Kit following the manufacturer’s instructions and quantified using a NanoDrop® 
ND-1000 UV-Vis Spectrophotometer. Sample purity was assessed according to the 
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ratio of absorbance at 260 nm and 280 nm, which was normally near 2.0. Sample 
concentration was automatically calculated based on the absorbance at 260 nm and 
displayed in ng/µl . After determination of the concentration, cDNA was synthesized 
from 500ng RNA using QuantiTect Reverse Transcription Kit 
following the manufacturer's instructions.  
2.3.1.11 Quantitative PCR 
Quantitative PCR (qPCR) reactions were performed in MicroAmp® Fast Optical 
48-Well Reaction Plate on  the Applied Biosystems® StepOne™ Real-Time PCR 
System (See Table 3 and 4 for the detailed reaction setup and thermal profile). Data 
acquisition and post-acquisition analysis was performed using StepOne™ Software 
v2.3 (ThermoFisher Scientific, Paisley, UK). 
Table 3 Standard qPCR reaction setup 
PCR Component Volume 
TaqMan® Universal PCR Master Mix 6.5 µl  
PCR-grade H2O 5.5µl  
Prime& probe Set 1µl  
cDNA template 2 µl  







Table 4 Standard thermal profile for qPCR 
Step Thermal profile 
1.Polymerase activation 95°C for 10 min 
2.Denature 95°C for 15 sec 
3.Anneal/extend 60°C for 60 sec 
5.Repeat steps 2–4 39 times (40 in total) 
 
2.3.2 SNP genotyping array 
2.3.2.1 Sample size estimation for the SNP array 
The estimated global minor allele frequencies (GMAF) of our candidate SNPs 
mainly range from 0.05 to 0.4. Sample size for the SNP array was estimated using 
Quanto version 1.2.4 under the assumption of 0.01% disease prevalence, 1:1 
case/control ratio, a range of odds ratio between 1.5 to 3 (RG), 5% Type I error rate 
and power at 80% under the log-additive genetic model (see Appendix 1 for the 
details). The log-additive model is the most frequently assumed genetic model in 
association studies, especially in GWAs and other array-based studies. For this 
project, an achievable sample size of 475 was chosen for both control and case 
groups.  
2.3.2.2 SNP array 
Genomic DNA samples were aliquoted and transported on dry ice to the Genetics 
core facility (Wellcome Trust Clinical Research Facility (WTCRF), Edinburgh) 
within low profile 96 well PCR plates. A subset of 32 biallelic SNPs was rationally 
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selected for the SNP array (See Chapter 3 for the selection of candidate SNPs). The 
array was performed by the WTCRF Genetics core using the QuantStudio 12K Flex 
Real Time PCR System, following TaqMan® OpenArray® Genotyping SOP version 
2. The raw data was analyzed using TaqMan Genotyper Software v1.3 
(ThermoFisher Scientific, Paisley, UK) by two experienced research technicians 
from the Genetics core facility (see Figure 4 for a representative allelic 
discrimination plot from the array) and then a genotyping report was generated. 
Allele and genotype frequencies of each SNP were obtained by direct counting and 
summarized in contingency tables. Hardy-Weinberg Equilibrium (HWE) were 
assessed for each SNP in both the control and case group using the Michael H. 
Court's (2005–2008) online calculator (Moscicki et al., 2010). For all the SNPs that 
passed HWE test (with a p value >0.05), Pearson’s 2 test (if all expected counts are 
≥ 5) and Fisher’s exact test (If any expected counts are <5) were performed by 
GraphPad Prism 5 (GraphPad Software, San Diego, CA) to assess whether the 
distribution of alleles differ between cases and controls under the log-additive 
genetic model. Raw p values obtained were further corrected for multiple 
comparisons through the false discovery rate (FDR) method (Benjamini and 
Hochberg, 1995) using p.adjust package in R. SNPs with a FDR value < 0.15 were 




Figure 4 Representative allelic discrimination plot for a biallelic SNP 
The raw data were imported into TaqMan genotyper software as allelic discrimination plots, 
which showed the genotype of each sample for each SNP. In this figure, each dot stands for 
a sample. Homozygote (blue or red) has the signal from only one probe while heterozygote 
(green) has signals from both probes. The black dot is the blank control on that plate. This 
figure showed genotyping data for rs1800629 in the first run of the SNP array. 
 
2.3.3 Validation of the SNP array  
To further validate the significant results of the SNP array, significant SNPs in the 
initial analysis were re-genotyped in the same set of samples using single tube 
TaqMan® SNP genotyping assay and LightSNiP assay with melting curve analysis. 
The single tube TaqMan® SNP genotyping assay was performed in the Genetics 
core facility following the manufacturer's instructions whilst the LightSNiP assay 
was performed by me in the Queen’s Medical Research Institute. In the LightSNiP 
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assay, PCR amplification was performed in a 10µl  reaction volume on the 
LightCycler® Nano Instrument in Strips of 8 low profile PCR tubes (See table 5 and 
6 for details).  
Table 5 Standard PCR reaction setup for LightSNiP assay 
PCR Component Volume 
LightCycler® FastStart Reaction Mix 
HybProbe, 
0.5 µl  
LightCycler® FastStart Enzyme 0.5 µl 
25mM MgCl2 0.4 µl  
PCR-grade water. 6.1μl 
diluted gDNA (~10ng/µl) 2 μl 
Primer/probe Mix 0.5 µl  
Total reaction volume 10 µl 
 
Table 6 Standard thermal profile for LightSNiP assay 
Step Thermal profile 
1.Polymerase activation 95°C for 10 min 
2.Denature 95°C for 10 sec 
3.Annealing 60°C for 15 sec 
4.Extension 72°C for 20 sec 
5.Repeat steps 2–4 44  times (45 in total) 
6. generate Melting curve( Extra cycle) 30s at 95°C, 45°C to 75°C at 0.2°C 






A negative DNA control consisting of PCR-grade water was included in all runs in 
order to ensure that no sample contamination had occurred. Melting peaks were 
generated by plotting negative derivative of fluorescence against temperature and 
the melting temperature (Tm) of the products was determined. For CXCR1 
rs2234671, melting peaks at 53.5 °C and 64 °C correspond to the presence of G and 
C allele respectively. For SULF1 rs2623047, melting peaks at 57 °C and 65 °C 
correspond to the presence of A and G respectively (see Figure 5 and 6 for the 
representative dissociation curves). The genotype of each sample was determined 
directly according to the melting peak profile and compared with the results obtained 
in the SNP array. For the purpose of quality control, the genotypes were read by at 
least two independent group members. Any unrecognizable results were repeated 
until 100% concordance was reached.  
 
Figure 5 Representative dissociation curve of the CXCR1 rs2234671 PCR 
product 
The figure shows the melting curves converted to melting peaks by plotting the negative 
derivative of fluorescence against temperature. The melting temperatures (Tm) are 53.5°C 
for G and 64 °C for C allele, respectively. In this figure, each curve stands for a sample. 
Green line shows a homozygous carrier of the G allele while pink line shows a homozygous 
carrier of the C allele. Purple line represents a G/C heterozygote. Negative control 




Figure 6 Representative dissociation curve of the SULF1 rs2623047 PCR 
product 
The figure shows the melting curves converted to melting peaks by plotting the negative 
derivative of fluorescence against temperature. The melting temperatures (Tm) are 57 °C 
for A and 65 °C for G allele, respectively. In this figure, each curve stands for a sample. Pink 
line shows a homozygous carrier of the G allele while purple line shows a homozygous 
carrier of the A allele. Blue line represents an A/G heterozygote. Negative control 
(PCR-grade water) was shown with the red line. 
 
In order to investigate the role of significant SNPs in a broader spectrum of 
HPV-related disease, genotyping results of an additional 83 HPV positive 
cytologically normal LBC cervical samples, 21 HPV positive cervical cancer 
samples, 129 HPV positive VIN samples and 23 HPV positive vulval cancer samples 
were combined with the validated array results. Association between each SNP and 
HR-HPV-related diseases was tested under five different genetic models (i.e. 
co-dominant, dominant, recessive, over-dominant and log-additive) using the 
SNPstat online tool (Solé et al., 2006). Odds ratios (OR), 95% confidence intervals 
(CI) were calculated for each inheritance model after age adjustment. The best–fit 
model for each SNP was determined according to the likelihood ratio test p value, 
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Akaike’s Information Criterion (AIC) and Bayesian Information Criterion (BIC) 
scores. 
2.3.4 Generation of CXCR1 mutations by Site Directed Mutagenesis  
2.3.4.1 Determination of allele present in the CXCR1 cDNA clone  
A cDNA clone for human CXCR1 was previously obtained from Mammalian Gene 
Collection (MGC) and cloned into the pDONR223 vector in Prof Jürgen Haas’s lab. 
For verification, the vector containing CXCR1 gene was sequenced by Source 
BioScience, Nottingham, UK with pDONR223 forward primer 
5’-TCGCGTTAACGCTAGCATG-3’ and pDONR223 reverse primer 5’ 
TAATACGACTCACTATAGGG 3’. The sequencing result was aligned with CCDS 
sequence data 2409.1 using EMBOSS Needle nucleotide alignment tool.  
CCDS sequence data 2409.1 starts from the initiation of the ATG codon in exon 2 of 
the CXCR1 gene and terminates with TGA codon, containing a total of 1053 
nucleotides. The major allele G of CXCR1 rs2234671 was found 827nt downstream 
from the start codon of the CCDS sequence data 2409.1 and therefore commonly 
designated as CXCR1 827G in published studies (Bellamy, 2003; Kato et al., 2000; 
Ragnarsdóttir et al., 2011). The minor allele C was correspondingly named as 
CXCR1 827C. For simplicity of notation, I also used CXCR1 827G and 827C 
throughout my project. This non-synonymous substitution results in an amino acid 
change from serine (AGC) to threonine (ACC) at the 276th amino acid residue of the 
CXCR1 protein.  
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The MGC CXCR1 cDNA clone matches the CCDS sequence data 2409.1 at 
nucleotide position 827. However, the two sequences have differences at three other 
nucleotide positions, which are 16, 92 and 1003 respectively. The MGC CXCR1 
cDNA clone possesses 16T, 92G and 1003T, of which the first one is an unreported 
missense mutation while the other two are both minor alleles of known SNPs 
(rs16858811 and rs16858808 separately). Based on SNAP analysis (Johnson et al., 
2008), these two SNPs are found in complete linkage disequilibrium (D’=1 and 
R2=1). Genotyping results of rs16858811, rs2234671 and rs16858808 were obtained 
from the 1000 Genomes Project Phase 3 European database (Consortium, 2015). 
These three SNPs formed only three haplotypes among a total of 503 European 
subjects (See Table 7 for haplotype frequencies). The minor allele of rs2234671 only 
appeared with the major alleles of the other two SNPs. In view of the fact that the 
frequency of the G-G-T haplotype is quite low in the European population, I decided 
to change 16T, 92G and 1003T into corresponding major alleles so as to focus on the 
functional effects caused by rs2234671. 
Table 7 CXCR1 Haplotype frequencies in 1000 Genomes Project Phase 3 
European super population 
Haplotype(rs16858811-rs2234671-rs16858808) Frequency 
T-G-C 92.94% (=935/1006) 
T-C-C 3.38% (=34/1006) 




2.3.4.2 Generation of a point mutation within the pDONR223 CXCR1 
construct using Site-directed mutagenesis 
2.3.4.2.1 Single site directed mutagenesis PCR 
pDONR223 CXCR1 construct with C, instead of G, at nucleotide position 827 was 
firstly generated by site-directed mutagenesis using KOD Hot Start DNA Polymerase 
kit, with the forward primer 5’-GTGATCCAGGAGACCTGTGAGCGCCGC-3’ and 
reverse primer 5’-GCGGCGCTCACAGGTCTCCTGGATCAC-3’ designed by the 
QuikChange® Primer Design Program (Agilent Technologies, Santa Clara, CA). 
PCR amplification was performed in a 50µl volume reaction on GeneAmp® PCR 
System 9700 (see Table 8 and 9 for details).  
Table 8 Standard PCR reaction setup for single site directed mutagenesis 
PCR Component Volume 
10X Buffer for KOD Hot Start DNA 
Polymerase 
5 µl 
2mM dNTPs 5 µl 
25mM MgSO4 4 µl 
DMSO 1 µl 
template DNA(100ng/µl) 1 µl 
KOD Hot Start DNA Polymerase (1U/µl) 1 µl 
Sense (5') Primer (10 μM) 1 µl 
Anti-Sense (3') Primer (10 μM) 1 µl 
PCR-grade H2O 31 µl 
Total reaction volume 50 µl 
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Table 9 Standard thermal profile for single site directed mutagenesis. 
Step Thermal profile 
1.Polymerase activation 94°C for 5 min 
2.Denature 94°C for 15 sec 
3.Annealing 60°C for 30 sec 
4.Extension 72°C for 59 sec 
5.Repeat steps 2–4 17 times (18 in total) 
6.Stop 72°C for 5min and 4°C forever 
2.3.4.2.2 PCR product purification 
After PCR, 1µl DpnI was added into the PCR reaction and incubated for 90min at 
37°C in the Eppendorf Thermomixer so as to remove parental methylated DNA and 
hemi-methylated DNA. The PCR product was further purified using QIAprep Spin 
Miniprep Kit. Briefly, the PCR product was transferred to the spin column provided 
by the kit and centrifuge at 15682G for 60s to discard the flow-though. The silica 
membrane of column was then washed with 750μl buffer PE at 15682G for another 
60s. Finally, the purified PCR product was eluted in 20µl PCR grade water. 
2.3.4.2.3 Diagnostic Restriction Enzyme Digestion  
5µl of eluted DNA was transformed into chemically competent Escherichia coli 
DH10β as described in Section 2.3.1.3 and then streaked onto an LB agar plate 
(containing 50µg/ml spectinomycin). 3 colonies were randomly selected, purified 
with QIAprep Spin Miniprep Kit as described in Section 2.3.1.6.1. According to the 
restriction map for pDONR223 (see Figure 7), XbaI and NheI were selected to digest 
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the Miniprep product at 37°C  in the thermomixer for 60min (see Table 10 for 
details).  
 
Figure 7 Restriction map of pDONR223 
The diagram was provided by Dr Samantha J. Griffiths, Division of Pathway Medicine, 
University of Edinburgh. cDNA clone for human CXCR1 was inserted between attL1 and 
attL2. 
Table 10 Standard fast double digestion reaction set-up for Miniprep product 
Component Volume 
Enzyme 1 0.2μl 
Enzyme 2 0.2μl 
FastDigest Green Buffer (10X) 2μl 
10% Bovine Serum Albumin 2μl 
ddH2O 13.6μl 
Miniprep product 2μl 
NheI (239bp)
NheI (505bp)
NheI to NheI - 265bp
XbaI to NheI - 2131bp
ORF end at 2896bp
216 bp to 3’ end
ORF start at 652bp
147 bp to 5’ end
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The digests were analyzed by gel electrophoresis as described in Section 2.3.1.7 (see 
Figure 8 for a representative gel picture of the CXCR1 gene in pDONR223). 
Plasmids with the correct insert size were sequenced to check for point mutation. As 
expected, the C allele was discovered at nucleotide position 827 while the rest of 
the sequence remained unchanged. 
 
Figure 8 Restriction digest of the CXCR1 pDONR223 plasmid with XbaI and 
NheI  
Restriction fragments were run on 1 % TAE agarose gel. SYBR® Safe DNA gel stain was used 
for visualization of DNA under UV light. A backbone of 2131bp, an additional band 0of 
265bp (NheI to NheI) and CXCR1 (1053bp) with an extra 147bp at the 5’ end and 216bp at 
the 3’ end can be seen for all samples (lanes 1-3). CXCR1 fragment in each lane are 
indicated with *. DNA molecular weight marker is shown next to the lane 1, with the band 




2.3.4.2.4 Correction for the other unexpected mutations using multiple site 
directed mutagenesis PCR 
pDONR223 CXCR1 827G or 827C construct with 16G, 92T and 1003C was 
generated by multiple site directed mutagenesis using KOD Hot Start DNA 
Polymerase kit. Three pairs of primers were designed by the QuikChange® Primer 
Design Program (See Table 11 for details of the primer sets) and used simultaneously 
in the PCR reaction. The reaction was performed in a 50µl volume on GeneAmp® 
PCR System 9700 (see Table 12 for the reaction set-up) with the same thermal 
profile as single site directed mutagenesis (see Table 9 for the detailed thermal 
profile). 
Table 11 Primer sets used for multiple site directed mutagenesis 
Site/Primer type Primer sequence 
T16G/Forward primer 5'-atgtcaaatattacagatccacagatgtgggattt-3' 
T16G/Forward primer 5'-aaatcccacatctgtggatctgtaatatttgacat-3' 
G92T Forward primer 5'-gaagattacagcccctgtatgctagaaactgagaca-
3' 
G92T Reverse primer 5'-tgtctcagtttctagcatacaggggctgtaatcttc-3' 
T1003C Forward primer 5'-gagttcttggcacgtcatcgtgttacctcctaca-3' 








Table 12 Standard PCR reaction setup for multiple site directed mutagenesis 
PCR Component Volume 
10X Buffer for KOD Hot Start DNA Polymerase 5 µl 
2mM dNTPs 5 µl 
25mM MgSO4 4 µl 
DMSO 1 µl 
template DNA(100ng/µl) 1 µl 
KOD Hot Start DNA Polymerase (1U/µl) 1 µl 
Sense (5') Primer (10 μM) 1 µl/ set×3 
Anti-Sense (3') Primer (10 μM) 1 µl/ set×3 
PCR-grade H2O 27 µl  
Total reaction volume 50 µl 
 
PCR products for pDONR223 CXCR1 827G or 827C were purified and transformed 
into Escherichia coli DH10β as described in Section 2.3.4.2.2 and 2.3.1.3. 12 
colonies were selected from each plate and cultured in 96-well deep well plate with 
2ml/well LB medium containing 50µg/ml spectinomycin. Plasmid DNA was then 
extracted using alkaline lysis method as described in Section 2.3.1.6.2. According to 
the restriction map for pDONR223 (see Figure 7), XbaI and NheI were selected to 
digest the alkaline lysis product at 37°C  in the thermomixer for 60min (see Table 13 
for details). For each construct, 6 out of 12 digests were randomly picked and 
analyzed by gel electrophoresis as described in Section 2.3.1.7. All digests were 
found with correct insert size and therefore were all sent out for sequencing. 
Plasmids with major allele at all three nucleotide sites (i.e. 16, 92 and 1003) were 
selected for the following experiments. 
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Table 13 Standard fast double digestion reaction set-up for alkaline lysis 
product 
Component Volume 
Enzyme 1 0.2μl 
Enzyme 2 0.2μl 
FastDigest Green Buffer (10X) 2μl 
10% Bovine Serum Albumin 2μl 
ddH2O 4.6μl 
RNase A(10mg/ml) 1μl 
Alkaline lysis product 10μl 
 
2.3.5 Establishment of cell based models for CXCR1 rs2234671 
2.3.5.1 Transient Transfection model 
2.3.5.1.1 Transfer CXCR1 gene from pDONR223 vector to pCR3 destination vector  
After introducing the point mutation into the CXCR1 gene, both CXCR1-827G and 
CXCR1-827C genes were cloned from pDONR223 Gateway® Donor vector into 
pCR3 destination vector using LR recombination reaction according to 
the manufacturer's instructions (Gateway cloning system, Invitrogen, UK). The 
pCR3 destination vector containing the Gateway® cassette at an EcoRV site was 
previously generated in Prof Jurgen Haas’s lab. In brief, 1.5µl  pDONR223 with 
CXCR1 insert, 1µl  pCR3 destination vector (300ng/μl), 1μl of LR clonase® II 
enzyme and 1μl double distilled H2O (ddH2O) were mixed together and incubated at 
room temperature (RT) overnight. 1μl of this reaction mixture was then used to 
transform Escherichia coli DH10β as described in Section 2.3.1.3. Bacteria were 
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subsequently streaked onto LB agar plates (containing 100µg/ml Ampicillin). 10 
Colonies were randomly selected from each plate, purified as described in Section 
2.3.1.6.1 and restriction-digested with EcoRV. The digests were analyzed 
by gel electrophoresis as described in Section 2.3.1.7 (see Figure 9 for a 
representative gel picture of the CXCR1 gene in pCR3 vector).  
 
Figure 9 Restriction digest of the CXCR1 pCR3 plasmid with EcoRV 
Digests were run on 1 % agarose gel. SYBR® Safe DNA gel stain was used for visualization of 
DNA under the UV light. A backbone of 5.1kb and CXCR1 fragment (1053bp) with an extra 
124bp at both 5’ end and 3’ end can be seen for both 827G and 827C plasmids (lanes 1 and 
2, respectively). CXCR1 fragment in each lane are indicated with *. DNA molecular weight 
marker is shown in lane 3, with the band sizes shown on the right. 
2.3.5.1.2 Transient transfection of HeLa cells and HEK293 cells 
HeLa cells or HEK293 cells were seeded in antibiotic free growth medium 24 hours 
before transfection. Please see Table 14 for optimal seeding density of HeLa cells 
and HEK293 cells under different conditions. 
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Table 14 Optimal seeding density of HeLa and HEK293 cells 
Culture plates HeLa cells HEK293 cells 
6 well plate 5×105/well 6.25×105/well 
24 well plate 1×105/well 1.25×105/well 
96 well plate 2×104/well 2×104/well 
8 well chamber slide 6×104/well 7×104/well 
 
Plasmids to be transfected were diluted in Opti-MEM I Reduced Serum Medium and 
mixed with diluted lipofectamine 2000 according to manufacturer's instructions. 
Reaction volume was adjusted according to the size of the culture (see Table 15 for 
details).  











Plasmid  Lipofectamine® 
2000 
6 well plate 2500ng 12.5ul 2500ng 7.5ul 
24 well plate 500ng 2.5ul 500ng 1.5ul 
96 well plate 100ng 0.5ul 100ng 0.3ul 
8 well chamber 
slide 
300ng 1ul 300ng 0.9ul 
 
The plasmid-lipid mixture was incubated at RT for 20 minutes and then added 
directly onto cells. For HeLa cells, medium was changed for antibiotic free growth 
medium 6h after transfection to avoid cell toxicity. However, medium did not need to 
be changed for HEK293 cells within 24h. 
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2.3.5.1.3 CXCR1 expression in HEK293 cells by fluorescence microscopy  
HEK293 cells were plated in 96-well plate and transfected with one of the CXCR1 
expressing plasmid (pCR3-CXCR1 827G or pCR3-CXCR1 827C) or the vector 
alone (pCR3) using Lipofectamine 2000 as described in Section 2.3.5.1.2. The next 
day, cells were fixed with 10% neutral buffered Formalin solution at RT for 10min 
and blocked with 1% Bovine Serum Albumin (BSA) in PBS at RT for 1h. Finally, 
cells were stained with APC Anti-human CD1817 antibody (1 in 200 diluted in 1% 
BSA blocking buffer) in dark at RT for 30min. After rinsing with PBS, cells were 
examined at 10X magnification under the EVOS™ digital inverted microscope. 








                                                             






Figure 10 CXCR1 is expressed in pCR3-CXCR1 827G and 827C transfected 
HEK293 cells 
Picture A: HEK293 cells transfected with pCR3 (Left: view visualised under the transmitted 
light cube, Right: exact same field visualised under the Cy5 cube); Picture B: HEK293 cells 
transfected with pCR3-CXCR1 827G (Left: view visualised under the transmitted light cube, 
Right: the exact same field visualised under the Cy5 cube); Picture C: HEK293 cells 
transfected with pCR3-CXCR1 827C (Left: view visualised under the transmitted light cube, 
Right: exact same field visualised under the Cy5 cube); All pictures were taken at 10X under 
an EVOS™ digital inverted microscope (Advanced Microscopy Group, Bothell, WA) and the 






A) HEK293 cells 















2.3.5.1.4 CXCR1 expression in HeLa cells by confocal microscopy 
HeLa cells (1.2× 105/well) were plated in 8-well chamber slide 24h before 
transfection. The next day, cells were transfected with CXCR1 expressing plasmid 
(pCR3-CXCR1 827G or pCR3-CXCR1 827C), green fluorescent protein expressing 
plasmid (pCR3-GFP) or vector alone (pCR3) using Lipofectamine 2000 according to 
the manufacturer's instructions (with a final concentration of 300ng DNA and 1μl 
Lipofectamine 2000 reagent /well). The medium was changed 6h after transfection 
and the cultures were maintained for an additional 24h. Then, cells were fixed with 
10% neutral buffered formalin solution at RT for 10min, permeabilized with 0.5% 
Triton ™ X-100 at RT for 5min, blocked with 1% BSA in PBS at RT for 1h. Finally, 
cells were stained with APC-labelled anti-human CXCR1 antibody (1 in 200 diluted 
in 1% BSA blocking buffer) in dark at RT for 30min. After rinsing thrice with PBS 
and ddH2O, the chamber was removed and the slide was mounted with ProLong® 
Gold Antifade Mountant with DAPI and observed under a Leica TCS SP5 
confocal microscope. Figure 11 shows representative pictures of CXCR1 expression 












Figure 11 Expression of CXCR1 in pCR3-CXCR1 827C or 827G transfected 
HeLa cells 
HeLa cells were transiently transfected with pCR3-GFP, pCR3-CXCR1 827G or pCR3-CXCR1 
827C in an 8-well chamber slide. 30h after transfection, cells were fixed, permeabilized and 
stained with APC-conjugated mouse anti-human CD181 (CXCR1) antibody. The slide was 
mounted using ProLong® Gold Antifade Mountant with DAPI. All images were obtained by 
confocal microscopy. In each condition, representative images of the same field of view 
visualised under different channels (i.e. DAPI, GFP, APC and Merged) were shown. (A) Cells 
transfected with pCR3-GFP were stained negative for CXCR1. (B) Cells transfected with 
pCR3-CXCR1 827G were stained positive for CXCR1. C) Cells transfected with pCR3-CXCR1 
827C were stained positive for CXCR1.The scale markers represent 50μm in A, 10μm in B 
and 25μm in C. 
                      
 





















2.3.5.2 Stably transduced cell lines 
2.3.5.2.1 Transfer of CXCR1 gene from pDONR223 vector to pLenti6⁄V5-DEST® 
Gateway® vector  
CXCR1 827G and CXCR1 827C genes were cloned from pDONR223 Gateway® 
Donor vector into pLenti6⁄V5-DEST™ Gateway® Vector using LR recombination 
reaction according to the manufacturer's instructions. pLenti6⁄V5-DEST™ 
destination vector contains Gateway® cassette between attR1 and attR2 sites. In brief, 
1µl  pDONR223 with CXCR1 insert, 1µl  pLenti6⁄V5-DEST™ Gateway® Vector 
(300ng/μl), 2μl of LR clonase® II enzyme and 1μl double distilled H2O (ddH2O) 
were mixed together and incubated at RT (RT) overnight. 2μl of this reaction mixture 
was then used to transform electrocompetent Escherichia coli Stbl3TM as described in 
Section 2.3.1.4. Bacteria were subsequently streaked onto LB agar plates (containing 
100µg/ml Ampicillin). 10 Colonies were randomly selected from each plate, purified 
as described in Section 2.3.1.6.1 and restriction-digested with EcoRV. The digests 
were analyzed by gel electrophoresis as described in Section 2.3.1.7 Figure 12 shows 





Figure 12 Restriction digest of CXCR1 pLenti6⁄V5-DEST™ plasmid with EcoRV 
Digests were run on 1 % agarose gel. SYBR® Safe DNA gel stain was used for visualization of 
DNA under the UV light. A backbone of 6.9kb and CXCR1 fragment (1053bp) with an extra 
129bp at the 5’ end and 128bp at the 3’ end can be seen for both 827G and 827C plasmids 
(lanes 2 and 3, respectively). CXCR1 fragment in each lane is indicated with *. DNA 
molecular weight marker is shown in lane 1, with the band sizes shown on the left. 
2.3.5.2.2 Generation of lentivirus particles containing CXCR1 827G or827C  
1.5×106 293T cells were seeded in antibiotic-free growth medium in 10cm dishes and 
cultured overnight at 37°C, 5% v/v CO2, 100% humidity as described in Section 
2.3.1.8. The next day, each dish of cells was transfected with a mixture of the pLP1, 
pLP2, pLP/VSVG vectors, pLenti-based expression vector containing gene of 
interest and Lipofectamine 2000 (each dish finally contained 1μg of each plasmid 
and 12.5μl of Lipofectamine 2000). 24h after transfection, medium was changed for 
10ml fresh antibiotic-free growth medium. Cells were kept in culture for another 
three days with the morphology being closely monitored. Once syncytia were formed 
by the majority of cells (Figure 13), supernatant was collected by centrifuging at 




Figure 13 Syncytium formation in 293T cells producing recombinant 
lentiviruses 
Representative picture of lentivirus producing 293T cells 3 days after transfection with 
ViraPower™ lentiviral products. Syncytia formed by lentivirus producing cells were 
highlighted with white arrows. The picture was taken at 10X under an EVOS™ digital 
inverted microscope (Advanced Microscopy Group, Bothell, WA) and the scale bar=400μm. 
2.3.5.2.3 Determination of the minimum concentration of blasticidin used for 
selection 
CaSki and SiHa cells were chosen for the transduction. Both cell lines were seeded in 
24-well plate at a concentration of 1×105 cells/well. The next day, the normal growth 
medium was changed into medium containing a range of concentrations of 
blasticidin (0, 1, 2, 4, 6, 8, 10, 12µg/ml). Cells were cultured in blasticidin containing 
medium as described in Section 2.3.1.8 with the viability being closely monitored. 
Medium was changed every two days to maintain the blasticidin concentration until 
the minimum concentration of blasticidin that killed all the cells after 7 days was 
determined for each cell line. The optimal blasticidin selection concentration was 




2.3.5.2.4 Generation of stably transduced cell lines  
Cell lines were seeded in 12-well plates at a concentration of 2.5×105 cells/well. The 
next day, cells were transduced with 1ml supernatant containing lentivirus. Mock 
transduced cells were included for each cell line as controls for viability assessment. 
Medium was changed into normal growth medium on Day 3 and the selection was 
started on Day 4, with 4µg/ml blasticidin for CaSki cells and 2µg/ml blasticidin for 
SiHa cells. After reaching confluence, cells were split 1:4 into 6-well plates. 
Blasticidin containing medium was changed every two days to maintain stable 
selection concentration for each cell line. Once all the control cells were killed by 
blasticidin treatment, stably transduced cells were collected and expanded in 10cm 




Figure 14 Transduction of SiHa cells 
Representative pictures of transduced SiHa cells and mock-transduced cells under 2µg/ml 
blasticidin selection. Picture A: Parental SiHa cells (Mock transduced) were nearly all dead 
under blasticidin selection; Picture B: SiHa cells transduced with the CXCR1 827G gene 
survived after blasticidin selection; Picture C: SiHa cells transduced with the CXCR1 827C 
gene survived after blasticidin selection. All pictures were taken at 10X under an EVOS™ 
digital inverted microscope (Advanced Microscopy Group, Bothell, WA) and the scale 
bar=400μm. 
 





Figure 15 Transduction of CaSki cells 
Representative pictures of transduced CaSki cells and mock-transduced cells under 4µg/ml 
blasticidin selection. Picture A: Parental CaSki cells (Mock transduced) were nearly all dead 
under blasticidin selection; Picture B: CaSki cells transduced with the CXCR1 827G gene 
survived after blasticidin selection; Picture C: CaSki cells transduced with the CXCR1 827C 
gene survived after blasticidin selection. All pictures were taken at 10X under an EVOS™ 
digital inverted microscope (Advanced Microscopy Group, Bothell, WA) and the scale 
bar=400μm. 
2.3.5.2.5 Checking the genotypes of the parental cell lines, transduced cell lines 
and other cervical epithelial lines using Melting curve analysis 
Genomic DNA was extracted from each cell line using MasterPure™ Complete 
DNA and RNA Purification Kit following the manufacturer's instructions and then 
genotyped for rs2234671 using LightSNip assay described in Section 2.3.3. Figure 











Figure 16 Genotypes of Parental SiHa cells and transduced SiHa cells 
Picture A: Parental SiHa cells were G homozygotes for CXCR1 rs2234671; Picture B: SiHa 
cells transduced with the CXCR1 827G gene were still G homozygotes for CXCR1 rs2234671; 
Picture C: SiHa cells transduced with the CXCR1 827C gene became G/C heterozygotes for 
CXCR1 rs2234671. All pictures were generated using LightCycler ® Nano software V1.1.0.  
 
 
Figure 17 Genotypes of Parental CaSki cells and transduced CaSki cells 
Picture A: Parental CaSki cells were C homozygotes for CXCR1 rs2234671; Picture B: CaSki 
cells transduced with the CXCR1 827G gene became G/C heterozygotes for CXCR1 
rs2234671; Picture C: CaSki cells transduced with the CXCR1 827C gene were still C 
homozygotes for CXCR1 rs2234671. All pictures were generated using LightCycler ® Nano 
software V1.1.0.  
2.3.5.2.6 Assessment of CXCR1 expression using fluorescence microscopy  
Parental cells and transduced cells (1.2×105/well) were plated in 8-well chamber 
slide and cultured overnight. The next day, cells were fixed with 10% neutral 
buffered formalin solution at RT for 10min, permeabilized with 0.5% Triton 
™ X-100 at RT for 5min, blocked with 1% BSA in PBS at RT for 1h. Finally, cells 
A) Parental SiHa         B) CXCR1 827G SiHa            C) CXCR1 827C SiHa            
A) Parental CaSki          B) CXCR1 827G CaSki           C) CXCR1 827C CaSki          
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were stained with APC-labelled anti-human CXCR1 antibody (1 in 200 diluted in 1% 
BSA blocking buffer) in dark at RT for 30min. After rinsing thrice with PBS and 
ddH2O, the chamber was removed and the slide was mounted with ProLong® Gold 
Antifade Mountant with DAPI and observed 40X under the EVOS™ digital inverted 
microscope. Figure 18 and 19 show representative pictures of CXCR1 expression. 
 
 
Figure 18 Expression of CXCR1 in parental and transduced SiHa cells 
Parental SiHa cells and SiHa cells transduced with CXCR1 827G or CXCR1 827C were seeded 
in an 8 well chamber slide and cultured overnight. The next day, cells were fixed, 
permeabilized and stained with APC conjugated mouse anti-human CD181 (CXCR1) 
antibody (1:200). The slide was mounted using ProLong® Gold Antifade Mountant with 
DAPI. All images were obtained 40X under the EVOS™ digital inverted microscope. For each 
cell line, representative merged image taken under both DAPI and APC channels was shown. 
Picture A: parental SiHa cells were not positively stained with APC anti-CXCR1; Picture B: 
positively APC anti-CXCR1 stained cells were detected within SiHa cells transduced with the 
CXCR1 827G gene; Picture C: positively APC anti-CXCR1 stained cells were detected within 











Figure 19 Expression of CXCR1 in Parental and transduced CaSki cells 
Parental CaSki cells and CaSki cells transduced with CXCR1 827G or CXCR1 827C were 
seeded in an 8 well chamber slide and cultured overnight. The next day, cells were fixed, 
permeabilized and stained with APC conjugated mouse anti-human CD181 (CXCR1) image 
antibody (1:200). The slide was mounted using ProLong® Gold Antifade Mountant with 
DAPI. All images were obtained 40X under the EVOS™ digital inverted microscope. For each 
cell line, representative merged taken under both DAPI and APC channels was shown. 
Picture A: parental CaSki cells were not positively stained with APC anti-CXCR1; Picture B: 
positively APC anti-CXCR1 stained cells were detected within CaSki cells transduced with 
the CXCR1 827G gene; Picture C: positively APC anti-CXCR1 stained cells were detected 
within CaSki cells transduced with the CXCR1 827C gene.  
2.3.5.2.7 Check CXCR1 expression using flow cytometry 
Cells were washed with PBS and detached from the T75 flask by either 3ml 
Trypsin-EDTA solution or 5ml EDTA solution. Following cell detachment, cells 
were pelleted by centrifuging at 190G, 4°C for 5min and further washed twice with 
PBS. During the wash steps, cell clumps were broken up by 
gently pipetting up and down. Cells were resuspended at ~1 × 106 cells/100μl FACS 
wash buffer (PBS containing 2% FBS) and transferred to a 5ml Corning™ Falcon™ 
Round-Bottom Polystyrene Tubes. 5µl  Human TruStain FcX™ were mixed with the 
cells and incubated at RT for 10 min. APC Anti-human CXCR1 antibody 
(5ul/million cells) was then added to the cells and incubated in the dark for 30min 
(2–8º C). Excess antibody was removed by washing the cells with 2mL FACS wash 
A) Parental CaSki        B) CXCR1 827G CaSki       C) CXCR1 827C CaSki          
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buffer. The final pellet was resuspended in 400µl  FACS wash buffer 
before flow cytometric analysis with a 5 laser BD Biosciences LSR Fortessa analyser. 
FacsDiva software v6.1 (BD Biosciences, Oxford, UK) was used for digital data 
acquisition and post-acquisition analysis was performed using FlowJo software 
v7.6.5 (Tree Star Inc., Ashland, Oregon, USA). 
During flow cytometry, debris, dead cells and doublets were excluded step by step. 
Cells were identified according to their Forward light scatter, FSC (proportional to 
cell size) and Side light scatter, SSC (proportional to cell granularity or internal 
complexity) and investigated for their expression of CXCR1 (Figure 20 and 21 show 
representative flow cytometry plots for SiHa cells and CaSki cells respectively). The 
expression of CXCR1 by transduced cells was determined on a univariate histogram 
and a cut-off fluorescence intensity value of 5×103 was applied to determine CXCR1 
transgene expression in transduced cells. Since trypsinization did not affect CXCR1 
expression on transduced cells (see Figure 22), Trypsin-EDTA solution was used to 





Figure 20 Representative flow cytometry plots for parental and transduced 
SiHa cells 
A1-A3: pseudocolor plot with a gate encompassing singlets, pseudocolor plot with a gate 
encompassing parental SiHa cells and histogram of CXCR1 expression by parental SiHa cells, 
respectively; B1-B3: pseudocolor plot with a gate encompassing singlets, pseudocolor plot 
with a gate encompassing CXCR1 827G transduced SiHa cells and histogram of CXCR1 
expression by CXCR1 827G transduced SiHa cells, respectively; C1-C3: pseudocolor plot with 
a gate encompassing singlets, pseudocolor plot with a gate encompassing CXCR1 827C 
transduced SiHa cells and histogram of CXCR1 expression by CXCR1 827C transduced SiHa 
cells, respectively. By comparing with parental cells, a ranged gate is delineated in 
histograms to highlight transgene expression in transduced SiHa cells.  
A1                                                      A2                                                       A3
B1                                                      B2                                                       B3




Figure 21 Representative flow cytometry plots for parental and transduced 
CaSki cells 
A1-A3: pseudocolor plot with a gate encompassing singlets, pseudocolor plot with a gate 
encompassing parental CaSki cells and histogram of CXCR1 expression by parental CaSki 
cells, respectively; B1-B3: pseudocolor plot with a gate encompassing singlets, pseudocolor 
plot with a gate encompassing CXCR1 827G transduced CaSki cells and histogram of CXCR1 
expression by CXCR1 827G transduced CaSki cells, respectively; C1-C3: pseudocolor plot 
with a gate encompassing singlets, pseudocolor plot with a gate encompassing CXCR1 827C 
transduced CaSki cells and histogram of CXCR1 expression by CXCR1 827C transduced CaSki 
cells, respectively. By comparing with parental cells, a ranged gate is delineated in 
histograms to highlight transgene expression in transduced CaSki cells.  
 
A1                                                      A2                                                       A3
B1                                                      B2                                                       B3




Figure 22 Trypsinization does not affect CXCR1 expression on transduced 
cells 
A1-A3: pseudocolor plot with a gate encompassing singlets, pseudocolor plot with a gate 
encompassing CXCR1 827C transduced CaSki cells (detached with EDTA solution) and 
histogram of CXCR1 expression by CXCR1 827C transduced CaSki cells, respectively; B1-B3：
pseudocolor plot with a gate encompassing singlets, pseudocolor plot with a gate 
encompassing CXCR1 827C transduced CaSki cells (detached with Trypsin-EDTA solution) 
and histogram of CXCR1 expression by CXCR1 827C transduced CaSki cells, respectively; FSC 
parameter and SSC parameters of the cells were slightly different between the two 







2.3.5.2.8 Collect cells expressing high levels of CXCR1 by cell sorting 
As shown in Section 2.3.5.2.7, each transduced cell line is essentially 
a polyclonal pool of cells stably expressing different levels of CXCR1. Since 
variation in gene expression could hinder our ability to investigate the functional 
effects caused by CXCR1 rs2234671, transduced cells expressing the highest levels 
of CXCR1 were sorted so as to get a relatively uniform population. Briefly, 
transduced cells were cultured in T162 flask as described in Section 2.3.1.8. Once 
reaching confluence, cells were detached from the flask using Trypsin-EDTA (0.5%) 
and pipetted up and down to get rid of remaining clumps. Next, cells were counted, 
pelleted, washed with PBS and resuspended in 300µl FACS wash buffer (PBS with 2% 
FBS). Then, cells were stained with 15µl APC Anti-human CXCR1 antibody in the 
dark for 30min. Excess antibody was removed by washing the cells with 10ml FACS 
wash buffer at 190G, 4°C  for 5min. Cells were further filtered onto 40µm  Falcon™ 
Cell Strainers and resuspended in 1ml Pre-sort buffer (DMEM medium containing 1% 
FBS, 1% L-glutamine, 100μg/ml streptomycin and 100U/ml penicillin) at 10 
million/ml. Cells were sorted on FACSAria II with a 100µm nozzle with the help of 
Dr Mari Pattison at the Flow Cytometry and Cell Sorting Facility in the Queen's 
Medical Research Institute. Sorted cells were collected in 3ml collection medium 
(DMEM medium containing 50% FBS, 1% L-glutamine, 100μg/ml streptomycin and 
100U/ml penicillin) within Falcon™ 15mL Conical Centrifuge Tubes, spun down at 
190G, 4°C  for 5min and immediately cultured in normal growth medium. Genotypes 
of the sorted cells were checked using LightSNiP assay as described in Section 
2.3.5.2.5. Expression of CXCR1 in sorted cells was assessed using flow cytometry as 
described in Section 2.3.5.2.7. Mean fluorescence intensity (MFI) of CXCR1 
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expression was comparable between CXCR1 827G and CXCR1 C transduced cells 
after sorting (Figure 23 and 24 show representative flow cytometry plots for sorted 
SiHa cells and CaSki cells respectively). The MFI of CXCR1 expression on stably 
transduced cells showed little variance over time, regardless of passage number (data 
not shown). I also checked CXCR28 expression on these transduced cells. However, 
staining with PE anti-human CD182 (CXCR2) antibody did not produce any signal 
above background (data not shown).  
                                                             




Figure 23 Representative flow cytometry plots for parental and sorted 
transduced SiHa cells 
A1-A3: pseudocolor plot with a gate encompassing singlets, pseudocolor plot with a gate 
encompassing parental SiHa cells and histogram of CXCR1 expression by parental SiHa cells, 
respectively; B1-B3: pseudocolor plot with a gate encompassing singlets, pseudocolor plot 
with a gate encompassing CXCR1 827G transduced SiHa cells and histogram of CXCR1 
expression by CXCR1 827G transduced SiHa cells, respectively; C1-C3: pseudocolor plot with 
a gate encompassing singlets, pseudocolor plot with a gate encompassing CXCR1 827C 
transduced SiHa cells and histogram of CXCR1 expression by CXCR1 827C transduced SiHa 
cells, respectively. By overlaying the image of isotype control on each histogram (red 
outline), CXCR1 positive cells are identified as the blue peak on the right. Mean 
fluorescence intensity (MFI) of CXCR1 expression was 357 for parental SiHa cells, 1.7×104 
for CXCR1 827G transduced SiHa cells and 1.1×104 for CXCR1 827C transduced SiHa cells. 
A1                                                            A2                                                      A3
B1                                                            B2                                                      B3




Figure 24 Representative flow cytometry plots for parental and sorted 
transduced CaSki cells 
A1-A3: pseudocolor plot with a gate encompassing singlets, pseudocolor plot with a gate 
encompassing parental CaSki cells and histogram of CXCR1 expression by parental CaSki 
cells, respectively; B1-B3: pseudocolor plot with a gate encompassing singlets, pseudocolor 
plot with a gate encompassing CXCR1 827G transduced CaSki cells and histogram of CXCR1 
expression by CXCR1 827G transduced CaSki cells, respectively; C1-C3: pseudocolor plot 
with a gate encompassing singlets, pseudocolor plot with a gate encompassing CXCR1 827C 
transduced CaSki cells and histogram of CXCR1 expression by CXCR1 827C transduced CaSki 
cells, respectively. By overlaying the image of isotype control on each histogram (red 
outline), CXCR1 positive cells are identified as the blue peak on the right. Mean 
fluorescence intensity (MFI) of CXCR1 expression was 286 for parental CaSki cells, 8391 for 
CXCR1 827G transduced CaSki cells and 5398 for CXCR1 827C transduced CaSki cells. 
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2.3.6 Assays to investigate functional effects of rs2234671 
2.3.6.1 Investigation of the effects of rs2234671 on cell mobilization 
2.3.6.1.1 Chemotaxis assay 
To assess the functional consequence of the non-synonymous SNP CXCR1 
rs2234671 on IL-8 induced cell mobilization, a chemotaxis assay was performed in a 
transwell system (ABNOVA, 2010) which consists of hanging inserts (8.0µm  pore, 
6.5mm diameter) and a 24-well cell culture plate. HEK293 cells were seeded at 
6.25×105/well in a 6-well plate and transiently transfected with CXCR1 
expressing plasmid (pCR3-CXCR1 827G or pCR3-CXCR1 827C) or the control 
vector (pCR3). 24h after transfection, cells were trypsinized with 0.05% 
Trypsin-EDTA, quenched with 0.05% Soybean Trypsin Inhibitor solution and 
resuspended in low-serum medium (DMEM with 0.5% FBS) at 1×106 cells/ml. The 
bottom wells of the transwell system were filled with either 600μl DMEM plus 10% 
FBS medium containing 100ng/ml recombinant human IL-8 (see Figure 25 for the 
determination of the IL-8 concentration for the chemotaxis assay) or 600μl DMEM 
plus 10% FBS medium alone. To pre-wet the top compartment, 100μl of low-serum 
medium (DMEM with 0.5% FBS) was added first into each insert. Then, 100μl of 
the cell suspension was loaded into the insert and incubated for 6h (37°C , 5% v/v 
CO2, 100% humidity). After incubation, cells on the lower side of the insert 
(migrated cells) were carefully washed into the bottom well using 1ml PBS. This 
step was repeated 10 times and all the cell-containing fluid in the bottom well was 
transferred into a 15ml Falcon tube. Cells were pelleted by centrifugation at 190G for 
5min, and then resuspended in 500μl PBS, stained with 5μM 
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5(6)-Carboxyfluorescein diacetate N-succinimidyl ester (CFSE) in the dark at 37°C  
for 10min and quenched with 2ml ice cold DMEM plus 10%FBS medium. After 
being transferred to a new 24-well plate, cells were settled evenly at the bottom of 
each well by centrifugation at 190G for 3min and were observed under an EVOS™ 
digital inverted microscope. 
 
Figure 25 Determination of the IL-8 concentration for the chemotaxis assay 
In a single pilot experiment, 1×106 MM6 cells, which naturally express CXCR1, was loaded 
into the insert and incubated in the transwell system for 6h (37°C, 5% v/v CO2, 100% 
humidity). Cell migration towards different concentration of IL-8 (i.e.0, 30,100 and 
300ng/ml) were assessed by counting the total number of migrated cells in the lower 
chamber of the system after incubation. Since more cells were migrated towards growth 
medium containing 100ng/ml of IL-8, this concentration was determined as the optimal IL-8 
concentration for the following chemotaxis assays. Additionally, 100ng/ml of IL-8 has 
previously been used in chemotaxis assay for transfected HEK293 cells (Han et al., 2012). 
 
The assay was repeated three times with each condition performed in triplicate. 10 
non-overlapping images were taken at 10× magnification for cells migrated from 
each transwell and the average number of cells on these images was calculated. 
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Results for each assay were normalized to the average migration of pCR3 transfected 
cells in response to IL-8 and were presented as chemotactic index (see the equation 
below). Statistical analysis was performed using ordinary two-way ANOVA test and 
Sidak's multiple comparisons test. 
Chemotactic index=  
the number of cells that migrated in each transwell
  the average number of pCR3 transfected cells that migrated in response to IL−8 in triplicate tests in each assay
 
2.3.6.1.2 Wound healing assay 
To assess the functional consequence of the non-synonymous SNP CXCR1 
rs2234671 on IL-8 induced tumour cell migration, wound healing assay was 
performed in 24-well plate with parental CaSki cells and transduced CaSki cells 
expressing high level of CXCR1. Before seeding the cells, the plate was turned over 
and drawn with straight reference lines using a waterproof maker pen on the bottom, 
which cross each row of wells in parallel. Then, each cell line was seeded in 
sextuplicate at a concentration of 5×106cells/well in growth medium containing 10% 
or 2% of concentration of FBS. Once monolayer was formed in each well, a straight 
wound was made perpendicularly to the reference line using 200μl tips. The wound 
was washed twice with PBS and then observed under the EVOS™ digital inverted 
microscope. Two images were taken above and below the reference line at 10× 
magnification (see Figure 26 for the detailed experimental design of the wound 
healing assay) and the initial area of the wound was calculated using the ImageJ 
software. Briefly, the wound was demarcated manually using the Freehand selections 
Tool and the area was measured using the Analyze/Measure command. 
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For each cell line, three wells of cells were then treated with 100ng/ml IL-8 for 12h 
while the other three were cultured without IL-8. The incubation time was 
determined by a pilot experiment, in which nearly 50% of the initial area of the 
wound was covered by migrated CXCR1 827C transduced CaSki cells after 6h of 
IL-8 treatment (see Figure 27 for the determination of the incubation time for the 
wound healing assay). Upon completion of the incubation, the wound was washed 
twice with PBS and two images were taken above and below the reference line at the 
same locations. The area of the wound after 6h of incubation was also measured 
using the ImageJ software as described previously. Reduced area for each image was 
calculated by deducting the final area of the wound from the initial area (unit: pixels 
square). The migration of the cells was assessed based on the average reduced area of 
each well. The assay was repeated three times for each condition and statistical 








Figure 26 Schematic representation of the experimental design employed in 
the wound healing assay 
Parental CaSki cells and CaSki cells transduced with CXCR1 827G or CXCR1 827C were 
seeded in 24-well plate and cultured overnight. The next day, a straight scratch was made 
in each well using 200μl tips perpendicularly to the reference line. Images were obtained at 
10X magnification under the EVOS™ digital inverted microscope before and after IL-8 
treatment or mock treatment. In the figure above, the thick black line stands for the 
reference line while blue lines represent boundaries of the wound. The orange areas 
highlight the sites where images were taken. MRI Wound Healing Tool was obtained from 
http://dev.mri.cnrs.fr/projects/imagej-macros/wiki/Wound_Healing_Tool. Each image was 
firstly processed with the Find Edges function of ImageJ (Select Process> Find edges).Then, 
the "MRI Wound Healing Tool" toolset was selected from the >> button of the ImageJ 
launcher. Wound area was automatically calculated after pressing the m button. Manual 
measurements were only accepted if the boundaries could not be properly recognized by 
the tool.  
 
Figure 27 Determination of the incubation time for the wound healing assay 
In a pilot experiment, CaSki cells transduced with CXCR1 827C were seeded in 24-well plate 
and cultured overnight. The next day, a straight scratch was made in each well using 200μl 
tips perpendicularly to the reference line. Images were obtained at 10X magnification 
under the EVOS™ digital inverted microscope at 0h, 4h, 6h, 8h and 12h after 100ng/ml IL-8 
treatment. Reduced area at each time point for each image was calculated by deducting the 
final area of the wound from the initial area (unit: pixels square).The time point, at which 
nearly 50% area of the initial wound was covered by migrated cells, was determined as the 

























2.3.6.2 Investigation of the effects of rs2234671 on cell proliferation 
To assess the functional consequence of the non-synonymous SNP CXCR1 
rs2234671 on IL-8 induced tumour cell proliferation, proliferation assays were 
performed with both transduced CaSki cells and SiHa cells expressing high level of 
CXCR1 using Cell Counting Kit-8. Parental cells and cells transduced with CXCR1 
827G or CXCR1 827C were separately seeded in a 96-well plate at a concentration 
of 5000 cells/well. Then, the cells were treated with a range of concentrations of IL-8 
(0, 0.1, 1, 10 and 100ng/ml) for 48h. Each condition was performed in triplicate. 
Three wells containing only normal growth medium were included in each plate as 
blank controls. After IL-8 treatment, 10μl of CCK-8 solution was added to each well 
and incubated at 37°C, 5% CO2 for 3 hours. Each plate was then centrifuged at 190G 
for 10 minutes to get rid of bubbles. The absorbance of each well was measured at 
wavelength of 450nm and 650nm respectively using Synergy 
HT Multi-Mode microplate Reader. In order to correct for optical imperfections, 
readings at 650nm was deducted from the readings at 450nm. OD results of all the 
test wells were normalized to the blank controls within the same plate. Corrected OD 
value was directly employed in the proliferation rate calculation (see equation below) 
since it presented a good linear correlation with the cell number in each well. The 
proliferation assay was repeated three times and statistical analysis was performed 
using ordinary one-way ANOVA test and Sidak's multiple comparisons test. 
Proliferation rate= 
Average OD for test wells − Average OD for correspoding  non − IL − 8 wells 




2.3.6.3 Investigation of the effects of rs2234671 on angiogenesis  
To investigate whether CXCR1 rs2234671 affect angiogenesis indirectly by inducing 
vascular endothelial growth factor A (VEGFA) production, transcript variant 4 of 
VEGFA (NM_001025368.2, which encodes the most abundant and potent isoform 
VEGF165) was measured in both transient transfection model and stable 
transduction model in response to IL-8 stimulation. 
2.3.6.3.1 Investigation of the effects of rs2234671 on angiogenesis using transient 
transfection model 
HEK293 cells were transfected with pCR3, pCR3-CXCR1 827G or pCR3-CXCR1 
827C vectors as described in Section 2.3.5.1.2. Transfected HEK293 cells, together 
with mock transfected HEK293 cells, were treated with 100ng/ml IL-8 for a range of 
time periods (i.e. 6h, 8h, 12h and 24h). After treatment, cells were trypsinized, 
washed with PBS by centrifuging at 190G for 5min and harvested. RNA was isolated 
from each pellet and then cDNA was made as described in Section 2.3.1.10.  
The expression of VEGFA transcript variant 4 and GAPDH was analyzed in each 
cDNA sample using qPCR. VEGFA primers (forward: 5′-TCC TAT CTG AGC 
CAG ATG ACA TCC-3′; reverse: 5′-CCG GTC TCC CCC GGG TAC C-3′) were 
designed by Universal ProbeLibrary Assay Design Center according to 
NM_001025368.2 and used together with Universal ProbeLibrary probe: #51 
(Cat#: 04688481001, Roche Diagnostics Ltd. Burgess Hill, UK). qPCR reactions 
were performed as described in Section 2.3.1.11. Table 16 shows the detailed 
reaction setup.  
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Table 16 Standard qPCR reaction setup 
PCR Component Volume 
TaqMan® Universal PCR Master Mix 6.5 µl  
PCR-grade H2O 5.5µl  
GAPDH Prime& probe Set 
Or VEGFA Prime& probe Mix  
(fwd primer + rev primer + probe#51) 
1µl  
Or( 0.45µl +0.45µl +0.1µl ) 
cDNA template 2 µl  
Total reaction volume 15µl  
 
Data acquisition and post-acquisition analysis was performed using StepOne™ 
Software v2.3.VEGFA cycle threshold (CT) value of each sample was normalized to 
GAPDH by calculating ∆CT (∆CT= CTVEGFA-CTGAPDH). Then, the relative 
expression of VEGFA of each sample was calculated using ∆∆CT in comparison 
with average ∆CT for IL-8 treated mock transfected cells (∆∆CT=∆CT test sample 
-∆CTIL-8 treated mock transfected cells). Finally, fold change in each test sample compared 
with IL-8 treated mock transfected cells was calculated by 2-∆∆CT. Each condition was 
repeated at least three times and the qPCR was performed in duplicate for each 
sample. Statistical analysis was performed using ordinary two-way ANOVA test and 
Sidak's multiple comparisons test. 
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2.3.6.3.2 Investigation of the effects of rs2234671 on angiogenesis using stable 
transduction models 
Parental SiHa cells and SiHa cells transduced with CXCR1 827G or 827C were 
cultured with or without 100ng/ml IL-8 for 8h and then trypsinized, washed with 
PBS by centrifuging at 190G for 5min and harvested. RNA was extracted from each 
pellet using RNeasy Micro Kit and made into cDNA as described in Section 
2.3.6.3.1. PCR amplification and statistical analysis was also performed as described 
in Section 2.3.6.3.1. VEGFA fold change of each sample was compared with 
non-IL-8 treated parental SiHa cells. Same procedure was also performed with CaSki 



































Designing a SNP genotyping array to identify novel 














As mentioned in Chapter 1, with the results from GWAS studies there is a clear 
need to bridge the knowledge gap between genotype and phenotype to speed up 
conversion into real clinical benefits for individual patients. The ideal pipeline would 
start with the discovery of novel SNPs associated with a particular disease, followed 
by the replication and validation of the identified genetic associations, and 
supplemented with the translation of the genetic associations into biological insights.  
In comparison with traditional candidate gene approaches, GWA studies have been 
demonstrated to be a promising approach to identify novel susceptibility loci without 
needing prior knowledge. Examination of the literature showed that, based on 
NHGRI-EBI GWAS Catalog (MacArthur et al., 2016), four GWA studies have been 
published for cervical cancer, together with a newly published GWA study, which 
identified four potential predictive variants for platinum-based neoadjuvant 
chemotherapy (Li et al., 2017). However, validation and functional annotation of the 
significant findings turned out to be very tough.  
According to Google Scholar search results, the first GWA study performed in 
Swedish population for cervical cancer (Chen et al., 2013) has been cited 58 times. 
This GWA study directed researchers’ attention to the HLA region at 6p21.3, within 
which all 55 SNPs reaching genome-wide significant threshold (P < 5 ×10 −8) were 
identified. The authors of this study further confirmed their findings by independent 
replication in Swedish population (Chen et al., 2014b) and by pooling the results of 
two GWAS studies for CIN3 and cervical cancer (Chen et al., 2014a; Chen et al., 
2016). Apart from the three independent novel loci discovered in the original GWA 
study (rs2516448, rs9272143 and rs3117027), the group confirmed the associations 
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between previously reported HLA loci and risk of CIN3 and cervical cancer, which 
include HLA-B*07:02, -B*15:01, -DRB1*13:01, -DRB1*15:01,-DQA1*01:03,  
-DQB1*06:03 and -DQB1*06:02 and HLA-C*07:02. Also, they identified novel 
association signals at MICA-A4 and MICA-A5, and further pinpointed potential 
functional loci, including expression quantitative trait locus (eQTL) rs73730372, 
cis-eQTL rs9272143 and frameshift mutation rs67841474 (Chen et al., 2016; Chen 
and Gyllensten, 2014; Chen et al., 2013). A follow-up study was performed in an 
American population and associations between HLA-B*07:02, -DRB1*13:01, 
-DQB1*06:03, C*07:02, DQB1*06:04, DRB1*13:02 and cervical adenocarcinoma 
were identified. However, except for the studies mentioned above, the majority of the 
58 publications cited this GWA study only for general background. 
The situation was the same for the second most cited GWA study, in which 11 SNPs 
attained genome-wide significance in combined samples (Shi et al., 2013). Among 
all the significant SNPs, the association between rs8067378 and cervical cancer was 
confirmed in a Japanese population and a Polish population, but not in the previously 
mentioned Swedish population (Chen et al., 2016; Lutkowska et al., 2017; Miura et 
al., 2016). In the Polish study, the risk allele G was shown to correlate with increased 
Gasdermin B Expression. The association between rs4282438 and cervical cancer 
was replicated in a HPV positive Chinese population (Jia et al., 2016). The rest of the 
associations have neither been confirmed in Chinese population or any other 
population, and no functionally relevant SNPs have been further identified. Another 
GWA study performed in a Japanese population did not identify any SNP reaching 
genome-wide significance and the subsequent studies did not lead to discovery of 
novel disease related variants (Miura et al., 2014).   
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There is no doubt that GWA studies contributed to our knowledge about heritability 
of HPV related cervical disease, but it is not superior to a traditional candidate gene 
approach for providing well-validated actionable genetic variants. Although 
reproducible associations have been identified and some novel biological insights 
have been obtained from published GWA studies, many factors frustrate the 
continuation of the follow-up studies and functional annotation.  
One factor is the conservative threshold set for GWA studies due to statistical 
reasons. In array-based GWA studies usually around 750,000 tagSNPs are tested in 
parallel, and correction for multiple testing thus leads to the requirement of p-values 
of 5x10-8 for statistical significance. As a consequence, some real but weak or even 
moderate genetic associations would be missed by GWA studies unless an extremely 
large sample size was employed. Regarding this point, GWA studies mentioned 
above serve as good examples. Significant results were limited to within the HLA 
region at chromosome 6, of which the importance had already been shown 
extensively in pre-GWAS era. Chen et al showed that these genome-wide significant 
loci attributed only 2.1% of variation in susceptibility to cervical cancer (Chen et al., 
2015), which was much lower than the 27% estimated from nationwide family-based 
studies (Czene et al., 2002; Magnusson et al., 2000). Even though genome-wide 
complex trait analysis based on GWAS findings showed that common SNPs (defined 
as those with GMAF>5%) could tag 88.9% of estimated heritability of cervical 
cancer, the majority of the disease associated variants could not be unveiled from 
current GWA studies individually because of the small effect size (Chen et al., 2015). 
To detect such variants with small individual effects, GWA studies need to be 
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performed in a much larger sample population. Correspondingly, efforts and costs 
required will necessarily soar. 
Another factor affecting the outcome of GWAS is the coverage of the occurring 
genetic polymorphisms. GWAS findings highly depend on the genomic coverage of 
tagSNPs. Research on SNPs has been booming for the last two decades. According 
to Build 150 (released in 2017), dbSNP now has ~114 million validated SNPs with 
GMAF<1%, ~6 million SNPs with GMAF between 1% and 5%, and ~12.8 million 
SNPs with GMAF>5%. Even the number of common SNPs is now nearly twice as 
many as the one given in the previous estimate (Kruglyak and Nickerson, 2001). 
Within such a fast-growing field, SNP chips used in published GWASs were very 
unlikely to have good coverage and efficiency. In fact, whole-genome coverage rates 
of the chips used in the three published GWA studies of cervical cancer were all 
shown to be lower than 40% in the corresponding evaluated population (Ha et al., 
2014)9. Except for those long-established HLA loci, none of the previously reported 
non-HLA loci associated with cervical cancer was detected in the GWA study 
performed by Chen et al. Among the 82 cervical cancer-related gene/regions tested, 
25 were poorly covered in Human OmniExpress chip (Chen et al., 2015; Johanneson 
et al., 2014). If selected tagSNPs are not adequately covered, the actual causative 
SNPs (i.e. in high LD with causative SNPs) association signals would be too weak to 
be detected.  
                                                             
9 Human OmniExpress had 21% whole-genome coverage rate in evaluated European population. 
Axiom Genome-Wide CHB1 Array had 37% whole-genome coverage rate in evaluated Asian 
population. Axiom GW SNP Array 6.0 had 31% whole-genome coverage rate in evaluated Asian 
population.   
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In addition, limited access to the raw GWAS data also hinders the progress of 
functional validation and annotation. Currently, there is no complete GWAS raw 
dataset available to the public. The two most commonly used databases, GWAS 
central10 and GWAS Catalog11, only host significant results from published GWA 
studies (Beck et al., 2014; MacArthur et al., 2016). GRASP Search12 includes 
supplements and web-based content from publications on the basis of significant 
findings, but this database offers no more information than a comprehensive manual 
literature search (Leslie et al., 2014). dbGAP13 accommodates controlled-access 
primary data from some studies but it requires a complicated and time-consuming 
approval process to use (Wong et al., 2017) and unfortunately, this database has few 
data for HPV-related cervical disease.  
Furthermore, even though the use of tagSNPs saves costs for sequencing, it does not 
provide many functional biological insights. On most occasions, tagSNPs act as 
surrogate markers rather than actual functional variants. The real causal variants 
might be found more than 100kb away from the tagSNPs in high LD and they may 
exist as any forms (e.g. common variant, rare variant, structural variant etc.). (Reich 
et al., 2001). Therefore, extra efforts, such as extensively re-sequencing and 
dense-genotyping the up/downstream regions containing disease-associated tagSNPs, 
are always required to further locate the actual causal SNP. For example, Galarneau 
and colleagues successfully identified novel independent fetal haemoglobin 







associated SNPs and rare functional mutations through fine-mapping (Galarneau et 
al., 2010). However, because this kind of follow-up methods are usually quite costly 
and laborious, they have not been widely used and proved to be fruitful. In 
HR-HPV-related cervical disease, these methods have rarely been used. 
Thus, currently causal SNPs accounting for the majority of the heritability of cervical 
disease are still to be detected. With the rapid reduction in sequencing costs, high 
expectations have been placed on genome sequencing technologies, such as WGS 
and whole exome sequencing (WES), to drive this process (Bush and Moore, 2012). 
These studies are expected to identify novel disease related genetic variations with a 
higher resolution, to surpass the previously predicted “second generation of GWAS” 
and fully replace the chip-genotyping. Although some researchers have expressed 
concerns that the sharply increased amount of data generated from WGS and WES 
could make the cumbersome statistical analyses even more difficult (King and 
Nicolae, 2014), the shift from genotyping to genome sequencing now seems 
inevitable. With the launch of projects like Precision Medicine Initiative and the 
100,000 Genomes study (Collins and Varmus, 2015; England, 2016), together with 
the establishment of data sharing platforms and the development of new 
computational tools, more novel associations will be identified in the near future and 
underlying genetic mechanisms for HPV-related cervical cancer will be uncovered.   
While awaiting the progress from those large-scale genotyping or sequencing 
projects, researchers like me are also keen to make efforts to bridge the knowledge 
gap between genotypes and the underlying biological mechanisms. In the absence of 
strong financial and information resources, we still have to rely on traditional 
candidate gene approaches to identify novel disease associated variants and literature 
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mining to select potentially functional variants within candidate genes. The rationale 
of this method is pleiotropy (Stearns, 2010). Pleiotropy in this context is to describe a 
phenomenon that certain genes or some SNPs within or close to those genes are 
associated with multiple phenotypes and that these phenotypes are not necessarily 
overlapping or related to each other. A classic study published in 2011 confirmed the 
commonness of pleiotropy based on GWAS findings and showed the characteristics 
of pleiotropic SNPs. In this study, ~17% and ~5% known disease associated genes 
and SNPs respectively were conservatively estimated to be pleiotropic. Compared to 
non-pleiotropic SNPs, pleiotropic SNPs were shown to be enriched in exonic regions 
and more likely to be structurally functional (Sivakumaran et al., 2011). The ubiquity 
of pleiotropy was further supported by a number of studies (Bulik-Sullivan et al., 
2015; Pickrell et al., 2016). According to the findings from these studies, pleiotropic 
SNPs are plausible candidates to start a new candidate gene based association study. 
They have association signals detected previously in multiple diseases only because 
they are causal SNPs themselves or closely correlate with the real causal SNPs. If 
they are truly causal, they may affect multiple traits through a shared biological 
process or though different pathways, which makes them conspicuous targets for 
further functional assays. Although often being criticized for low region coverage, 
the candidate gene approach benefits from its flexibility in choosing potential targets, 
a characteristic welcomed by researchers aiming to make functional translations. 
When performing such an association study, researchers can focus on pleiotropic 
SNPs with known functions or those that reside within the coding regions or 
regulatory regions of a certain gene. If selected pleiotropic SNPs are known to be 
functional and they are associated with HPV-related cervical disease, the knowledge 
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about their functional effect can directly be employed to further elucidate the 
pathogenesis. On the other hand, if selected pleiotropic SNPs with no functional 
annotations are shown to be associated with HPV-related cervical disease, once their 
functional effects are identified in functional assays, the findings might be 
generalized to other related traits. The whole process, to some extent, is similar to 
drug repurposing. Since this process effectively reduces costs and saves efforts, it 
was chosen for this project. 
The aim of this chapter is to describe the panel design for the subsequent SNP array 
study. The panel targeted identification of novel functional variants in HPV-related 
cervical disease. The selection of the SNPs for this study was based on the 
hypothesis that “some known pleiotropic SNPs within genes affecting 
HR-HPV-related diseases are functionally associated with HR-HPV-related 
diseases”. All candidate SNPs were selected from pleiotropic SNPs within a group 
of genes of interest on the basis of a comprehensive literature search. The selection 
of the candidate genes is described in Section 3.2.The literature search performed for 
the extraction of pleiotropic SNPs is described in Section 3.3. And the final panel 
applied in the SNP array is described in Section 3.4. 
3.2 Selection of the candidate genes for the SNP array  
For ease of handling, I mainly focused on a small group of genes/regions rationally 
selected from a chemokine profile study of cervical disease previously performed in 
our group, and, from two published array-based genetic association studies (Safaeian 
et al., 2012; Wang et al., 2010). The selected panel consisted mainly of genes 




3.2.1 Candidate genes from the chemokine profile study   
The chemokine profile study was previously performed with R&D Systems 
Proteome Profiler™ Human Chemokine Array using protein samples extracted from 
LBC samples. A number of chemokines were found to be up-regulated in pooled 
HR-HPV positive CIN 1, CIN2 or CIN3 samples, compared with pooled HR-HPV 
negative samples. Since very few SNPs within the chemokine or chemokine receptor 
genes have been investigated in HPV-related diseases (as mentioned in Chapter 1), 
genes encoding these chemokines were all chosen as candidate genes for further 
selection steps. In particular, some chemokines (e.g.CCL2, CXCL1, CXCL8, 
CXCL10, CXCL12 etc.) were found to be up-regulated in HR-HPV positive high 
grade cervical disease on both the Luminex® and the microarray platforms. Thus 
SNPs within genes encoding these chemokines or their corresponding receptors had 
some priority over other SNPs in the final selection step. 
3.2.2 Candidate genes from two published array-based genetic 
association studies  
Prior to the GWAS era, two consecutive large-scale array-based association studies 
performed in the same Costa Rican cohort aroused widespread attention (Safaeian et 
al., 2012; Wang et al., 2010). By extensively genotyping SNPs within rationally 
selected genes (e.g. immune genes, DNA repair genes, viral binding and cell entry 
genes, etc.), a number of novel susceptibility loci were identified for persistent HPV 
infection and for the progression to pre-cancer/cancer (See Chapter 1 for details). 
Some of the findings were shown to be reproducible in studies involving simple 
replication (Colacino-Silva et al., 2017; Famooto et al., 2013). In order to increase 
132 
 
the power to explore the underling genetic architecture and disease mechanisms, the 
adaptive rank truncated product method was used to condense SNP level p values 
within genes and regions in these two array-based studies. Briefly, top K smallest 
single SNP p values within a certain gene/region were combined through the 
truncated product method and the optimal truncation point k was determined in an 
adaptive way (Dudbridge and Koeleman, 2004; Yu et al., 2009).  
In complex diseases, it is very common to find that a given gene contains more than 
one causal SNP and the association signals generated by these causal SNPs are 
loosely captured by other SNPs in strong or moderate LD. Since tagSNPs selected in 
these two studies could not completely cover the gene/regions, the gene-level 
summary statistics sparked later researchers’ interest in mining for novel disease 
associated variants either dependent or independent of the original association 
signals within the same related gene/regions. For example, Castro and colleagues 
further genotyped 12 novel SNPs within the TMC6 and TMC8 genes and 
successfully identified two novel SNPs (rs16970849 and rs2290907) independently 
associated with cervical cancer susceptibility in the Swedish population (Castro et al., 
2012). In this project, I included all 37 genes with gene-level p value <0.01 in the 
two mentioned array-based studies as candidate genes but mainly focused on 
pleiotropic SNPs that are independent of the original 19 significant findings. Since 
only a small fraction of women with persistent HPV infection will finally develop 
pre-cancer lesions and cervical cancer, genes involved in this transition merit more 
attention in further investigations. For this reason, 17 genes with p value <0.05 in 
tests for associations with progression to cervical pre-cancer/cancer were also 
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included. However, SNPs within genes with smaller p values were given higher 
priority in the final selection step. 
3.2.3 The final list of candidate genes  
As mentioned above, candidate genes were confined to those that were highlighted in 
HPV-related cervical disease and with key roles in multiple biological processes. The 
final candidate gene list consists of 22 chemokine genes, 7 chemokine receptor genes 
and 54 other genes that are potentially associated with persistent HPV infection or 
cervical cancer (see Table 17 for the complete list of candidate genes/regions 
involved in the project). Borrowing ideas from the pathway-based approach, Search 
Tool for the Retrieval of Interacting Genes/Proteins (STRING)14 was also used to 
provide supplementary information for the next selection step at pathway level (see 
Appendix 2 for the protein-protein interactions among the proteins encoded by 
candidate genes). However, since no distinct pathways other than chemokine system 
related processes were identified, this piece of information was not taken into 
account when determining the priority of the candidate SNPs in the next step. 
 
                                                             














3.3 Selection of pleiotropic SNPs within candidate genes  
Literature mining was used for the selection of candidate SNPs within candidate 
genes/regions (see Figure 28 for the flow chart showing the whole selection 
procedure for candidate SNPs). In order to pick out all previously reported 
pleiotropic SNPs, I performed a comprehensive literature search using PubMed SNP 
database on all the candidate genes/regions (https://www.ncbi.nlm.nih.gov/pubmed/) 
and carefully reviewed all the SNPs that have been investigated in articles published 
in English before February 2015 within each gene/region.  
Since an extremely large sample size would have been required to detect rare variant 
associations but only a limited number of clinical samples were available for the SNP 
array, SNPs with a GMAF<5% were excluded in the first round of selection. 70 of 
the 83 candidate genes had at least one published common SNP (GMAF≥5%) in the 
PubMed SNP database. No published common SNPs were identified for the other 13 
candidate genes, including CXCL4, Midkine, EVPL, GJA1, MBD3L1, MOCS2, 
PRLH, FLJ35220, ITGA7, GSTCD, XCR1, MED24 and C1RL.  
In total, 630 validated common SNPs were identified in candidate genes/regions. 
Among all the validated common SNPs (see Appendix 3 for the complete list), only 
clinically significant SNPs or disease associated SNPs were included in the second 
round of selection. 275 of these 630 SNPs were found to be associated with at least 
one disease. In order to fit in a custom multiplex SNP array with a reasonable cost, a 
set of 32 SNPs was further selected from the 275 disease-related SNPs based on at 
least one of the following criteria: 1) previously shown to be functional; 2) 
non-synonymous SNPs or SNPs reside within regulatory regions (e.g. promoter, 
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enhancer, insulator, microRNA binding site etc.); 3) in high linkage disequilibrium 
with other candidate SNPs; 4) within chemokine or chemokine receptor genes 
identified in the previous chemokine profile study; 5) previously shown to be 
associated with multiple diseases, especially infectious diseases and cancers; 6) with 
high GMAF; 7) within genes with confirmed functional effects in HPV associated 
diseases. 
 
Figure 28 Flow chart with the selection procedure for candidate SNPs 
3.4 The final panel of 32 SNPs involved in the SNP array 
A subset of 32 SNPs was chosen for the final SNP array (see Table 18 for the full 
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chemokine genes found to be up-regulated in HR-HPV positive high grade cervical 
disease in the chemokine profile study, 3 chemokine receptor genes which encode 
receptors bound for more than one of the chemokines of interest, and 12 genes (9 
with p<0.01 and 3 with p<0.05) from the two published array-based genetic 
association studies. All of the 32 SNPs are biallelic. The global minor allele 
frequency of these 32 SNPs ranges from 0.06 to 0.48. Most of these 32 SNPs were in 
high LD with other candidate SNPs in the long-list and thereby were also used as 
proxies for other unselected SNPs. Among the 32 SNPs, 17 were shown to have 
impacts on gene expression or function; 31 were involved in other cancers or 
infectious diseases; 4 were missense SNPs and 13 were found in the promoter region. 
In addition, 29 of the 32 SNPs had off-the-shelf TaqMan® SNP Genotyping Assays 
available. Custom TaqMan® Assays were designed by Applied Biosystems™ for the 
other 3 SNPs, including rs16970849, rs2234671 and rs17849071. Another 
noteworthy point is that TMC8 rs16970849, CD83 rs853360, TNF-α rs1800629, 
TNF-α rs361525 were deliberately included in the array as they all had been reported 
to contribute to cervical cancer susceptibility in other populations (Bodelon et al., 
2012; Castro et al., 2012; Liu et al., 2012a; Zhang et al., 2007). Their associations 
with HPV-related diseases would be assessed in Scottish population in this project. 
Additionally, OAS1 rs34137742 had been shown to be associated with cervical 
cancer in a pilot experiment in our group compared with female European controls 
extracted from 1000Genomes database (data not shown). This association would be 
re-validated in comparison with samples from HPV negative cytologically normal 
Scottish women as controls. 
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Table 18 the 32 candidate SNPs selected for the SNP array 
 
 










































CXCL1 rs4074 intron variant A/G G=0.4044/2024 Hepatitis C 22173151 YES YES
CXCL1 rs3117604 upstream variant 2KB C/T T=0.4728/2367 Ischemic stroke 23198952 No upstream






























































































































































































































































A/G A=0.1430/715 Cervical diseases 21387292 YES No downstream
TYMS rs2790
intron variant,






























































































































YES YES upstream 








ACKR2 rs4683336 intron variant C/T C=0.3664/1835 Hepatitis C 18822328 YES YES
CXCR1 rs2234671 missense C/G G=0.1442/721 Hepatitis B 23396733 YES No missense
CXCL12























Very few follow-up studies have been performed to verify the results of the previous 
association studies and to further locate functional variants within the genes 
differentially expressed in HPV-related diseases. According to past experience, 
traditional candidate gene/SNP studies based solely on prior knowledge and 
hypothesis are quite inefficient and unlikely to accelerate the discovery of functional 
variants. Simply deep re-sequencing the genomic regions highlighted by GWASs or 
array-based studies for causal variants is costly and was unfeasible in the current 
project. There are no conventional guidelines or well-established selection 
procedures available to cost-effectively follow up existing genetic association studies 
and pinpoint SNPs for functional studies. Hence, an evidence-based strategy was 
proposed for choosing potentially functional SNP on the basis of the biological 
pleiotropy at the allelic level, with the goal of improving the power to detect novel 
causal variants and minimizing the number of samples needed. Since this strategy 
allowed the prioritization of known functional SNPs, non-synonymous SNPs and 
SNPs in promoter regions, it was expected to speed functional variant identification 
in HPV-related diseases in a small scale project with a limited budget. It might also 
be applied in other diseases for the identification of functional SNPs  
This whole project was started in October, 2014 and the literature search was 
completed by the end of January, 2015. Considering present-day standards, 
several limitations of the panel design have to be acknowledged. Unavoidably, this 
design suffered from a common failing of many candidate gene approach based 
studies: inadequate coverage of the candidate gene/regions. Although rationally 
selected SNPs rather than randomly chosen SNPs were employed to improve the 
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power to detect the potentially functional variants and reduce the number of samples 
required, the possibility that real causal variants were missed within the same 
gene/region could not be excluded. Furthermore, since only one or two SNPs in weak 
linkage disequilibrium or in complete linkage equilibrium within each gene were 
included in the SNP array, it was impossible to perform haplotype based analysis or 
assess the joint effects of the association signals.  
Another limitation is the lack of knowledge regarding genomic characterization and 
gene annotation. Identification of disease related SNPs is a very active and dynamic 
research field. A lot of powerful predictive tools used extensively at the moment 
were either not available or not being aware at the beginning of the project. For 
example, to determine priority of the candidate genes or SNPs at the gene-level, a 
piece of evidence frequently used now is the survival assessment of each gene based 
upon TCGA cervical squamous cell carcinoma and endocervical adenocarcinoma 
(CESC) database15. Using the newly released web based tool GEPIA (Tang et al., 
2017), it is really convenient to evaluate the prognostic value of a particular gene in 
the mentioned database. Out of all the chemokines and chemokine receptors 
identified to date, higher expression of CCL20 [hazard ratio (HR) 1.6, P = 0.043], 
CXCL1 [HR1.7, P = 0.035], CXCL3 [HR1.8, P = 0.019], CXCL4 [HR1.7, P = 
0.029], CXCL5 [HR1.8, P = 0.012], CXCL8 [HR2.9, P = 3.4e-05] and CXCR1 
[HR1.6, P = 0.048] were predictive for poor overall survival in this dataset. While 
higher expression of CCL17 [HR0.49, P = 0.003], CCL25 [HR0.6, P = 0.035], 
CX3CL1 [HR0.48, P = 0.0036], CCR2 [HR0.52, P = 0.0067] and CCR7 [HR0.47, P 
= 0.0019] was associated with a reduced overall survival in cervical cancer patients. 




Among all the candidate genes selected from the two published array-based studies, 
GJA1 [HR1.8, P = 0.02], TMC8 CCR7 [HR0.46, P = 0.0014], TYMS [HR0.62, P = 
0.044] and CD83 [HR0.61, P = 0.041] were also found to be associated with the 
overall survival (see Appendix 4 for the Kaplan Meier curve of each gene 
mentioned). Except for the predictive tools at gene level, there were also some tools 
used to forecast the functional effects of known SNPs, such as SIFT16, PolyPhen-217, 
SNPnexus18 and MutationTaster19. If findings like these were available or aware at 
the time of panel design, unquestionably they would affect the strategy making. 
However, although the current panel failed to highlight all the above genes and SNPs 
within them, it still successfully covered some intriguing targets. For instance, at 
least one SNP was selected in the actual array for CXCL1, CXCL8, CXCR1, TMC8, 
TYMS and CD83 and most of them were known as functional variants or located 
within functional regions of the corresponding genes. 
Furthermore, my newness to this research field and my inexperience at the beginning 
of the project also contributed to the limitations of the panel design. As a rookie 
researcher, I was incapable of selecting disease related SNPs with a critical eye. The 
initial inclusion of the disease related SNPs only relied on the statistical significance 
reported in the main text or supplementary documents but without any further 
evaluation. It now seems that more attention should have been paid to the details of 
the studies since mistakes were not infrequently observed in published association 







studies. For example, improper interpretation of the statistical analysis was observed 
in a study mentioned previously (Jia et al., 2016). In their table 3, illogical 
comparisons were made and conclusions without biological meaning were drawn. 
Similar mistake was also observed in the supplementary Table 3 of another 
association study (Hsing et al., 2008). Additionally, overt plagiarism and potentially 
fabrication of data was also found in one publication (Li et al., 2016)20. Taking all 
these conditions into account and re-evaluating the whole list of published SNPs, the 
current long list of candidate SNPs might be slightly changed. However, since more 
stringent standards were applied in the following selection steps, candidate SNPs in 
the short list were unlikely to be affected.  
The rationally selected panel used was an active attempt to pinpoint potentially 
functional variants in HPV-related disease in a rational and inexpensive way. 
Although it was not perfect and only fitted in a small scale array, its feasibility and 
effectiveness are shown in the following results chapters. Just as statesman Deng 
Xiaoping said “It does not matter if a cat is black or white, so long as it catches 
mice”. Like everyone working in the same field, I look forward to every new 
cost-saving method and strategy that could accelerate the identification of functional 
variants and I believe a widely applicable method will come out in the near future, 
along with the rapid development of sequencing techniques. But still, no matter how 
fancy and comprehensive are the in silico prediction tools and computational 
methods, the key results and the basis of clinical translation would always be direct 
functional and biological evidence. 
                                                             









Chapter 4  
Results of the SNP array and further validation of the 












As mentioned before, a few SNPs associated with HPV-related diseases, especially 
cervical cancer, were identified through traditional candidate gene based association 
studies and GWA studies. These findings provide unequivocal evidence that cervical 
cancer, like other complex diseases, is highly polygenic and the majority of disease 
related SNPs have fairly small effects, of which the odds ratios are usually below 2 
(Wang et al., 2015).  
Most of these studies were performed with a case-control setting. As a classic 
experimental design, the history of case control study can be traced back to 1926 
(Paneth et al., 2002). It was not only the preferred design for genetic association 
studies but was also extensively used for other epidemiological studies due to its 
effectiveness and resource saving property. In this project, the SNP array was also 
performed in a case-control setting. The association between the presence of a 
particular SNP and disease susceptibility was assessed by comparing the differences 
of allele frequencies or alternatively genotype frequencies between case and controls.   
Theoretically, genomic DNA extracted from any source can be used for genetic 
association studies, with the success and outcomes of such studies being heavily 
reliant on the genotyping or sequencing methods employed. The most commonly 
used sample types including blood, saliva, normal cytology specimens and tissue 
specimens. In recent years, a consensus has been gradually reached in the cancer 
research field that SNPs can be distinguished from somatic mutations through their 
concordance between germline DNA and tumour DNA, and from germline mutation 
by its higher prevalence in the population (Karki et al., 2015). Therefore, frozen 
tumour tissue specimens and formalin-fixed paraffin-embedded tumour tissue 
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specimens are frequently used as well. Focus on the allelic imbalance phenomenon 
also led to the justification of analysing mRNA and cDNA samples. In this case, 
discordance might be observed between tumour and normal tissue even if no 
difference was observed in the genomic primary sequence.  
The choice of genotyping methods selected for association studies is dependent on 
the number of SNPs under investigation and the number of individuals tested. 
Two PCR based methods were chosen in this project: the TaqMan® SNP genotyping 
assay and the LightSNiP assay. The TaqMan® SNP genotyping assay is the most 
commonly used genotyping method in candidate gene based studies. It is designed 
based on 5’ Nuclease assay process (see Figure 29 for the schematic diagram of 5’ 
Nuclease assay process). For a particular biallelic SNP, probes are made for each 
allele with different reporter dye attached to the 5′ end and a non-fluorescent 
quencher at the 3′ end. In each reaction, AmpliTaq Gold DNA polymerase cleaves 
only the probes hybridizing to the template strands and releases the reporter dye from 
the suppression of the quencher molecule. The released reporter dye then becomes 
fluorescent and the cumulative fluorescent signals are detected by the PCR Platform 
(AppliedBiosystems, 2010). A substantial increase in fluorescence intensity of a 
reporter dye during PCR amplification indicates the existence of the corresponding 
allele in the test sample (see Figure 4 in Section 2.3.2.2 for the representative raw 




Figure 29 Schematic diagram representing the principle of the TaqMan® SNP 
genotyping assay 




The LightSNiP assay had been adopted by our group as a “gold-standard” method. It 
was designed by TIB Molbiol (Berlin, Germany) on the basis of the SimpleProbe® 
and LightCycler Technology (see Figure 30 for the schematic diagram of 
SimpleProbe® detection). Although this genotyping method is also PCR based, the 
SimpleProbe® probes do not participate in the PCR amplification. A specific probe 
is designed to span the locus of interest with a reporter dye and a non-fluorescent 
quencher linked at the same end of the oligonucleotide. While hybridizing to the 
template DNA, the quenching effects of the probes are reduced, allowing the signals 
to be detected. A subsequent melting curve analysis follows the final cycle of the 
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PCR reactions where the PCR products are gradually heated up to 75°C . As the 
temperature increases, the hybridization between the probe and the template become 
disturbed and the quenching effects gradually enlarge. By plotting the negative 
derivative of the sample fluorescence against temperature, melting peaks of each 
sample are generated (see Figure 5 and 6 in Section 2.3.3 for the representative 
melting peaks generated by the LightSNiP assay). Perfectly matched probe and DNA 
template will always have higher melting peaks than mismatched probe and DNA 
template due to higher hybridization stability and this difference is used to determine 
which alleles are present in the test samples. For a biallelic SNP, homozygotes will 
have either the higher (if the allele present is the same as the probe oligonucleotide) 
or lower melting peaks (if the allele present differs from the probe oligonucleotide) 
while heterozygotes will have both peaks (Cheli et al., 2015).  
 
Figure 30 Schematic diagram representing the principle of the LightSNiP 
assay 





In this project, TaqMan® SNP genotyping assay was used in both the SNP array and 
the subsequent validation step. In the SNP array, TaqMan® SNP genotyping assays 
for selected SNPs were pre-loaded and dried down in the through holes of the 
microscope slide–sized plate platform while for the validation of the significant 
findings, the single tube TaqMan® SNP genotyping assay was applied. In contrast, 
LightSNiP assay was only used in the validation experiments.  
Before assessing the association between a particular SNP and the disease condition 
based on the genotyping results, a critical routine test of Hardy-Weinberg 
equilibrium (HWE) was performed for each SNP in the disease free controls. The 
Hardy-Weinberg principle was named after its discoverers Wilhelm Weinberg and G. 
H. Hardy. They demonstrated that when a random-mating general population was not 
disturbed by evolutionary forces, such as mutation, selection, genetic drift and gene 
migration etc., HWE would be reached and the allele and genotype frequencies of 
individual loci would be constant among generations (Wigginton et al., 2005). If the 
source population do not violate HWE, representative controls sampled from this 
population should also compatible with HWE while the purposively selected cases 
do not necessarily maintain HWE. A significant departure from HWE for a single 
locus observed in sampled controls often indicates a failure to reflect 
representativeness and homogeneity and this is may be driven by a selected 
population, non-random genotyping errors and non-random missing genotype data 
(Namipashaki et al., 2015). A goodness-of-fit chi-square test was utilized to detect 
the deviation between actual genotype counts and the expected HWE genotype 
counts, which were calculated on the basis of the frequency of each allele following 
154 
 
HWE law. Normally, SNPs that significantly deviated from HWE (with a p value < 
0.01) were excluded from the association analyses (Lunetta, 2008).   
SNPs that passed the HWE criterion were further evaluated in the association 
analyses. Since the underlying genetic model is unknown beforehand, statistical 
approaches have been proposed separately for each possible genetic model. In 
genetic association studies, the five most commonly seen models are co-dominant, 
dominant, recessive, over-dominant and log-additive inheritance models (Horita and 
Kaneko, 2015; Solé et al., 2006). These models are defined according to the number 
of copies of the risk allele needed to alter the disease risk. Binary logistic regression 
can be applied for all of these models in conjunction with adjustment of possible 
confounding variables. The co-dominant model assumes that each allele confers a 
different and non-additive risk. Under this model, each genotype is treated as a 
nominal categorical variable in a logistic regression. The dominant model assumes 
the risk allele confers the same risk irrespective of the numbers of risk allele a person 
has. In contrast, the recessive model assumes that only the homozygous carrier of the 
risk allele has an increased risk. In logistic regression analysis, homozygotes and 
heterozygotes of the risk allele are treated as the same variables for a dominant 
model while according to the recessive model, homozygotes of the non-risk allele 
and heterozygotes are treated in the same way. The over-dominant model, where 
homozygotes of both alleles are treated equally, is less common in the natural world, 
which suggests that heterozygotes have a more pronounced or better adapted 
phenotype than either homozygote. Unlike the models described, the log-additive 
model (also called multiplicative or allelic model) assesses the association based on 
allele counts rather than genotype frequencies and it is valid only when cases and 
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controls are both in HWE. It assumes that if heterozygous carriers of a risk allele 
confer r-fold increased risk, homozygotes of the risk allele will bear r2-fold increased 
risk. This method is often criticized by geneticists as an unrealistic model since its 
unit of analysis is the chromosome rather than individual person, which hinders the 
biological interpretation of the association signals. However, it is commonly used as 
a primary analysis tool for association studies since the adoption of the chromosomes 
as test units intentionally doubles the sample size and therefore improves the chances 
to detect deep-hidden associations (Dorak, 2016).  
Under each genetic model, the strength of the association between a particular SNP 
and disease outcome is measured by the odds ratio (OR). Here, a biallelic SNP with 
major allele M and minor allele m is used as an example. Under log-additive model, 
the allelic OR of m allele was estimated by the ratio of the odds of developing the 
disease with m allele to the odds of developing the disease with M allele 21 . 
Comparatively, according to the four genotype based models, genotypic OR is used 
rather than allelic OR. A specific genotype or the combination of two genotypes is 
chosen as the reference genotype depending on the model employed. Genotypic OR 
of a particular genotype is calculated according to the ratio of the odds of developing 
the disease with the genotype of interest to the odds of developing the disease with 
the reference genotype22. 95% confidence interval (CI) was calculated using the 
following equation: ln(OR) ± 1.96 × standard error of ln(OR) for each OR 
estimated, which means that if we use same sampling methods to select different sets 
                                                             
21 OR m allele=
m counts in cases
m counts in controls
M counts in cases
M counts in controls
⁄  
22 OR genotype of interest(GOI)= 
GOI Counts  in cases
GOI counts in controls
Reference genotype counts in cases




of samples and calculate CIs, approximately 95% of the CIs calculated will include 
the true mean. If the 95% CI does not span the null value 1, the association is 
statistically significant at the 5% level. The lower limit of the 95% CI above 1 
usually indicates a positive association with the disease outcome while the upper 
limit below one denotes a negative correlation (Dorak, 2016). 
When testing the association between a single SNP and a disease outcome, a 
conventional 0.05 significance level cut-off is generally used. It indicates that the 
null hypothesis has only 5% of chance to be incorrectly rejected. However, when 
multiple SNPs are involved in the association study and the cut-off is still 0.05 for 
each test, the probability of incorrectly rejecting at least one null hypothesis can 
escalate considerably (e.g. Inclusion of 32 independent SNPs results in 80.6% of 
chance of getting at least one false positive results)23. To counteract the above 
problem, many correction methods have been suggested by researchers, such as 
Bonferroni (Dunnett, 1955), Holm (Holm, 1979), Hommel (Hommel, 1988), 
Hochberg (Hochberg, 1988), Benjamini & Hochberg (Benjamini and Hochberg, 
1995) and Benjamini and Yekutieli (Benjamini and Yekutieli, 2001).  
The two most commonly used methods are the Bonferroni method and the Benjamini 
& Hochberg method, respectively. The Bonferroni method is the most stringent 
method for multiple comparisons, which corrects the p value by multiplying it by the 
total number of tests. After Bonferroni correction, if a significance cut-off of 0.05 is 
used, it expects that the probability of incorrectly rejecting at least one null 
hypothesis is 5%. Although this method minimizes false-positive associations 
                                                             
23 Calculated by 1 − (1 − 0.05)32 
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identified, it also minimizes the power to detect genuine associations. Benjamini & 
Hochberg method is also called false discovery rate (FDR) method. Compared with 
Bonferroni method, FDR method is preferred by geneticists since it strikes a good 
balance between false positive and false negative errors. This method can be 
performed by programming software R using command p.adjust (p, method="fdr", 
length (p)) 24 , which was written by Prof Gordon Smyth 25  based on the 
re-interpretation of both Benjamini & Hochberg and Benjamini and Yekutieli (BY) 
procedures. It ranks the raw p values from smallest to the largest and then corrects 
each p value using formula: adjusted p value=raw p value × total number of tests
the rank of the raw p value
. 
Sometimes the adjusted p value of a target with a smaller raw p value is larger than 
that for its less significant counterparts. In order to maintain the monotonicity, a 
second step was used to replace the non-monotonic adjusted p values with the 
smallest adjusted p value of all the less significant targets in original analysis. 
Conventionally, a false discovery rate cut-off of 0.15 is used, which indicates 15% of 
the statistically significant associations identified are really false positives.   
In this project, a log-additive model was chosen for initial screening of the 
genotyping results and crude (unadjusted) allelic OR was obtained for each SNP 
using Pearson’s 2 test (if all expected counts are ≥ 5) or Fisher’s exact test (If any 
expected counts are <5). After multiple testing corrections with the FDR method 
(with FDR cut-off of 0.15), significant SNPs were further validated and examined 
under all five genetic models using age-adjusted binary logistic regression. In order 
to determine how well each model fitted the genotyping data, a likelihood ratio test 
                                                             
24 https://stat.ethz.ch/R-manual/R-devel/library/stats/html/p.adjust.html 
25 Prof Gordon Smyth, Division Head at Walter and Eliza Hall Institute of Medical Research, The 
University of Melbourne 
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(LRT) was performed for each model in comparison with the null model (only 
including the intercept)(González et al., 2007). When the LRT test was not sensitive 
enough to determine the best-fit model, both Akaike's information criterion (AIC) 
and Bayesian information criterion (BIC) scores were calculated so as to find the 
model that minimized the information loss (Akaike, 1974; Burnham and Anderson, 
2003). The model with lowest AIC or BIC scores were preferred (González et al., 
2007; Solé et al., 2006).  
As with other experimental designs, genetic association studies require an adequate 
sample size to capture the genuine associations. In fact, a sample size estimation or 
power calculation should be considered a priority, which only surpassed by the 
establishment of the research question and the selection of the proper sample type. In 
this project, Quanto developed by Jim Gauderman and John Morrison was selected 
for sample size estimation under the assumption of the log-additive model 
(Gauderman, 2006). Please see Section 2.3.2.1 and Appendix 1 for the estimation of 
the sample size under the log-additive model. When multiple SNPs are involved in 
the study, the sample size required is larger than that calculated for a single SNP, 
which can be calculated by multiplying the estimated sample size by a factor: 
log10(number of SNPs to be genotyped) (Stram, 2014). In this study, the factor 
used was roughly 1.526. Therefore an achievable sample size of 475 was selected for 
controls and cases for this project, which reconciled with the format of the PCR 
platform and gave enough power under the majority of conditions for log-additive 
model. 
                                                             
26 Factor=log10 32 
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In order to precisely determine the genotypes of each sample in an array based study, 
a validation step is usually performed to confirm significant findings by genotyping 
the same set of samples with a different genotyping method. This kind of validation 
mainly focuses on the analytical validity of the genotyping results. Another kind of 
validation which can be performed is to assess another set of samples from the 
original population or a set of samples from a different population to confirm the 
generalizability of the associations identified. The latter usually requires an even 
larger sample collection to overcome the possible overestimation of effect size in the 
initial study (a phenomenon known as winner’s curse). Within the timeframe of 
the project, only the former could be conducted. The validated association could then 
be interpreted in one of three possible ways, including direct association (i.e. caused 
directly by the typed causal SNP), indirect association (i.e. caused by an unknown 
causal SNP in high LD with the typed SNP itself) or spurious association (i.e. caused 
by chance or artefacts). Although a lot of prediction tools have been developed to 
further evaluate significant findings, it is challenging to tease out direct associations 
from the other two situations unless further validation (or functional evidence) is 
provided. In this project, rational selection of the candidate SNPs according to their 
functional potential to some extent increased the possibility to detect direct 
associations. 
In complex disease with a long natural history and progression process, the role of a 
SNP might not be the same during the different disease stages. By genotyping a 
particular SNP in samples belonging to different disease categories or stages, a better 
understating of the genetic associations between this SNP and a broad spectrum of 
transition states could be obtained. Good examples have been given previously 
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(Safaeian et al., 2012; Wang et al., 2010). These studies investigated the associations 
between candidate SNPs and two transition states of cervical cancer (i.e. viral 
persistence and progression to pre-cancer/cancer) and successfully identified SNPs 
that specifically corresponded to each state and SNPs associated with both states. In 
this project, thanks to Dr Michelle Etherson and Luhan Jiang, significant SNPs 
identified from the SNP array were genotyped in additional samples with 
HPV-related diseases and the results were pooled with the array results. The 
inclusion of additional samples increased the robustness of the association analysis. 
In general, the aim of this chapter is to assess the associations between candidate 
SNPs and HPV-related diseases and to further validate the significant findings using 
different genotyping methods. The general results of the SNP array were described in 
Section 4.2. The validations of the significant results were described in Section 4.3 
and Section 4.4.  
4.2 Overview of the SNP array 
In total, 27 out of 32 SNPs yielded analyzable results in the array. TMC8 rs16970849, 
ACKR2 rs4683336，NEIL2 rs804270, IL-8 rs4073 and PGR rs11224561 were 
excluded from analysis since they were either shown to be monomorphic or had a 
significant departure from Hardy-Weinberg equilibrium in the controls. DNA 
extracted from FFPE samples performed poorly in the array compared to that 
extracted from LBC samples, especially those extracted from FFPE cervical cancer 
samples. Therefore, genotyping results of all the cancer samples (n=62) were omitted 
in the initial analysis. The actual cases used in the initial analysis only consisted of 
HR-HPV positive high-grade squamous intraepithelial lesions. Characteristics of the 
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case group (n=413) and control group (n=475) in the initial analysis of the SNP array 
are provided in Table 19. As shown in this table, the mean age of the cases was 
significantly younger than that of controls, which indicated that age adjustment was 
necessary in the final association analysis. Sample sources of the cases also 
significantly differed from the controls, although this was were very unlikely to 
affect the genotyping results and the subsequent analysis. 
Table 19 Characteristics of the case and control group in the initial analysis 
Variables HR-HPV positive HSIL Cases 
(n=413) 
Control(n=475) p values 
Age, y (mean ± 
SD) 
20.12 ±0.51 38.18±11.43 <0.0001
a 
Source, n (%)   <0.0001b 
FFPE 149(44.4%) 0(0%)  
LBC samples 264(55.6%) 475(100%)  
a. Two-sided Mann Whitney test for difference between cases and controls; 
b. Two-sided Fisher’s exact test for distributions between cases and controls. 
 
Genotyping results for all the samples tested are shown in Table 20. The highest and 
lowest call rates obtained for the 27 analyzable SNPs were 99.32% and 76.01% 
respectively. The frequency of the minor allele homozygotes was found to be lower 
than 1% in our sample set for three SNPs: rs17849071, rs1799724 and rs361525.  
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Table 20 OpenArray genotyping report for 27 analyzable SNPs 
 
To assess the associations between analyzable SNPs and HPV-related high-grade 
squamous intraepithelial lesion (HSIL), raw p value and FDR adjusted p value were 
calculated for each SNP under the log-additive model as described in Section 2.3.2.2. 
Please see table 21 for the list of raw p values and FDR adjusted p-values under the 
log-additive model. 
NCBI reference call rate Have all three genotypes AA AB BB undetermined 
rs1042838 97.30% yes 14 243 607 24
rs10774671 86.04% yes 309 342 113 124
rs1126579 87.84% yes 228 390 162 108
rs11556218 92.23% yes 207 433 233 15
rs12452890 98.31% yes 10 116 693 69
rs17849071 86.60% minor allele homozygotes<0.01 3 113 653 119
rs1799724 96.17% minor allele homozygotes<0.01 746 103 5 34
rs1800629 98.99% yes 35 279 565 9
rs1801157 86.82% yes 512 225 34 117
rs2069705 93.02% yes 361 369 96 62
rs2104286 95.50% yes 65 335 448 50
rs2107538 84.80% yes 498 226 29 135
rs2234671 91.33% yes 4 143 664 77
rs2596542 76.01% yes 344 273 58 213
rs2623047 79.62% yes 257 340 110 181
rs266085 87.39% yes 352 325 99 112
rs2699887 95.72% yes 479 310 61 38
rs2790 85.47% yes 471 253 35 129
rs2857656 94.37% yes 68 347 423 50
rs3117604 96.40% yes 79 351 426 32
rs34137742 99.32% yes 654 212 16 6
rs361525 96.96% minor allele homozygotes<0.01 2 73 786 27
rs3760396 80.29% yes 29 230 454 175
rs3921 93.69% yes 184 410 238 56
rs4073 47.75% yes 82 216 126 464
rs4074 88.96% yes 97 364 329 98
rs7072793 96.17% yes 156 420 278 34
rs804270 75.34% yes 141 300 228 219
rs853360 97.64% yes 462 341 64 21
NCBI reference call rate Have all three genotypes AA AB BB undetermined 
rs1042838 97.30% yes 14 243 607 24
rs10774671 86.04% yes 309 342 113 124
rs1126579 87.84% yes 228 390 162 108
rs11556218 92.23% yes 207 433 233 15
rs12452890 98.31% yes 10 116 693 69
rs17849071 86.60% minor allele homozygotes<0.01 3 113 653 119
rs1799724 96.17% minor allele homozygotes<0.01 746 103 5 34
rs1800629 98.99% yes 35 279 565 9
rs1801157 86.82% yes 512 225 34 117
rs2069705 93.02% yes 361 369 96 62
rs2104286 95.50% yes 65 335 448 50
rs2107538 84.80% yes 498 226 29 135
rs2234671 91.33% yes 4 143 664 77
rs2596542 76.01% yes 344 273 58 213
rs2623047 79.62% yes 257 340 110 181
rs266085 87.39% yes 352 325 99 112
rs2699887 95.72% yes 479 310 61 38
rs2790 85.47% yes 471 253 35 129
857656 94 3 68 347 423 50
311 04 6 40 79 51 6 32
4 377 2 9 32 654 212 1 6
6 525 6 96 minor allele homozygotes<0.01 2 73 78 27
760396 80 29 yes 29 230 454 175
921 93 6 184 41 238 56
4073 47 75 2 2 6 126 464
4 88 96 97 364 3 9 98
7 2793 96 17 156 420 278 34
8 4 0 75 34 41 30 2 219
5336 97 6 462 41 64 21
NCBI reference call rate Have all three genotypes AA AB BB undetermined 
rs1042838 97.30% yes 14 243 607 24
rs10774671 86.04% yes 309 342 113 124
rs1126579 87.84% yes 228 390 162 108
rs11556218 92.23% yes 207 433 233 15
rs12452890 98.31% yes 10 116 693 69
rs17849071 86.60% minor a lele homozygot <0.01 3 113 653 119
rs1799724 96.17% minor allele homozygotes<0.01 746 103 5 34
rs1800629 98.99% yes 35 279 565 9
rs1801157 86.82% yes 512 225 34 117
2069705 3 02 361 369 96 62
210 286 95 5 yes 65 335 448 50
rs2107538 84.80% yes 498 226 29 135
rs2234671 91.33% yes 4 143 664 77
2596542 7 01 344 73 58 2 3
623047 79 62 257 40 110 181
rs266085 87.39% yes 352 325 99 112
rs2699887 95.72% yes 479 310 61 38
rs2790 85.47% yes 471 253 35 129
8576 6 94 7 68 7 423 50
rs3117604 96.40% yes 79 351 426 32
rs34137742 99.32% yes 654 212 16 6
rs361525 96.96% minor allele homozygotes<0.01 2 73 786 27
760396 80 29 2 30 54 175
rs3921 93.69% yes 184 410 238 56
rs4073 47.75% yes 82 216 126 464
rs4074 88.96% yes 97 364 329 98
rs7072793 96.17% yes 156 420 278 34
8 4 0 75 34 41 0 219
rs853360 97.64% yes 462 341 64 21
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Table 21 Genotyping results for 27 analyzable SNPs in crude analysis (a list of 
raw p values and FDR adjusted p-values under the log-additive model) 
 
 
In the crude analysis, allele frequencies of 4 SNPs, including PIK3CA rs17849071, 
CXCR1 rs2234671, SULF1 rs2623047 an IL2RA rs2072793, exhibited significant 
differences between HR-HPV positive HSIL cases vs. cytologically normal, 
HR-HPV negative controls (with a raw p value< 0.05). The four SNPs intentionally 
included due to their associations with cervical cancer were not found to be 
associated with HR-HPV positive HSIL 27 . The associations of the CXCR1 
rs2234671, SULF1 rs2623047 and PIK3CA rs17849071 remained after multiplicity 
adjustment (FDR<0.15). Accordingly, SULF1 rs2623047 and CXCR1 rs2235671, 
                                                             
27 TMC8 rs16970849 was monomorphic in our sample set while the other three was found to be 
insignificant in the initial analysis. 






























the two most significant SNPs identified in crude analysis were chosen as targets for 
further validation and functional analysis. PIK3CA rs17849071 was not followed in 
this project due to its low frequency of the minor allele homozygotes in the sample 
set.  
4.3 The association between SULF1 rs2623047 and HR-HPV-related 
diseases 
4.3.1 Analytical validity of the array results for SULF1 rs2623047 
For SULF1 rs2623047, 707 samples had valid genotype calls in the original array. 
656 of these 707 samples were picked and re-genotyped using LightSNiP assay 
and/or single tube TaqMan® SNP Genotyping assay28 as described in Section 2.3.3 
and Section 4.1 ) according to their availability. In total, 139 samples were verified 
by all three genotyping methods (i.e. SNP array, LightSNiP assay and single tube 
TaqMan® SNP Genotyping assay). Genotyping results were relatively consistent 
among the three methods and only 5 samples (out of 656) had discordant results (i.e. 
inconsistent between any two methods). Although the call rate of this SNP (80%) 
was just above the threshold for the array, the overall concordance was satisfactory 
(99.2%). In order to check whether the significance was caused by a high no-call rate, 
all the no-call samples (888-707=181) in the array were re-genotyped using 
LightSNiP assay.  
Genotyping results for 475 controls and HR-HPV positive HSIL cases are 
summarized in Table 22. Both controls and cases were in HWE, with HWE 2 
p-value of 0.64 and 0.47 respectively. Significant associations between this SNP and 
HR-HPV positive HSIL were observed under four genetic models after age 
                                                             
28 Also performed by WTCRF Genetics core 
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adjustment, including over-dominant model, dominant model, recessive model and 
log-additive model (see Table 23 for details). According to the AIC and BIC values, 
the best-fit model for this SNP was the Log-additive model (OR: 0.50, 95%CI 
0.32-0.77), suggesting a possible multiplicative protective effect of G alleles against 
HR-HPV-related HSIL. 
Table 22 SULF1 rs2623047 genotype frequencies for all the subjects and 
separately for controls and HR-HPV positive HSIL cases. 
SULF1 rs2623047 genotype frequencies (Total n=888) 
Genotype, n (%) All subjects Controls HR-HPV positive HSIL 
Cases 
A/A 314(36%) 155(33%) 159(38.8%) 
A/G 422(48%) 235(50%) 187(45.6%) 
G/G 146(17%) 82(17%) 64(15.6%) 
No call 6 3 3 --- 
 
Table 23 The association between SULF1 rs2623047 and HR-HPV positive HSIL 
under five different genetic models (adjusted by age) 
 
This table depicts the association between SULF1 rs2623047 genotypes and HR-HPV 
positive HSIL. Data displayed as n (%cases). OR, 95%CI, p-value, AIC and BIC were calculated 
for each inheritance model. Samples with missing genotype data or age records were 




4.3.2 SULF1 rs2623047 is associated with HR-HPV infection rather than 
the development of high-grade squamous intraepithelial lesion and 
cancer   
Unlike the SNP array and the single tube TaqMan® SNP Genotyping assay, the 
LightSNiP assay required less genomic DNA to make an accurate genotype call and 
showed good compatibility with FFPE samples. Therefore, this method was applied 
to re-genotype the omitted FFPE cancer samples in the array sample set. Due to 
limited sample volume, valid genotype results for this SNP were finally obtained for 
39 of the 62 cancer samples. As described in Section 2.3.3, genotyping results of an 
additional 83 HR-HPV positive cytologically normal LBC samples and 21 HR-HPV 
positive cervical cancer samples annotated as a consequence of work performed by 
Luhan Jiang and Dr Michelle Etherson were pooled with the array results. 
Characteristics and genotyping results of the control group and different disease 
categories are summarized in Table 24. HR-HPV positive cytologically normal group 
and HR-HPV positive cervical cancer group were also in HWE, with HWE 2 
p-value of 0.78 and 0.81 respectively. 
Table 24 Characteristics and genotyping results of the control group and 









Age, y  
(mean ± SD) 
38.18±11.43 20±0 20.12 ±0.51 48.27±16.07 
Genotype, n (%)     
A/A 155(33%) 37(48.1%) 159(38.8%) 23(38.3%) 
A/G 235(50%) 32(41.6%) 187(45.6%) 29(48.3%) 
G/G 82(17%) 8(10.4%) 64(15.6%) 8(13.3%) 




Similar to HR-HPV positive HSIL, the HR-HPV positive, cytologically normal 
group was also significantly different from the HR-HPV negative, cytologically 
normal group under four genetic models after age adjustment (see Table 25 for 
details).  
Table 25 Association of SULF1 rs2623047 in HR-HPV positive cytologically 
normal cases versus HR-HPV negative cytologically normal controls under five 
different genetic models (adjusted by age) 
 
This table depicts the association between SULF1 rs2623047 genotypes and HR-HPV 
infection. Data displayed as n (%cases). OR, 95%CI, p-value, AIC and BIC were calculated for 
each inheritance model. Samples with missing genotype data or age records were 
automatically removed from the statistical analysis by the SNPstats software. 
The G allele of this SNP was shown to be associated with decreased susceptibility to 
HR-HPV infection under the best fit model: log-additive model (OR: 0.34 95%CI 
0.19-0.63). However, there was no significant difference observed in the allele or 
genotype frequencies of SULF1 rs2623047 among HR-HPV positive cytologically 
normal group, HR-HPV positive HSIL group and HR-HPV cervical cancer group, 
which suggested that this SNP was not related the development of high-grade 
squamous intraepithelial lesion and the progression to cervical cancer. 
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4.4 The association between CXCR1 rs2234671 and HR-HPV-related 
diseases 
4.4.1 Analytical validity of the array results for CXCR1 rs2234671 
For CXCR1 rs2234671, 811 samples had valid genotype calls in the array. All except 
two were re-genotyped using either LightSNiP assay or single tube TaqMan® SNP 
genotyping assay. In total, 572 samples were genotyped with all three methods. The 
concordance between LightSNiP assay and single tube TaqMan® SNP Genotyping 
assay was 99.0%. However, compared with these two methods, 56 samples (out of 
572) had different calls in the SNP array. Genotyping data of this SNP was thereby 
sent to the Technical support team at ThermoFisher Scientific and a bridging issue 
was identified subsequently. The details were not clear but I was advised to discard 
all the results for this SNP in the original array due to low analytical validity. 
4.4.2 The minor allele frequency of CXCR1 rs2234671 was significantly 
increased in HR-HPV positive cancer cases, especially in HPV16 
positive cancers 
Since both LightSNiP assay and single tube TaqMan® SNP Genotyping assay were 
shown to give reproducible results for this SNP, the whole set of samples in the array 
for this SNP were re-genotyped using either of these two methods. Meanwhile, an 
additional 83 HR-HPV positive cytologically normal LBC samples, 21 HR-HPV 
positive cervical cancer samples, 129 HR-HPV positive vulval intraepithelial 
neoplasia (VIN) samples and 23 HR-HPV positive vulval cancer samples were 
genotyped for this SNP by Luhan Jiang and Dr Michelle Etherson with results pooled 
in the association analysis. Characteristics and genotyping results of the control 
group and different disease categories are summarized in Table 26. 
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Table 26 Characteristics and genotyping results of the control group and 



























38.18±11.43 20±0 20.12 
±0.51 
48.27±16.07 47.5±12.4 56.6±12.2 
Genotype, 
n (%) 
      
G/G 410(87%) 70(85%) 360(89%) 64(79%) 103(83%) 15(65%) 
G/C 58(12%) 12(15%) 45(11%) 16(20%) 20(16%) 7(30%) 
C/C 3(1%) 0(0%) 1(0%) 1(1%) 1(1%) 1(4%) 
No call 4 1 7 2 5 0 
Allele, n 
(%) 
      
G 878(93.2%) 152(92.7%) 765(94.2%) 144(88.9%) 226(91.1%) 37(80.4%) 
C 64(6.8%) 12(7.3%) 47(5.8%) 18(11.1%) 22(8.9%) 9(19.6%) 
 
All the groups were in HWE, with HWE 2 p-value of 0.55, 0.47, 0.74, 1, 0.98 and 
0.87 respectively. No significant difference was found in the allele frequencies of 
CXCR1 rs2234671 among HR-HPV negative, cytologically normal control group (G 
93.2%, C 6.8%), HR-HPV positive cytologically normal group (G 92.7%, C 7.3%), 
HR-HPV positive cervical HSIL group (G 94.2%, C 5.8%) and HR-HPV positive 
VIN group (G 91.1%, C 8.9%). Also, the genotype counts did not vary among these 
groups. However, significantly enriched C allele was observed in HR-HPV positive 
cervical cancer cases and vulval cancer cases, compared with HR-HPV positive 
cervical HSIL cases and HR-HPV positive VIN respectively. Pearson’s 2 test p 
value was 0.0132 for the former and 0.0301 for the latter. 
Since the small sample size in some of the individual groups was not well-fitted for 
analysis based on genotypes, the two cancer groups (cervical and vulval) were 
merged and the results of the HR-HPV positive cervical HSIL group were combined 
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with the HR-HPV positive VIN group. An interesting finding was obtained by 
analysing the data set this way. When stratifying each disease category using HPV 
status, the enrichment of C allele was only observed in HPV16 positive cancers (see 
Figure 31).  
 
Figure 31 Genotype frequencies of CXCR1 rs2234671 in the HR-HPV negative, 
cytologically normal control group and other disease categories (stratified by 
HPV16) 
As can be seen from the above figure, the frequency of the C allele carriers was 
significantly higher in the combined HPV16 positive cancer group, compared with 
the HPV16 positive HSIL or VIN group (32.7% vs. 12.3%, Pearson’s 2 test 
p<0.0001) or the HR-HPV negative, cytologically normal control group (32.7% vs. 
13%, Pearson’s 2 test p<0.0001). Apart from the combined HPV16 positive cancer 
group, no significant difference was found in genotype frequencies or 
allele frequencies of CXCR1 rs2234671 among all other groups. 
The association between this SNP and the progression of HPV16 related cancer was 

























HPV16- other HR-HPV+ HSIL or VIN(n=130)
HPV16+ HSIL or VIN(n=400)
HPV16- Cervical or Vulval cancers(n=26)




positive HSIL or VIN group controls under different genetic models after age 
adjustment (see Table 27 for details). The CXCR1 rs2234671 SNP was shown to be 
associated with the development of HPV16 related cancer under 4 of the 5 genetic 
models and the best-fit model for this SNP was the log-additive model (OR: 3.23, 
95%CI 1.56-6.67). The likelihood ratio test p value for this model is 0.0018. 
Table 27 The association between CXCR1 rs2234671 and the progression of 
HPV16 positive cancers under five different genetic models (adjusted by age) 
 
This table depicts the association between CXCR1 rs2234671 genotypes and the progression 
of HPV 16 positive cancers, compared with the HPV16+ HSIL or VIN group. Data displayed as 
n (%cases). OR, 95%CI, p-value, AIC and BIC were calculated for each inheritance model. 
Samples with missing genotype data or age records were automatically removed from the 
statistical analysis by the SNPstats software. 
 
4.5 Discussion 
The individual susceptibility to the development of cervical cancer is considered to 
be associated with genetic variations in specific genes. In this chapter, 32 rationally 
selected SNPs within 22 genes were genotyped to determine their association with 
HR-HPV-related diseases and 27 of them yielded analyzable genotyping results.  
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Unlike the majority of candidate gene based association studies and GWAs, genomic 
DNA extracted from LBC and FFPE samples, instead of routinely-used blood 
samples, was used in this project for SNP genotyping. As mentioned in Section 4.1, 
theoretically, this should not cause any changes to the genotyping results. Vieira et al 
previously showed that the Taqman® OpenArray® genotyping assay could be used to 
genotype genomic DNA extracted from FFPE samples (Vieira et al., 2013). All the 
FFPE cervical cancer samples in my array sample set were freshly extracted using 
QIAGEN GeneRead DNA FFPE Kit, which could enzymatically remove artificial 
C>T mutations caused by cytosine deamination to maximise yield and purity of 
genomic DNA from FFPE samples suitable for next-generation 
sequencing  applications. In our group, quality control of the extracted DNA was 
performed by measuring both 260/230 nm and 260/280 nm absorbance ratios using a 
NanoDropTM 1000 spectrophotometer. Meanwhile, quality control of the extracted 
DNA was also performed by a PicoGreen dsDNA quantitation assay (ThermoFisher 
Scientific) in WTCRF Genetic core. However, although these samples passed the 
quality control by both laboratories, few of them had valid genotyping results in the 
SNP array and they also fared poorly in the single tube TaqMan® SNP Genotyping 
assay in the validation step (data not shown). These findings suggested that genomic 
DNA extracted from FFPE samples may not be suitable for the Taqman® SNP 
genotyping system.  
In spite of the poor performance of genomic DNA from FFPE samples in the array, 
genotyping results of genomic DNA from LBC samples were very promising. LBC 
samples have been shown to be reliable for the application of molecular techniques, 
such as fluorescence in situ hybridization, methylation-specific PCR and denaturing 
173 
 
high-performance liquid chromatography (Li et al., 2014; Spathis et al., 2011; Sun et 
al., 2012). However, not many genetic association studies have been performed with 
genomic DNA extracted from LBC samples (Casalicchio et al., 2014; Mehta et al., 
2015). As cervical screening programmes become more and more widespread, LBC 
samples might provide an alternative to blood tests for genetic marker detection. 
Previous work done in our group indicated that properly-stored LBC samples could 
yield DNA of good quality and quantity. Genotyping results in the array further 
supported the utility of genomic DNA extracted from LBC samples in TaqMan® 
SNP genotyping system. In the validation step, the LightSNiP assay was applied, 
which showed many advantages over single tube TaqMan® SNP Genotyping assay. 
Much less genomic DNA (i.e. ~10ng/reaction) was required while a much higher call 
rate was reached. Most surprisingly, even problematic FFPE extracts had valid and 
reproducible results in LightSNiP assay. The application of the LightSNiP assay 
effectively avoided the potential pitfalls caused by wrong call and no call samples.  
In the SNP array, I intentionally included 5 SNPs that have been shown to be 
associated with cervical cancer in other studies so as to check the generalizability of 
these associations in Scottish population. However, since all the cancer samples were 
excluded from the initial analysis, these associations could not be reproduced in this 
project. Among these five SNPs, TMC8 rs16970849 was excluded from the analysis 
because all the subjects in our sample set were homozygotes of the major allele. 
Technical validation of the other four SNPs, including rs361525, rs1800629, 
rs853360 and rs34137742, was not performed due to the time and cost constraints of 
this project. In spite of this, the call rates of these three SNPs were all acceptable (see 
Table 20) and the genotype groups were well separated in the allelic discrimination 
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plot. According to the initial analysis, the allele frequencies of these four SNPs were 
not significantly different between HR-HPV negative cytologically normal controls 
and those HR-HPV positive HSILs, which suggested that these SNPs were not 
associated with the development of the HR-HPV positive HSIL (see Table 20). This 
project is the first to assess the associations between HR-HPV-related squamous 
intraepithelial lesions and rs853360 or rs34137742. Although 
controversial observations of the association between TNF rs1800629 and cervical 
cancer were found in published studies, this SNP was consistently shown to be 
unrelated to the development of squamous intraepithelial lesions (Li et al., 2013; 
Rotar et al., 2014; Sousa et al., 2014). The results obtained in this project provided 
further evidence for the lack of association of rs1800629 with HR-HPV-related HSIL. 
Similarly, results of rs361525 in this project were consistent with a previous finding 
in a Mexican population (Nieves-Ramirez et al., 2011). However, firm conclusions 
could not be drawn without further verification and validation. 
Intriguingly, two SNPs, SULF1 rs2623047 and CXCR1 rs2234671, were found to be 
significantly associated with HR-HPV related diseases and were subsequently 
followed-up. They were genetically linked to two different transition states during 
the natural history of the disease. SULF1 rs2623047 revealed a strong significant 
association with the susceptibility to HR-HPV infection while CXCR1 rs223671 was 
solely associated with the development of HR-HPV-related cancers, especially in 
HPV16+ cancer cases.  
SULF1 rs2623047 is located upstream of the sulfatase 1 (SULF1) gene. This gene 
encodes a heparan sulfate modifying enzyme, which is involved in the activation of 
many signalling pathways by selectively modifying heparan sulfate proteoglycans 
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(HSPGs) (Pascale et al., 2016). The role of SULF1 in cancers is not entirely clear 
according to the current literature. A cell type-specific impact of SULF1 on 
carcinogenesis has been suggested (Bret et al., 2011; Chen et al., 2009; Lai et al., 
2008; Yang et al., 2011). SULF1 has also been shown to be important in 
host-pathogen interactions. Kim et al showed that over-expression of SULF1 in 
HeLa cells inhibited Chlamydia binding through HSPG 6-O-desulfation (Kim et al., 
2013). While the receptor for HPV is poorly characterized, viral entry has also been 
shown to be facilitated by HSPGs (Horvath et al., 2010; Kines et al., 2016; Raff et al., 
2013). However, the specific roles of SULF1 in HPV persistence and the 
development of HR-HPV-related cervical cancer have not been investigated 
comprehensively. In the previously mentioned array-based study performed by Wang 
and colleagues, SNPs in the SULF1 gene were found to be significantly associated 
with HPV persistence (HPV persistence vs. Random control, P=0.0056). No 
significant differences were observed between the HPV persistence group and 
the cervical pre-cancer/cancer group (CIN3/cervical cancer vs. HPV persistence, 
P=0.6935). Within the gene, three intronic tagSNPs were found to reach the 
significance threshold individually in the array, which were rs4737999, rs4284050 
and rs10108002 respectively. All these three SNPs were strongly associated with 
HPV persistence but did not differ between the HPV persistence group and 
the cervical pre-cancer/cancer group (Wang et al., 2010). Our findings for SULF1 
rs2623047 added to the evidence that SULF1 played a pivotal role in the 
pathogenesis of HR-HPV infection. It is noteworthy that none of the tagSNPs in the 
published studies, including those failed to reach significant levels, was in high 
linkage disequilibrium with rs2623047, which indicated that SULF1 rs2623047 
176 
 
contributed to HR-HPV infection risk genetically independent of the previously 
reported susceptibility loci.  
According to the Phase 3 1000 Genomes Browser based on Ensembl v80 GRCh3729, 
SULF1 rs2623047 locates at chromosome 8, the promoter region of the SULF1 gene. 
Two alleles, A and G, exist at this locus. The G allele was shown to be the major 
allele in African and East Asian populations and considered to be the ancestral allele. 
However, in South Asian, American and European populations, the A allele became 
the major one (Consortium, 2015). The allelic distribution of this SNP in our 
HR-HPV negative cytologically normal control group is almost the same as that of 
the British population in the 1000 Genomes database. To date, only two studies on 
SULF1 rs2623047 have been published (Han et al., 2011; Okolicsanyi et al., 2014). 
Han et al showed that rs2623047 AA genotype was related to shorter 
progression-free survival in ovarian cancer. As a promoter SNP, rs2623047-G allele 
was found to confer a 1.4-fold higher promoter activity than A allele in SKOV3 cell 
line (Han et al., 2011). The study performed by Okolicsanyi also suggested 
rs2623047-A allele was a risk allele for breast cancer. In this study, rs2623047 alleles 
were reported in reverse orientation to genome. C actually means G and T 
corresponds to A (Okolicsanyi et al., 2014). Our genotyping results consistently 
indicated that carriers of rs2623047-A were at increased risk of developing HR-HPV 
infection, although the underlying biological mechanisms involved in cancer and 
viral infection are clearly very different. Apart from for the study performed by Han 
et al, no functional evidence published to elucidate a mechanism behind the 
observations. This SNP was not selected for functional follow-up within the 




timeframe of this project. However, the functional effects of this SNP and potential 
functional SNPs in high LD with this SNP could be roughly predicted using online 
tools, such as HaploReg v430, F-SNP31, SNPinfo Web Server32 or PROMO33. For 
example, both HaploReg v4.1 and SNPinfo Web Server predicted that rs2623047 
could affect transcription factor binding. Also, HaploReg v4 provided a list of SNPs 
in high LD with rs2623047, which were potential candidates for further functional 
analysis. More functional predictions of this SNP are described in Section 6.2.2. 
Another significant SNP identified in this study was found within CXCR1 gene, 
which encodes a G protein–coupled receptor (GPCR). This receptor had been shown 
to be a high affinity receptor for IL-8 (Griffith et al., 2014). CXCR1 rs2234671 is a 
non-synonymous biallelic SNP located at the coding region of the gene (see Figure X 
for the position of rs2234671). The major allele is G and the G-C substitution leads 
to an amino acid substitution from serine (AGC) to threonine (ACC) at the third 
extracellular loop of the encoded receptor (see Figure 32 for the amino acid position 
affected by rs2234671). 








Figure 32 Two-dimensional diagram of human CXCR1 receptor and the amino 
acid position affected by rs2234671. 
The diagram was extracted from the GPCRdb (http://gpcrdb.org/protein/cxcr1_human/). 
The amino acid residue affected by rs2234671 is highlighted in green. 
In an evolutionary survey study comparing the sequences of CXCR1 in humans and 
five non-human primates, CXCR1 rs2234671 was found to be specific to humans 
and considered to be caused by Darwinian positive selection in an accelerated 
unilateral receptor evolution (Liu et al., 2005). Conventionally, the major allele and 
the minor allele of a non-synonymous SNP were determined according to the coding 
strand instead of the template strand. Most researchers interested in this SNP 
followed this convention and I did the same in this project. However, in dbSNP 
database, this SNP was reported in reverse orientation to the genome. Although 
annotated clearly in dbSNP database, this difference was not emphasized sufficiently 
in the 1000 Genomes database and some other key reference database. This has led 
to ambiguity in the definition of the major and minor alleles leading to 
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misunderstanding in the scientific community. For example, conflicting descriptions 
were observed in a recent publication (de Haas et al., 2014). 
Unlike the rarely-investigated SULF1 rs2623047, the association of CXCR1 
rs2234671 has been assessed in many diseases. The first disease that linked to 
CXCR1 rs2234671 was acute pyelonephritis (APN). In this study, minor alleles of 
both rs2234671 and rs313806034 were found to be associated with the risk of APN. 
These two SNPs were in complete LD. However, only rs3138060 was tested in a 
functional assay and shown to affect transcription factor binding which reduced the 
transcription of CXCR1 (Lundstedt et al., 2007). The C allele was also found to be 
associated with the susceptibility of cutaneous and mucosal leishmaniasis (OR: 1.84, 
95%CI 1.04-3.23) when compared with unaffected controls (Castellucci et al., 2010). 
In women with asymptomatic bacteriuria, increased urine IL-8 levels was observed 
in C allele carriers in a gene-dose dependent manner (i.e., concentration increased by 
every additional C allele) (Hawn et al., 2009). In metastatic colorectal cancer patients, 
CXCR1 rs2234671 was shown to be predictive of bevacizumab based treatment 
outcome. Frequency of C allele was found to be significantly increased in patients 
with stable or progressive disease in comparison with those with complete or partial 
remission (Gerger et al., 2011). Furthermore, the C allele has been associated with 
the risk of active HBV infection (Almajhdi et al., 2013). In addition, Hsing and 
colleagues reported that the C allele carriers of this SNP had a significantly higher 
risk of developing gallbladder cancer among patients with gallstones (Hsing et al., 
2008). However, their conclusion was drawn due to misuse of statistical methods. 
                                                             
34 In this study, rs2234671 and rs3138060 were named as variant 2 and variant 1 respectively. 
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After re-examining and re-analysing their raw data, I was unable to find any 
significant associations.  
Only one published study has investigated the role of this SNP in HPV-related 
diseases and the authors failed to find an association between this polymorphism and 
the susceptibility to CIN3 or cervical cancer (Wang et al., 2009a). Contrary to this, 
the data from this project suggests that the C allele was significantly enriched in 
HPV16-positive cervical cancer. My colleague Dr Michelle Etherson also observed 
the enrichment of the C allele in HR-HPV positive vulval cancers, especially in 
HPV16 positive vulval cancers. The pooled results were shown in Section 4.4.2. The 
contradictory results between the published study and this study may be due to the 
ethnic difference and the difference of the grouping strategy. Their study was 
performed in a set of samples from the Costa Rican population with a minor allele 
frequency of 18% in the controls and 16% in HPV persistence and CIN3+ cases 
(Wang et al., 2009a). In our studies, the minor allele frequency in Scottish controls 
was 6.8%, which is close to that of the British population (8%) and East Asian 
population (7%) but much lower than the Global minor allele frequency (14%) 
according to the 1000 Genomes project (Consortium, 2015). More studies are needed 
to assess the role of this SNP in MAF-similar populations since the association 
identified might be ethnic-specific. Besides, our results showed that the allele and 
genotype frequencies were significantly different between HSILs and cancers. 
However, in the published study, CIN3 was grouped together with cervical cancer 
cases, which might hinder the ability to detect the underlying association specific to 
the cancer development. Moreover, it is noteworthy that significant interactions 
between HPV16 and this polymorphism were observed in the progression process 
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from high grade squamous intraepithelial lesions to the cancer, but not in other 
transition states. This finding suggested a potential specific synergistic effect of this 
SNP and HPV16 on cancer development. Intriguingly, a study performed by 
Almajhdi et al also showed a joint effect of active HBV infection and this SNP on 
the development of cirrhosis and hepatocellular carcinoma (Almajhdi et al., 2013). 
Since the biological role of CXCR1 rs2234671 has rarely been investigated, this SNP 


































As described previously, it is always difficult to investigate the functional roles of a 
given SNP even if it is truly functional. Phenotypic changes caused by most SNPs 
are almost never as obvious as those caused by rare mutations in monogenic 
disorders inherited according to Mendelian genetics. In particular, non-synonymous 
SNPs are more likely to fine–tune the functions of a gene rather than completely 
abrogate or re-shape its original functions. Therefore, it is necessary to have a more 
concrete understanding of the pathway in which the SNP-containing gene was 
involved. The CXCR1 SNP rs2234671 further investigated in this project is involved 
in the chemokine signalling pathway IL-8-CXCR1.  
Since discovered and purified by Yoshimura and colleagues in 1987 (Yoshimura et 
al., 1987), the functional role of IL-8 has been extensively studied in different 
physiological and pathological conditions. As the accepted prototypic chemokine of 
the ELR+ CXC chemokine family, IL-8 is characterized by the glutamic 
acid-leucine-arginine motif (ELR motif) immediately preceding the first cysteine of 
the conserved CXC motif35. It has been shown to mediate its effects through two 
receptors, CXCR1 and CXCR2 (Griffith et al., 2014). Both receptors belong to the 
GPCR superfamily and have been found to be naturally expressed on a variety of 
cells, including neutrophils (Stillie et al., 2009), natural killer cells (Lima et al., 
2015), endothelial cells (Li et al., 2003; Li et al., 2002; Singh et al., 2011), epithelial 
cells (Palter et al., 2001), mast cells (Inamura et al., 2002) and bone marrow-derived 
mesenchymal stem cells (Park et al., 2015; Ringe et al., 2007). Although these two 
                                                             
35 CXC motif: the first two adjacent cysteines of the four conserved cysteine residues near the 
N-terminus are separated by a random single amino acid. 
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receptors are frequently co-expressed and share high similarity (75.3%36 amino acid 
identity), there is plenty of evidence showing that they are not completely 
functionally redundant.  
The ligand selectivity of the two receptors is distinctly different. CXCR1 has only 
been consistently shown to bind IL-8 (or called CXCL8) and CXCL6 with high 
affinity (Holmes et al., 1991; Wuyts et al., 1998). A recent study also demonstrated 
an essential role for CXCR1 in CXCL3 induced airway smooth muscle cell 
migration (Al-Alwan et al., 2013). Unlike the highly selective CXCR1, CXCR2 
serves as a relatively promiscuous receptor, which responds to nearly all ELR+ CXC 
chemokines and even some of their orthologs in other species (Gilli et al., 2005; 
Griffith et al., 2014). Although both receptors bind to IL-8 with comparable affinity 
(Jones et al., 1997; Lowman et al., 1996), whether they act similarly or differently 
depends upon the intracellular signalling machinery they are coupled to, and more 
importantly, the biological condition and the cell types they are found in. 
Physiologically, neutrophils are the main cell type expressing both CXCR1 and 
CXCR2. In neutrophils, intracellular Ca2+ mobilization, actin reorganization, 
chemotaxis, exocytosis and suppression of apoptosis have been shown to be 
mediated by both receptors, while superoxide production and the activation of 
phospholipase D are only mediated through CXCR1 and the release of MMP-9 
exclusively depends on CXCR2 (Aul et al., 2012; Chakrabarti and Patel, 2005; 
Glynn et al., 2002; Jones et al., 1997; Jones et al., 1996; Kredel et al., 2014). Hartl 
and colleagues also demonstrated that both the oxygen-dependent and 
oxygen-independent bacterial killing function of neutrophils are solely facilitated by 
                                                             




CXCR1 (Hartl et al., 2007). Endothelial cells are another cell type that 
exhibit widespread expression of IL-8 receptors but there are inconsistent results in 
the literature in terms of their roles in endothelial cell proliferation and migration. 
The discrepancies are likely due to the different sources of the cells and different 
culture methods (Li et al., 2005; Okada et al., 2009; Schraufstatter et al., 2001). More 
recently, both CXCR1 and CXCR2 were found to be involved in promoting the 
survival, proliferation, migration and invasion of endothelial cells in response to IL-8. 
Additionally, they are also responsible for the induction of adhesion molecules and 
the formation of filopodia, microvilli and capillary-like structure (Singh et al., 2011; 
Whittall et al., 2013). In airway smooth muscle cells, both receptors were found to be 
responsible for IL-8 induced cell contraction, migration and increase of intracellular 
Ca2+ (Govindaraju et al., 2006). In contrast, bladder urothelial cells bear both IL-8 
receptors but only CXCR1 could functionally support cell survival and proliferation 
following IL-8 stimulation (Tseng-Rogenski and Liebert, 2009). Gingival 
keratinocytes also have both IL-8 receptors but each has a different pattern of 
intracellular distribution (Sfakianakis et al., 2002). Apart from cells that co-express 
both IL-8 receptors, there are many cell types reported to express only one of the 
receptors. For example, CXCR1, but not CXCR2, was detected on CD8+ cytolytic 
effector T cells, regulatory T cells and endometrial stromal cells and was shown to 
mediate migration or proliferation of these cells in response to IL-8 (Eikawa et al., 
2010; Li et al., 2012; Takata et al., 2004). 
CXCR1 and CXCR2 can be activated in vitro by IL-8 at relatively low concentration, 
usually 10-50ng/ml. Much higher concentration of IL-8 (e.g.1000ng/ml) can lead to 
the internalization and desensitization of both receptors (Feniger-Barish et al., 2003). 
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Compared with CXCR2, CXCR1 is less susceptible to the desensitization effect of 
IL-8 and its recovery occurs very fast. Therefore it was thought to act predominantly 
within the inflammatory site where a relatively high concentration of IL-8 was found 
(Chuntharapai and Kim, 1995). The different responses towards IL-8 between 
CXCR1 and CXCR2 were considered to be largely dependent on their amino 
acid differences, which are unevenly distributed across the whole sequence. 
Structurally, the two receptors diverge from each other mainly in four regions: the 
extracellular N-terminus (residues 1-3937), the 4th trans-membrane domain (residues 
155-174), the second extracellular loop (residues 175-199) and the intracellular 
C-terminus (residues 209-250). All of these regions were shown to be functionally 
important. Previous studies demonstrated that the N terminus, the 4th trans-membrane 
domain and the second extracellular loop are essential for the sequential two-step 
ligand binding (Joseph et al., 2010; Rajagopalan and Rajarathnam, 2004). The C 
terminus and the second extracellular loop together were found to be involved in 
receptor internalization and desensitization (Nasser et al., 2007; Richardson et al., 
2003). Additionally, the presence of two disulfide bonds in CXCR1, Cys30-Cys277 
and Cys110-Cys187 respectively, was also shown to be important in maintaining the 
three-dimensional structure of the receptor and facilitating ligand binding (Park et al., 
2012). 
In pathological conditions, cell based models and model organisms are frequently 
used to explore the functional effects of each participant in a signalling pathway. 
However, unlike other well investigated chemokine-chemokine receptor pairs, no 
IL-8 ortholog has been identified in conventional rodent models. Although both 
                                                             
37 According to the amino acid sequence of CXCR1 
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mouse and rat orthologs of CXCR1 have been identified, they exhibit only 64.7% 
and 65.5% 38amino acid identity to the human CXCR1 respectively. Rat CXCR1 
was shown to be expressed in the lung and in macrophages but was undetectable in 
neutrophils with/without LPS stimulation (Dunstan et al., 1996). Similarly, mouse 
CXCR1 is also not a good representative for human CXCR1. Although this mouse 
ortholog has a similar distribution to the human counterpart, conflicting results were 
observed in terms of their functions induced by corresponding human and murine 
ligands (Fan et al., 2007; Fu et al., 2005; Moepps et al., 2006). Collectively, these 
data suggest that rodent orthologs were unable to fully mimic the human 
IL-8-CXCR1 signalling. 
Due to the lack of the IL-8 orthologs in rodents, cell models were widely utilized to 
investigate the role of IL-8-CXCR1 signalling in disease conditions. To investigate 
the functional effects of CXCR1 and CXCR2 separately, selective blockade 
or knock-down of either receptor has often been performed on cells endogenously 
expressing both receptors using neutralizing antibodies, small molecule antagonists 
or RNA interference (Ha et al., 2017; Singh et al., 2010; Stillie et al., 2009). Cells 
that express neither IL-8 receptor were also used to clarify mechanisms through 
overexpression of either or both receptors. The most frequently used cell lines for 
transfection and transduction include HEK293 cells and RBL-2H3 cells. There is 
plenty of experimental evidence that, although not naturally bearing CXCR1 or 
CXCR2, these cell lines do possess the signalling machinery required for IL-8 
                                                             





induced activities (Cohen-Hillel et al., 2009; Cohen-Hillel et al., 2006; 
Feniger-Barish et al., 2003; Han et al., 2012). 
Since CXCR1 is extensively expressed on immune cells, its role in infectious and 
inflammatory diseases has been widely investigated. In benign inflammatory 
diseases, increased expression of CXCR1 on circulating immune cells or cells at the 
site of inflammation was frequently observed and targeting IL-8-CXCR1 signalling 
by antagonists or blockers was found to be beneficial in a broad range of diseases, 
such as asthma, chronic obstructive pulmonary disease, ulcerative colitis, cystic 
fibrosis and type I diabetes (Russo et al., 2014). In infectious diseases, expression of 
CXCR1 in each cell type is elaborately regulated after exposure to different 
pathogens and any inappropriate changes may lead to detrimental outcomes. CXCR1 
plays a critical role in mediating the migration of neutrophils towards the infectious 
site. This IL-8 induced recruitment has frequently been shown to be beneficial in 
infectious diseases (Ha et al., 2017; Lundstedt et al., 2007; Ragnarsdottir et al., 2008). 
Various strategies have been developed by pathogens so as to break or weaken this 
defence. For example, Helicobacter pylorus was shown to decrease CXCR1 
expression through rapid degradation and endocytosis (Schmausser et al., 2004). 
Mycobacteria could reduce IL-8 secretion from alveolar epithelial cells by CXCR1 
and CXCR2 mediated GRK2 expression and inhibit subsequent neutrophil 
recruitment (Håkansson et al., 2013). Staphylococcus aureus was shown to kill 
neutrophils and monocytes by releasing Leukotoxin ED that specifically targets 
either of the IL-8 receptors (Reyes-Robles et al., 2013). However, in some other 
cases (e.g. Klebsiella pneumoniae infection), recruitment of neutrophils mediated by 
CXCR1 may do more harm than good due to severe neutrophilic inflammation (Wei 
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et al., 2013). In viral infections, IL-8 triggered by adenovirus from macrophages was 
found to promote virus binding to epithelial cells through CXCR1 mediated ανβ3 
integrin relocation (Lütschg et al., 2011). In HIV-1 infection, IL-8 was shown to 
enhance viral replication in T lymphocytes, monocyte-derived macrophages and 
microglia through CXCR1 mediated activation of the NF-κB pathway (Lane et al., 
2001; Mamik and Ghorpade, 2014). Higher expression of both IL-8 and CXCR1 was 
found in PBMCs from antiretroviral therapy naïve children with progressive disease, 
compared with their long-term non-progressive counterparts (Pananghat et al., 2016). 
In addition, HIV-1 matrix protein p17 was found to mimic IL-8 via interacting with 
CXCR1 expressing cells, including monocytes, lymph node-derived lymphatic 
endothelial cells, umbilical vein endothelial cells (Caccuri et al., 2012; Caccuri et al., 
2014; Giagulli et al., 2012). 
Apart from infectious diseases and benign inflammatory diseases, IL-8-CXCR1 
signalling has been studied in a wide variety of cancers, including melanoma, 
prostate cancer, breast cancer, gastric cancer, pancreatic cancer, colorectal cancer 
and lung cancer. Up-regulated CXCR1 was observed in many cancer types and was 
commonly linked to poor prognosis and resistance to chemotherapy (Chen et al., 
2014c; David et al., 2016; Han et al., 2015). In colorectal cancer, expression of 
CXCR1 correlated with the metastatic potential of tumour cells and could be 
regulated by epithelial-mesenchymal transition (Bates et al., 2004; Li et al., 2001). In 
prostate cancer, CXCR1 was found to be highly expressed only by 
non-neuroendocrine secretory-type tumour cells and the distribution of CXCR1 
became more non-apical and cytoplasmic as disease severity increased (Huang et al., 
2005; Murphy et al., 2005). In melanoma cell lines, expression of CXCR1 was 
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decreased in cells put into suspension but increased noticeably after reattachment as 
a consequence of phosphorylation of Jun amino-terminal kinases (Uen et al., 2015). 
In general, the IL-8-CXCR1 pathway has been shown to act directly on tumour cells 
in both autocrine and paracrine manners and mainly exert oncogenic effects (Ha et 
al., 2017; Liu et al., 2016b; Waugh and Wilson, 2008). Suppression of IL-8 
signalling through CXCR1 knockdown or antagonist in various types of tumour cells 
demonstrated that this pathway could fuel tumour growth by promoting cell cycle 
entry, supporting tumour proliferation, preventing spontaneous apoptosis and 
enhancing angiogenic activity, migration, invasion and metastasis (Chen et al., 2014c; 
Liu et al., 2012b; Shamaladevi et al., 2009; Singh et al., 2010; Wang et al., 2016a).  
CXCR1 was also found to be enriched in cancer stem cells in many cancer types and 
to facilitate their functions in response to IL-8 (Chen et al., 2014c; Ginestier et al., 
2010). Although only CXCR1 was detected on glioma cell lines, both CXCR1 and 
CXCR2 were expressed on the cancer stem cells isolated from glioblastoma tumour 
specimens and both were responsible for the proliferation, migration and neurosphere 
formation of these cells induced by IL-8 (Infanger et al., 2013; Raychaudhuri and 
Vogelbaum, 2011). Both receptors were also shown to be able to maintain the 
stem-like features of glioblastoma stem cells through phosphorylation of STAT3 but 
CXCR1 was dominant (Zhou et al., 2014). Intriguingly, in breast cancer, 
tumoursphere formation and survival of the cancer stem population were found to be 
solely mediated by CXCR1 rather than CXCR2 (Ginestier et al., 2010). In melanoma, 
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CXCR1 was involved in the maintenance of the quiescent state of stem cells in an 
ABCB539 controlled IL-1β/IL-8/CXCR1 signalling loop (Wilson et al., 2014).  
Apart from the tumour cells, many other cells in the tumour environment can 
participate in carcinogenesis via CXCR1. For example, increased circulating 
myeloid-derived suppressor cells (MDSCs) correlated with tumour progression and 
infiltration of MDSCs into the tumour environment could suppress the anti-tumour 
activity of T cells. Previous studies demonstrated that CXCR1 is expressed on 
granulocytic MDSCs and was responsible for its recruitment by IL-8 (Alfaro et al., 
2016; David et al., 2016). Also, migration of Foxp3+ CD4+ regulatory T cells, was 
shown to be mediated through CXCR1 (Eikawa et al., 2010). In prostate cancer, 
CXCR1 was highly expressed on adipose stromal cells. It was shown to facilitate the 
induction of α-smooth muscle actin  on adipose stromal cells and consequently 
promote endothelial cell proliferation in a contact dependent manner (Zhang et al., 
2016). Additionally, activation of CXCR1 on endothelial cells can directly promote 
tumour angiogenesis (David et al., 2016). In bone metastases of breast cancer, 
CXCR1-expressing osteoclasts and their precursors were found to be responsible for 
pro-osteoclastogenic activity (Kamalakar et al., 2014).  
The role IL-8 has also been investigated in HPV-related disease. However, the 
majority of published studies concentrate on the expression of IL-8 and its potential 
upstream regulators, such as HPV viral proteins, seminal plasma, thymidine-derived 
sugars and tumour associated macrophages (Carrero et al., 2015; Ding et al., 2014; 
Liu et al., 2016a; Sales et al., 2012; Tabata et al., 2012). Very few studies have 
explored the role of IL-8 receptors in depth. In HPV-related cervical disease, as 
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mentioned in Chapter 1, a chemokine profile study done in our group found that 
both IL-8 and CXCR1 were upregulated with increased disease severity (Data not 
shown). Both IL-8 and CXCR1 seem to affect the overall outcomes of cervical 
cancer patients (see Appendix 4). The estimated prognostic effect of IL-8 based on 
TCGA-CESC database is consistent with an early finding (Fujimoto et al., 2000).  
Wu and co-workers showed that IL-8 increased proliferation and migration of 
cervical cancer cells in vitro and promoted tumour growth and metastasis in their 
xenograft model (Wu et al., 2013b). In another study performed by Liu and 
colleagues, IL-8 and CXCR1, but not CXCR2 were found to be significantly 
increased in cervical cancer tissues in comparison with cervicitis and these 
differences were postulated as the consequence of hypoxia. Furthermore, the authors 
found that IL-8 could enhance the viability of HeLa and SiHa cells and reduce their 
apoptosis (Liu et al., 2014). It is noteworthy that the expression patterns of CXCR1 
and in cervical cancer tissue have not been well characterized yet.  
The targeted CXCR1 rs2234671 SNP causes a missense amino acid substitution in 
the third extracellular loop of the CXCR1 (at amino acid position 276) and the minor 
allele was significantly enriched in HPV16 positive cervical cancers and vulval 
cancers. Based on the known roles of IL-8-CXCR1 signalling in other physiological 
and pathological situations and after due consideration of the identified genetic 
association and related findings in cervical cancer, the effect of CXCR1 rs2224671 
on cell migration, proliferation and angiogenesis was further investigated. The 
working hypothesis was that “The G-C substitution at nucleotide position 827 
(serine-threonine substitution at amino acid position 276) of CXCR1 results in 
increased IL8-induced cell motility, proliferation and angiogenic activity”. Like 
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previous studies using selective point mutations to locate the structural features 
involved in ligand binding, receptor activation and regulation, in this chapter, the 
hypothesis was tested using cell models generated though site directed mutagenesis, 
which were either transient or stably over-expressing CXCR1 827G or CXCR1 827C. 
The effects of CXCR1 827G or CXCR1 827C on cell migration towards IL-8 was 
compared using a chemotaxis assay (chemotactic gradient dependent migration) and 
a wound healing assay (non-gradient dependent migration). The results of the 
chemotaxis assay and the wound healing assay are described in Section 5.2. Also, to 
assess the functional consequence of the SNP rs2234671 on tumour cell proliferation, 
I measured the cell growth rate using a cell counting kit-8 (CCK8) assay with 
HPV16 positive cervical cancer cell lines over-expressing either CXCR1 827G or its 
C-substituted counterpart. The results of the proliferation assay are described in 
Section 5.3. In addition, the functional role of the SNP in angiogenesis was explored. 
Due to the lack of an accessible endothelial cell model, the direct effect of the SNP 
on endothelial cells in response to IL-8 could not be explored. Instead, the indirect 
effects of the SNP on the IL-8 induced production of angiogenic molecules were 
investigated using the established cell models. Previous studies showed that a 
CXCR1/2 antagonist could reduce vascular endothelial growth factor (VEGF) 
expression in a xenograft model for lung cancer(Khan et al., 2015). In prostate 
cancer cells, production of VEGFA was found to be significantly increased after 
transfected with an IL-8–secreting plasmid and significantly decreased after CXCR1 
depletion. (Araki et al., 2007; Shamaladevi et al., 2009). Collectively, these findings 
suggested a potential mechanism for IL-8-CXCR1 mediated angiogenic responses in 
cancer cells. Therefore, expression of VEGFA following IL-8 stimulation was 
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chosen to be measured in cells over-expressing CXCR1 827G or CXCR1 827C. The 
corresponding results are described in Section 5.4. 
5.2 Effects of CXCR1 rs223467 on IL-8 induced cell motility  
5.2.1 Overexpression of CXCR1-827C but not CXCR1-827G enhances 
chemotaxis towards IL-8 in HEK293 cells 
To assess whether the serine to threonine conversion at amino acid position 276 
could affect the chemotactic function of CXCR1, a chemotaxis assay was performed 
in a transwell system with HEK293 cells expressing plasmids encoding for the major 
and minor alleles, CXCR1 827G and 827C, respectively. The detailed design of this 
experiment was described in Section 2.3.6.1.1. Representative images of migrated 
cells in each condition were shown in Figure 33. Chemotaxis was analyzed using 
two-way ANOVA and Sidak's multiple comparisons test, with IL-8 and different 
transfectants (i.e. pCR3, pCR3-CXCR1 827G and pCR3-CXCR1 827C) as two 
independent variables. As expected, a significant main effect of the CXCR1 
rs2234671 genotype on chemotaxis was found, F (2, 48) =22.41, p<0.0001. 
Significantly more pCR3-CXCR1 827C-expressing cells were found to migrate in 6h 
than pCR3-transfected cells and pCR3-CXCR1 827G transfected cells. Also the 
presence of a significant effect of IL-8 (100ng/ml) on chemotaxis was confirmed, F 
(1, 48) =13.71, p<0.001, which indicated a significantly higher cell migration rate in 
IL-8 treated groups. More importantly, a significant interaction between IL-8 and 
CXCR1 rs2234671 genotype was observed, F (2, 48) = 4.869, p=0.0119. As can be 
seen from both Figure 33 and 34, the number of migrated cells did not differ among 
non-IL-8-treated groups, which suggested that the rate of non-specific migration was 
similar among groups in the assay. After incubation in the presence of IL-8 for 6h, 
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although very few pCR3-transfected cells and pCR3-CXCR1 827G transfected cells 
were observed to migrate towards the bottom chamber, cells expressing 
pCR3-CXCR1 827C exhibited significantly increased IL-8-dependent migration.   
 
 
Figure 33 Chemotaxis of HEK293 cells expressing CXCR1-827G/C alleles after 
IL8 stimulation 
This figure shows the representative images of migrated cells after 6h of incubation. 
Migrated cells were labelled with CFSE and shown as green dots. All these images were 
taken at 10X under an EVOS™ digital inverted microscope (Advanced Microscopy Group, 
Bothell, WA) with GFP cube and the scale bar=400μm. 
 Untreated                         IL-8 treated  
pCR3 








Figure 34 Chemotaxis in HEK293 cells transiently transfected with CXCR1 
827G/C alleles 
Chemotaxis assays were performed in a transwell system using HEK293 cells expressing 
pCR3, pCR3-CXCR1 827G and pCR3-CXCR1 827C.After 6h incubation in the presence or 
absence of IL-8(100ng/ml), cells migrated through the membrane were counted and the 
chemotaxis index was calculated for each transwell following the equation mentioned in 
Materials and Methods section. Data are presented as box-and-whiskers plots with median 
(horizontal line in box), the first and third quartiles (boxes) and range (whiskers) for three 
assays with each condition performed in triplicate. Since all groups passed normality tests, 
ordinary two-way ANOVA test and Sidak's multiple comparisons test were performed to 
test the effects of IL8 and transfectant type individually and the interaction between the 
two on chemotaxis. IL-8, transfectant type and the interactions between the two were all 
found to be significant (p value: =0.0005, <0.0001 and 0.0119 respectively). Figure 34A 
shows that the chemotaxis index of IL-8 treated pCR3-CXCR1 827C-expressing cells are 
significantly higher (Mean=2.702, SD=1.001) than their untreated counterparts 
(Mean=1.503, SD=0.618).No significant differences were observed for the other two groups 
before or after IL-8 treatment. Figure 34B indicates that the chemotaxis index of 
pCR3-CXCR1 827C transfected cells (Mean=2.702, SD=1.001) are significantly higher than 
cells transfected with pCR3-CXCR1 827G (Mean=1.324, SD=0.471) and pCR3 (Mean=1, 






5.2.2 Increased cell migration in CaSki cells over-expressing 
the CXCR1 827C allele   
Cell-cell contacts affect cell motility. Since the chemotaxis assay mentioned above 
could not indicate the influence of cell-cell contacts on cell migration, a wound 
healing assay was performed to investigate the role of rs2234671 in cell-cell contact 
related cell movement in the presence or absence of exogenous IL-8 stimulation. A 
previous study showed that the migration of cervical cancer cells can be promoted by 
IL-8 (Zhao et al., 2013). Considering that rs2234671 was found to be associated with 
the development of HPV16 positive cervical cancers, CaSki, a HPV16 positive cell 
line, was chosen to be transduced with CXCR1 827G or CXCR1 827C and used in 
the wound healing assay. This cell line has often been utilized in wound healing 
assays and forms a good quality monolayer. The details of the experiment were 
described in Section 2.3.6.1.2. Flow cytometry indicated that CXCR1 expression of 
the tested CXCR1 827G and CXCR1 827C transduced cells were generally 
comparable, whereas the MFI was slightly lower in CXCR1 827C transduced cells in 
comparison to their CXCR1 827G counterparts (Figure 24).  
The wound healing assay was first performed in culture media with 10% fetal bovine 
serum (FBS). Representative images of wound closure in each condition are shown 
in Figure 35 (in the presence of IL-8) and Figure 36 (in the absence of IL-8). Cell 
migration was evaluated as reduced area of the wound after 6h of incubation in the 
presence or absence of IL-8. Similarly to the analysis for chemotaxis, two-way 
ANOVA test and Sidak's multiple comparisons test were used to analyse the data, 
with IL8 treatment and CaSki cells with different transduction procedures (i.e. 
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parental (untransduced), CXCR1 827G transduced and CXCR1 827C transduced) as 
two independent variables. 
Again, main effects of both independent variables were observed. Significantly 
larger average reduced area was found in IL-8 treated groups compared with those 
untreated ones, with a p value of 0.0123, F (1, 48)=6.775. This main effect was 
mainly contributed by CXCR1 827C transduced cells. No significant differences 
were observed before or after IL-8 treatment for the CXCR1 827G transduced and 
parental CaSki cells, which was similar to the findings for the pCR3-CXCR1 827G 
and pCR3 transfected HEK293 cells in the chemotaxis assay. Additionally, the 
influences of parental, CXCR1 827G and CXCR1 827C transduced CaSki cells on 
cell migration were significantly different, p<0.0001, F (2, 48) =178.6. The 
interaction between IL-8 and different transductants were also found to be significant, 
with F (2, 48) = 4.779 and p =0.0128, even though it contributed to only 2.3% of 
overall variability. As shown in Figure 37, CXCR1 827C transduced cells 
consistently migrated more than CXCR1 827G transduced cells in both IL-8 treated 
and untreated conditions, though the relative difference was more pronounced in the 
presence of IL-8. The results suggested that rs2234671 did affect CaSki cell 
migration in a cell-cell contact condition and the effect depended only slightly on 
exogenous IL-8 stimulation. It is worthwhile to note that even without exogenous 
IL-8, significantly more cells migrated towards the wound region in CXCR1 827G or 
CXCR1 827C transduced groups, compared with the parental cells. This could 
possibly be explained by endogenous IL-8 produced by CaSki cells. An early study 
showed that local production of IL-8 is significantly higher in cervical cancer 
patients than those with benign lesions (Tjiong et al., 1999). Previous results in the 
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group of my PhD supervisor suggested that CaSki cells express a higher level of IL-8 
mRNA than other cervical cancer cell lines tested, including SiHa, HeLa and 
C-33A cells. This speculation could be experimentally tested by measuring the 
secreted IL-8 in the culture media or by targeting IL-8 using neutralizing antibodies. 
Hypoxia and nutrient deprivation often occur at the tumour site. In order to evaluate 
the influence of rs2234671 on cell-cell contact related cell movement in a serum 
nutrient-reduced environment and diminish the wound closure caused by cell 
proliferation, the wound healing assay was also performed in 2% serum culture 
medium (“serum-starved cultures”). Medium containing less than 2% serum was 
tested but could not support the formation of a good quality monolayer and the 
creation of the wound region. All other experimental conditions remained the same. 
Representative images of wound healing in serum-starved condition are shown in 
Figure 38 (in the presence of IL-8) and Figure 39 (in the absence of IL-8). In general, 
the findings in 2% serum condition were similar to the 10% serum condition, though 
the reduced area largely decreased in all the groups and the differences among the 
groups became more obvious. As can be seen from Figure 40, both independent 
variables were shown to be significant and the interaction between the two was also 
found to be significant, F (2, 48) =5.539, p=0.0068, though it was consistent with the 
patterns seen in the main effects. Only CXCR1 827C transduced CaSki cells 
exhibited significantly greater migration activity after stimulation with exogenous 
IL-8, which was consistent with the observations in 10% FBS. When the cells were 
incubated in the absence of exogenous IL-8, the average reduced area was 
significantly larger for CXCR1 827C transduced cells (M=110394.3, SD=13778.37) 
than that of CXCR1 827G (M=78978.56, SD=14082.2) and parental CaSki cells 
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(M=40194.39, SD=9807.423). Likewise, when the cells were treated with IL-8, the 
closure area was also significantly larger for CXCR1 827C transduced cells 
(M=143823.8, SD=1455.070) than for CXCR1 827G (M=78978.56, SD=14082.2) 
and parental CaSki cells, but the difference between CXCR1 827C and CXCR1 





Figure 35 Representative images of cells migrating towards the wound before and after 6h of incubation in normal medium with 
IL-8. 
All these images were taken at 10X under an EVOS™ digital inverted microscope (Advanced Microscopy Group, Bothell, WA) with the transmitted 
filter cube. The wound area of each image was circled and measured using the freehand selection tool and the analyze-measure tool of ImageJ. 
Reduced area covered by migrated cells after incubation was calculated by subtracting the wound area at 6h from the wound area at 0h. 
Parental CaSki  0h CaSki  CXCR1 827G 0h CaSki  CXCR1 827C 0h




Figure 36 Representative images of cells migrating towards the wound before and after 6h of incubation in normal medium 
without exogenous IL-8 
All these images were taken at 10X under an EVOS™ digital inverted microscope (Advanced Microscopy Group, Bothell, WA) with the transmitted 
filter cube. The wound area of each image was circled and measured using the freehand selection tool and the analyze-measure tool of ImageJ. 
Reduced area covered by migrated cells after incubation was calculated by subtracting the wound area at 6h from the wound area at 0h.
Parental CaSki  0h CaSki  CXCR1 827G 0h CaSki  CXCR1 827C 0h





Figure 37 Migration of the CXCR1 827G transduced, CXCR1 827C transduced 
and parental CaSki cells in the wound healing assay (10% serum)  
Wound healing assays were performed in 24 well plates using parental CaSki cells and CaSki 
cells stably transduced with CXCR1 827G or CXCR1 827C. After 6h incubation in the 
presence or absence of IL-8 (100ng/ml), reduced wound area covered by cells migrating 
towards the wound was measured as described in Materials and Methods section. Data are 
presented as box-and-whiskers plots with median (horizontal line in box), the first and third 
quartiles (boxes) and range (whiskers) for three assays with each condition performed in 
triplicate. Since all groups passed normality tests, ordinary two-way ANOVA test and Sidak's 
multiple comparisons test were performed to test the effects of IL8 and transductant type 
individually and the interaction between the two on cell-cell contact related migration. IL-8, 
transductant type and the interactions between the two were all found to be significant (p 
value: =0.0123, <0.0001 and 0.0128 respectively). Figure 37A shows that the reduced area 
of IL-8 treated CXCR1 827C transduced cells is significantly larger (Mean=341404.8, 
SD=17460.52) than their untreated counterparts (Mean=283902, SD=35043.66). No 
significant differences were observed for the other two groups before or after IL-8 
treatment. Figure 37B indicates that the reduced area of CXCR1 827C transduced cells is 
significantly larger than cells transduced with CXCR1 827G both in the presence 
(341404.8±17460.52 vs. 245944.3±39876.680) and in the absence of IL-8(283902±35043.66 







Figure 38 Representative images of cells migrating towards the wound before and after 6h of incubation in 2% serum medium with IL-8 
All these images were taken at 10X under an EVOS™ digital inverted microscope (Advanced Microscopy Group, Bothell, WA) with the transmitted 
filter cube. The wound area of each image was circled and measured using the freehand selection tool and the analyze-measure tool of ImageJ. 
Reduced area covered by migrated cells after incubation was calculated by subtracting the wound area at 6h from the wound area at 0h.
Parental CaSki  0h CaSki  CXCR1 827G 0h CaSki  CXCR1 827C 0h




Figure 39 Representative images of cells migrating towards the wound before and after 6h of incubation in 2% serum medium without 
exogenous IL-8 
All these images were taken at 10X under an EVOS™ digital inverted microscope (Advanced Microscopy Group, Bothell, WA) with the transmitted 
filter cube. The wound area of each image was circled and measured using the freehand selection tool and the analyze-measure tool of ImageJ. 
Reduced area covered by migrated cells after incubation was calculated by subtracting the wound area at 6h from the wound area at 0h
Parental CaSki  0h CaSki  CXCR1 827G 0h CaSki  CXCR1 827C 0h




Figure 40 Migration of the CXCR1 827G transduced, CXCR1 827C transduced 
and parental CaSki cells in the wound healing assay (2% serum) 
Wound healing assays were performed in 24 well plates using parental CaSki cells and CaSki 
cells stably transduced with CXCR1 827G or CXCR1 827C. After 6h incubation in the 
presence or absence of IL-8 (100ng/ml), reduced wound area covered by cells migrating 
towards the wound was measured as described in Materials and Methods section. Data are 
presented as box-and-whiskers plots with median (horizontal line in box), the first and third 
quartiles (boxes) and range (whiskers) for three assays with each condition performed in 
triplicate. Since all groups passed normality tests, ordinary two-way ANOVA test and Sidak's 
multiple comparisons test were performed to test the effects of IL8 and transductant type 
individually and the interaction between the two on cell-cell contact related migration. IL-8, 
transductant type and the interactions between the two were all found to be significant (p 
value: =0.0003, <0.0001 and 0.0068 respectively). Figure 40A shows that the reduced area 
of IL-8 treated CXCR1 827C transduced cells is significantly larger (Mean=143823.8, 
SD=14553.07) than their untreated counterparts (Mean=110394.3, SD=13778.37). No 
significant differences were observed for the other two groups before or after IL-8 
treatment. Figure 40B indicates that the reduced area of CXCR1 827C transduced cells is 
significantly larger than cells transduced with CXCR1 827G both in the presence 
(143823.8±14553.07 vs. 87210.61±21568.40) and in the absence of 






5.3 Effects of CXCR1 rs223467 on IL-8 induced proliferation 
CXCR1 is consistently reported to induce cell proliferation in response to IL-8. As 
mentioned in Section 5.1, IL-8 can promote the proliferation of both HeLa and SiHa 
cells (Liu et al., 2014). To assess whether rs2234671 could affect cell proliferation 
mediated by CXCR1 in response to IL-8 stimulation, proliferation assays were 
performed with stably transduced CaSki and SiHa cells over expressing either 
CXCR1 827G or 827C. Both these cervical cancer cell lines are HPV16 positive, 
which was considered to be an important feature according to the genetic association 
studies. Similar to the transduced CaSki cells, flow cytometry showed that CXCR1 
expression of the tested SiHa transductants was generally comparable, although the 
MFI of CXCR1 827C transduced cells was also slightly lower than those with 
CXCR1 827G (Figure 23). As mentioned in Section 2.3.6.2, cells were seeded and 
treated with concentrations of IL-8, ranging from 0.1 to 100ng for 48h and then 
evaluated for the proliferation rate in comparison with untreated controls.  
As shown in Figure 41 and 42, rs2234671 could affect cell proliferation in both 
CXCR1 827C transduced CaSki and SiHa cells, though the mode of action was a 
slightly different. CXCR1 827C transduced CaSki cells exhibited significantly higher 
proliferation rate than the untreated controls in response to 1ng/ml, 10ng/ml or 
100ng/ml exogenous IL-8 while significant increase of cell growth was observed for 
CXCR1 827C transduced SiHa cells only in the presence of 10ng/ml exogenous IL-8. 
Cell proliferation rates of CXCR1 827G transduced CaSki cells and parental CaSki 
did not significantly increased compared with corresponding untreated controls. 
Similarly, exogenous IL-8 did not promote proliferation of CXCR1 827G transduced 




Figure 41 Proliferation of CXCR1 827G, CXCR1 827C and parental CaSki cells 
in the presence of different concentration of exogenous IL-8 
Proliferation assay was performed to analyze the proliferation of CXCR1 827G, CXCR1 827C 
transduced SiHa cells and parental SiHa cells. Cells were seeded in 96-well plates and 
treated with different concentration of IL-8, ranging from 0.1-100ng/ml. 48h after 
incubation, proliferation was measured using CCK-8 cell counting kit as the increase in the 
absorbance and the proliferation rate was calculated compared with corresponding 
non-treated controls. The assay was performed three times with each condition in triplicate. 
Data are expressed as the mean ± SE. Since all groups passed normality tests, one-way 




Figure 42 Proliferation of CXCR1 827G, CXCR1 827C and parental SiHa cells in 
the presence of different concentration of exogenous IL-8 
Proliferation assay was performed to analyze the proliferation of CXCR1 827G, CXCR1 827C 
transduced SiHa cells and parental SiHa cells. Cells were seeded in 96-well plates and 
treated with different concentration of IL-8, ranging from 0.1-100ng/ml. 48h after 
incubation, proliferation was measured using CCK-8 cell counting kit as the increase in the 
absorbance and the proliferation rate was calculated compared with corresponding 
non-treated controls. The assay was performed three times with each condition in triplicate. 
Data are expressed as the mean ± SE. Since all groups passed normality tests, one-way 
ANOVA test and Sidak's multiple comparisons test were performed. When treated with 
10ng/ml IL-8, a promoting effect on cell proliferation of CXCR1 827C transduced cells was 
observed, of which the proliferation rate was significantly higher than untreated controls. 
When treated with 100ng/ml IL-8, proliferation rates of CXCR1 827G transduced and 
parental SiHa cell groups significantly decreased in comparison with their corresponding 
10ng/ml IL-8 treated counterparts (p value<0.001 and =0.024 respectively). No significant 
difference was observed between 10ng/ml and 100ng/ml IL-8 treated CXCR1 827 








5.4 Effects of CXCR1 rs223467 on angiogenesis indirectly induced by 
IL-8  
5.4.1 Measuring the induction of VEGFA by IL-8 using the 
transient transfection model 
Transiently transfected cell models were initially used for the measurement of 
VEGFA expression in response to IL-8 treatment (100ng/ml). pCR3, pCR3-CXCR1 
827G, pCR3-CXCR1 827C transfected HEK293 cells, together with mock 
transfected HEK293 cells, were incubated with 100ng/ml IL-8 for a range of time 
periods (i.e. 6h, 8h, 12h and 24h) afterwards, VEGFA mRNA was measured for each 
condition as described in Section 2.3.6.3.1. As can be seen from Figure 43, 
significant differences among tested groups were observed at both 6h and 8h, but 
were more pronounced at 8h. After incubation with IL-8 for 8h, VEGFA expression 
was significantly increased in all the transfected groups in comparison with the 
mock-transfected group. However, no significant differences were observed among 
the transfected groups. The induction of VEGFA did not differ between 
pCR3-CXCR1 827C transfected cells and their pCR3-CXCR1 827G counterparts. 
Since the pCR3 transfected group also significantly increased VEGFA expression, 
the induction of VEGFA observed in the assay was very unlikely to be mediated by 
the overexpression of CXCR1 in transfected HEK293 cells. 
In order to determine the factors that caused the induction of VEGFA expression in 
the transient transfection model, I repeated the same assay using the 8h time point, 
with two new groups added in, which were non-IL-8 treated pCR3 transfected 
HEK293 group and non-IL-8 treated mock transfected group respectively. The 
results were shown in Figure 44. Again no significant difference in VEGFA 
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expression was observed between pCR3-CXCR1 827C and pCR3-CXCR1 827C 
transfected cells. As shown in Figure 44, neither transfection with pCR3 in the 
absence of IL-8 nor mock-transfection with IL-8 exhibits any significant enhancing 
effect. These findings suggested that the induction of VEGFA expression in the assay 
was likely due to a synergistic effect of transfection with pCR3 and IL-8 treatment.  
 
Figure 43 Time course analysis of VEGFA expression in HEK293 expressing 
CXCR1 827G/C alleles after IL-8 stimulation. 
Expression of VEGFA mRNA extracted from pCR3, pCR3 CXCR1 827G, pCR3 CXCR1 827C 
transfected and mock-transfected HEK293 cells after incubation with IL-8(100ng/ml) for 6h, 
8h, 12h and 24 respectively, was determined by RT-qPCR. Three independent assays were 
performed to obtain the data and in each assay, qPCR was performed in duplicate for each 
sample. GAPDH was used as housekeeping controls and the fold change of VEGFA in each 
test sample compared with IL-8 treated mock transfected cells was calculated by 2-∆∆CT 
method as described in Section 2.3.6.3.1. Statistical analysis was performed using ordinary 
two-way ANOVA test and Sidak's multiple comparisons test. Data are presented as mean 




Figure 44 Expression of VEGFA in HEK293 cells transiently transfected with 
CXCR1 827G/C alleles with and without IL-8 stimulation. 
Expression of VEGFA mRNA extracted from IL-8 treated pCR3, pCR3 CXCR1 827G, pCR3 
CXCR1 827C transfected and mock-transfected HEK293 cells and non-IL-8 treated pCR3 
transfected and mock-transfected HEK293 cells was determined by RT-qPCR. Each condition 
was repeated at least five times and the qPCR was performed in duplicate for each sample. 
GAPDH was used as housekeeping controls and the fold change of VEGFA in each test 
sample compared with IL-8 treated mock transfected cells was calculated by 2-∆∆CT 
method as described in Section 2.3.6.3.1. Statistical analysis was performed using 
Kruskal-Wallis test and Dunn's multiple comparisons test. Data are presented as mean ±SD, 






5.4.2 Measuring the induction of VEGFA by IL-8 using the 
stable transduction model 
Although induction of VEGFA was observed in the transient transfection models, the 
effects were likely due to confounding factors instead of the overexpression of 
CXCR1. In order to make clear the influence of the SNP on VEGFA expression in 
response to IL-8, the same assay was performed in stably transduced cells to avoid 
the effects caused by the transfection procedure. 100ng/ml IL-8 was used for the 
assay and the 8h time point was chosen for the measurement.  
As shown in Figure 45 and 46, neither the transduced SiHa cells nor the transduced 
CaSki cells could significantly increase the expression of VEGFA in comparison 
with the corresponding parental cells and there was no significant difference 
observed between CXCR1 827G and CXCR1 827C transduced cells. The results 
suggested that exogenous IL-8 is unlikely to stimulate VEGFA expression in SiHa 
and CaSki cells and the SNP does not play a role. Considering that no positive 
findings were observed in either transiently or stably transduced cells, this was not 






Figure 45 Expression of VEGFA in IL-8 treated SiHa cells transduced with 
CXCR1 827G/C alleles 
CXCR1 827G or CXCR1 827C transduced SiHa cells and parental SiHa cells were incubated 
with or without 100ng/ml IL-8 for 8h.Afterwards, expression of VEGFA mRNA extracted 
from each sample was determined by RT-qPCR. Six independent assays were performed to 
obtain the data and in each assay, qPCR was performed in duplicate for each sample. 
GAPDH was used as housekeeping controls and the fold change of VEGFA in each test 
sample compared with IL-8 treated mock transfected cells was calculated by 2-∆∆CT 
method as described in Section 2.3.6.3.1. Statistical analysis was performed using ordinary 
two-way ANOVA test and Sidak's multiple comparisons test. Data are presented as mean 
±SD. 
 
Figure 46 Expression of VEGFA in IL-8 treated CaSki cells transduced with 
CXCR1 827G/C alleles 
CXCR1 827G or CXCR1 827C transduced CaSki cells and parental CaSki cells were incubated 
with or without 100ng/ml IL-8 for 8h.Afterwards, expression of VEGFA mRNA extracted 
from each sample was determined by RT-qPCR. Three independent assays were performed 
to obtain the data and in each assay, qPCR was performed in duplicate for each sample. 
GAPDH was used as housekeeping controls and the fold change of VEGFA in each test 
sample compared with IL-8 treated mock transfected cells was calculated by 2-∆∆CT 
method as described in Section 2.3.6.3.1. Statistical analysis was performed using ordinary 





Before this study, potential functional roles of CXCR1 rs2234671 have only been 
described in two studies. In one of the studies, candidemic patients with the minor 
allele40 of rs2234671 were shown to be more susceptible to disseminated infections. 
De-granulation and fungal killing abilities of neutrophils from minor allele carriers 
were found to be significantly lower than the major allele homozygotes (Swamydas 
et al., 2016). In the other study, the minor allele was found to be correlated with 
urine IL-8 levels in women with asymptomatic bacteriuria (Hawn et al., 2009). Apart 
from these two studies, the roles of CXCR1 rs2234671 in other biological processes 
and in other disease conditions have not been investigated yet. Therefore, this project 
focused on the impact of CXCR1 rs2234671 on IL-8 induced cell motility, cell 
proliferation and VEGFA expression in HR-HPV-related cervical disease.  
In the chemotaxis assay, HEK293 cells expressing the minor allele of CXCR1 
rs2234671 exhibited significantly higher chemotactic activity towards IL-8 than 
those cells expressing the major allele. This finding suggested that CXCR1 
rs2234671 might be functionally important in the pathogenesis of HR-HPV-related 
cervical disease by altering the IL-8 induced chemotactic activity of 
CXCR1-expressing cells. The HEK293 cell line was used in this assay because it 
was easy-to-transfect and had been shown to work in chemotaxis assays under 
different experimental conditions (Vinet et al., 2013; Wang et al., 2016b), including 
IL-8 induced chemotaxis (Boisvert et al., 2012; Feniger-Barish et al., 2003). 
However, it is noteworthy that this cell line does not express CXCR1 so it might not 
                                                             
40 In this study, subjects with a threonine at the amino acid position 276 of the CXCR1 protein were 
considered to have CG+GG genotype. The genotypes were called according to the non-coding strand, 
which did not comply with the conventional nomenclature. The equivalent genotypes in accordance 
with the conventional nomenclature system should be CG+CC and the minor allele should be C. 
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be the best cell line to reflect the real IL-8-CXCR1 signalling in physiological and 
pathological conditions. Thus, the difference between the two alleles of CXCR1 
rs2234671 in IL-8 induced chemotaxis has to be discussed cautiously. However, the 
fact that cell migration could be induced in HEK293 cells transiently transfected with 
CXCR1 827G/C alleles hints at a real functional difference between the two alleles. 
Unlike chronic liver diseases, inflammatory gastrointestinal diseases and glomerular 
diseases, the distribution of CXCR1 in different stages of HR-HPV-related cervical 
disease has not been well characterized yet. Since previous studies showed increased 
CXCR1 expression in cervical cancer tissues, cervical cancer cell lines were chosen 
to further evaluate the effects of CXCR1 rs2234671 on cell motility in response to 
IL-8 using the wound healing assay. Penetration of tumour cells through the 
basement membrane is the hallmark event in cervical cancer development and 
tumour cell migration is also an essential step in the metastatic process. Similar to the 
chemotaxis assay, in the wound healing assay, I observed that CaSki cells 
overexpressing CXCR1 827C have a significantly higher migration activity towards 
exogenous IL-8 than those expressing the major allele G in both the normal and the 
serum nutrient deficient culture conditions. These results indicated that the serine to 
threonine substitution of CXCR1 rs2234671 may functionally contribute to the 
development and the metastasis of cervical cancer through the enhancement of 
tumour cell migration in response to IL-8. In addition, it is notable that exogenous 
IL-8 does significantly enhance the migration capacity of CXCR1 827C transduced 
cells, but the migration activity of CXCR1 827G transduced cells did not differ 
before and after exogenous IL-8 stimulation. This finding also provides a 
hypothetical explanation for the shorter overall survival in cervical cancer patients 
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with high IL-8 expression, but clearly need to be further investigated. Furthermore, 
the reason for the absence of response to exogenous IL-8 in CXCR1 827G 
transduced CaSki cell is currently unknown and requires further study. 
Cell proliferation is another concern in the development of cancer. As mentioned 
previously, IL-8 could stimulate tumour cell proliferation in cervical cancer through 
its receptor CXCR1.  Therefore, proliferation assay were also performed to compare 
the effects of the two alleles on CXCR1 mediated tumour cell proliferation. In the 
proliferation assay with CaSki cells, the performance of the CXCR1 827G 
transduced cells was similar to that of the untransduced parental CaSki cells. 
Exogenous IL-8 could not increase cell proliferation in either group, compared with 
the corresponding controls. By contrast, proliferation of CXCR1 827C transduced 
CaSki cells was significantly increased by exogenous IL-8 stimulation over a very 
wide range of concentrations (i.e. from 1 to 100ng/ml), compared with untreated 
controls. Similar to the findings in the wound healing assay, the underlying 
mechanism for the lack of response to exogenous IL-8 in CXCR1 827G CaSki cell is 
not clear. But the results of the proliferation assay strongly confirmed the functional 
difference between the two alleles in the proliferative response towards exogenous 
IL-8.  
The proliferation assay was also performed in SiHa cells. In this assay, the 
proliferation rate of parental SiHa cells was not significantly enhanced by exogenous 
IL-8. This finding is slightly different from a previous study performed by Liu and 
colleagues, in which all concentrations of exogenous IL8, from 1 to 100ng/ml, were 
shown to enhance SiHa cell proliferation compared with untreated controls, although 
no significant difference were observed among these three IL-8 treated groups (Liu 
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et al., 2014). The inconsistency between the two studies might be due to differences 
in cell culture conditions, sources of the cells and the measurement methods for cell 
proliferation. Similar to CXCR1 827G transduced CaSki cells, the performance of 
CXCR1 827G transduced SiHa cells did not differ from parental SiHa cells. Only 
CXCR1 827C transduced SiHa cells exhibited an enhanced proliferative response 
towards exogenous IL-8 but only at the concentration of 10ng/ml. Unlike CaSki cells, 
when treated with 100ng/ml IL-8, proliferation rates of CXCR1 827G transduced and 
parental SiHa cell groups significantly decreased in comparison with their 
corresponding 10ng/ml IL-8 treated counterparts. These results suggested that SiHa 
cells might be less “tolerant” to high concentration of exogenous IL-8 and the 
decrease of the proliferation rates might be due to IL-8 toxicity or to increased 
desensitization and internalization of the receptors. However, even in this condition, 
CXCR1 827C transduced SiHa cells showed better tolerance to IL-8 than the two 
groups. Again these findings confirmed the functional difference between the two 
alleles in the proliferative response towards exogenous IL-8.  
Due to the differences in genetic background, it is not appropriate to compare SiHa 
cells and CaSki directly. But in general, SiHa cells exhibited a weaker response 
towards exogenous IL-8 and the response window seemed narrower than CaSki cells. 
The intrinsic genotype of SiHa cells at the SNP locus of interest is G/G while CaSki 
cells have the C/C genotype. It is not clear yet whether the intrinsic genotype could 
be linked to difference in response between the cell lines, but it is clear that in both 
assays, only cells overexpressing the minor allele exhibited an increased proliferative 
response towards exogenous IL-8. Considering that IL-8 is upregulated in high grade 
cervical intraepithelial lesions and cancers, the difference between the two alleles in 
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proliferative response towards exogenous IL-8 might be an explanation for the 
previously observed minor allele enrichment in HPV16 positive cervical cancers.  
Furthermore, I also tested the hypothesis that CXCR1 rs2234671 has a functional 
effect on the induction of VEGFA stimulated by exogenous IL-8 in cervical cancer 
cell lines but no effect was found. However, since IL-8 has been extensively shown 
to promote angiogenesis through a direct interaction with endothelial cells, whether 
the two alleles of the SNP act differently in IL-8 induced angiogenic responses 
of endothelial cells deserves further study.  
Although rs2234671 has been shown to be functional in this project, I could not rule 
out the possibility that other functional SNPs within the same LD bin also 
contributed to the association signal observed in the association study. It should also 
be considered that that SNPs within the same LD bin may have opposite functional 
effects (Bai et al., 2004; Zeng et al., 2017). It is likely that the observed association 
and the observed functional effects are the net effect of multiple functional loci in 
high LD. Thus there is still a need to further functionally characterise other possible 
disease related SNPs in LD with rs2234671.  
Since individuals with the same genotypes may bear different haplotypes, it is also 
important to pay attention to the functional effects of different combinations of 
haplotypes. While making the plasmids for the model cellular systems, I noticed that 
the haplotype carrying all minor alleles of the three markers (i.e. rs16858811, 
rs2234671 and rs16858808) does not exist in the population. This haplotype may 
have been eliminated by selection during evolution. Although this missing haplotype 
has not been investigated in this project, it is a promising target for future functional 
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assays. We might be able to draw direct inferences from the phenotypic changes led 

















































6.1 Summary of findings 
It is known since a long time that SNPs can be associated with common diseases. 
Enormous efforts and money have been invested in hunting for novel susceptible 
loci and the subsequent functional follow-up studies. However, for HR-HPV-related 
cervical cancer, findings from previous genetic association studies only explain a 
small proportion of the heritability. Besides this, very few of the reported associative 
findings have been further functionally validated or dissected so as to gain novel 
insights into the mechanisms by which they may contribute to disease. Although 
updated GWA studies with increased sample sizes and imputation data were 
predicted to yield new associations, these expectations have not been fulfilled yet. 
This project was initiated during the wait for new discoveries from genomic 
approach based studies. In this study, a hypothesis-driven candidate gene approach 
was used to identify novel functional SNPs associated with HR-HPV-related diseases, 
and one of the identified SNPs was subsequently investigated with regard to its 
functional mechanism. The overarching hypothesis was “there are functional SNPs 
within genes involved in host defence and/or oncogenesis that are associated with 
HR-HPV-related cervical cancer and precancerous cervical disease”. In order to 
increase the probability to detect genuine associations, candidate genes and SNPs 
were rationally selected using literature mining methods. The key findings of the 
project are summarised below  
• The SULF1 SNP rs2623047 revealed a strong significant association with the 
susceptibility to HR-HPV-related cervical disease in the genetic association 




• The CXCR1 SNP rs2234671 was significantly associated with the development 
of cervical and vulval cancer in the presence of HPV16. The minor allele C was 
found to be enriched only in HPV16 positive cervical and vulval cancers in the 
genetic association study. 
• The chemotactic response towards exogenous IL-8 was significantly higher in 
HEK293 cells overexpressing CXCR1 with the minor allele C of the CXCR1 
SNP rs2234671 than those with the major allele G. 
• The minor allele C of the CXCR1 SNP rs2234671, rather than the major allele G, 
resulted in significantly enhanced cell migration of stably transduced CaSki cells 
in response to exogenous IL-8. 
• The minor allele C of the CXCR1 SNP rs2234671, instead of the major allele G, 
led to significantly increased proliferative responses towards certain 
concentrations of exogenous IL-8 in stably transduced CaSki cells and SiHa 
cells. 
• Exogenous IL-8 could not induce VEGFA expression in SiHa and CaSki cells 
and the SNP CXCR1 rs2234671 did not affect this. 
6.2 Discussion and future directions 
6.2.1 Candidate gene approach in HR-HPV-related cervical 
disease 
In recent years, high rates of spurious associations and non-replication of previous 
findings markedly dampened researchers’ enthusiasm for pursuing functional disease 
related SNPs through a candidate gene approach. Since candidate gene based 
association studies could be conducted with ease, in numerous studies, casually 
selected genes and SNPs have frequently been tested. However, in such situations, 
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even if association was identified, it was likely to be caused by chance or by linkage 
with unknown causal SNP. Findings obtained in this way are usually considered less 
convincing than those of GWA studies. Even worse, functional interpretation and 
translation of these findings is no easier than those from GWA findings. This directly 
leads to the general impression that the candidate gene approach is inferior to 
genomic approaches and consequently hinders the application and the improvement 
of candidate gene based genetic association studies. Nevertheless, the study 
presented in this thesis provides evidence that a rational candidate gene approach 
could still be a powerful and efficient way to identify novel disease related SNPs and 
to proceed with functional translations, especially when an appropriate candidate 
gene and SNP selection strategy was applied to well characterised clinical samples 
from different stages of disease.  
The majority of susceptible loci previously identified in HR-HPV-related cervical 
disease are located in immune genes and genes known to be involved in 
carcinogenesis, which indicates that genetically-mediated alterations in host defence 
responses may play an essential role in the susceptibility to HR-HPV infection and 
cervical cancer (Mehta et al., 2017). In this project, the identification of the two 
SNPs associated with HR-HPV-related cervical disease provides further evidence 
for this indication. The associations between the two SNPs and HR-HPV related 
cervical disease still need to be validated in a larger sample set.  
As exploration deepens, more immune response gene polymorphisms are expected to 
be discovered and linked with HR-HPV-related cervical disease.  
As mentioned previously, since cervical cancer is a multistep disease, different SNPs 
may be involved in different transition states. The design of the case-control study, 
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especially the grouping strategy, directly determines what results could be achieved. 
In this project, the two key SNPs identified were found to be associated with 
different transition states of HR-HPV-related cervical disease. SULF1 rs2623047 
was associated with the acquisition of HR-HPV while CXCR1 rs2234671 was 
associated with the progression from HSIL to invasive cancer in the presence of 
HPV16. However, it is noteworthy that both associations were identified in the 
validation step, rather than the original discovery phase. 
Due to the poor performance of genomic DNA extracted from formalin-fixed, 
paraffin-embedded cancer samples, the original array could only compare the 
frequency of alleles or genotypes between HR-HPV negative, cytologically normal 
controls and HR-HPV positive, HSIL cases. This design was surely not ideal since it 
was not able to identify any SNPs that are involved in the transition from HSIL to 
cancer. I have to admit that the association between CXCR1 rs2234671 and the 
progression of the disease was picked out quite by chance. It would have been 
missed in the discovery phase if the genotyping error did not occur. The findings for 
CXCR1 rs2234671 suggest the possibility that the same array panel may yield new 
associations when re-evaluated in case-control studies including the transition from 
HSIL to cancer. By contrast, the association signal for SULF1 rs2623047 was 
successfully captured by the original array during the discovery phase. However, it 
left unanswered in this phase the question in which transition state the SNP got 
involved. As mentioned above, at least two noticeable transition states exist during 
the development of HSIL. Not until the additional samples had been genotyped did I 
find out that SULF1 rs2623047 was associated with HR-HPV infection rather than 
the formation of HSIL. 
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Based on the findings in this project, each candidate SNP needs to be separately 
evaluated in each transition state so as to draw a more precise conclusion. An ideal 
case-control candidate gene based study in HR-HPV-related cervical disease should 
start with a comparison between HR-HPV negative, cytologically normal controls 
and HR-HPV positive cancer cases. This kind of design ensures that all the known 
transition states are included and increases the power to detect association in the 
discovery phase. In the following step, HR-HPV positive, cytologically normal or 
LSIL cases and HR-HPV positive, HSIL cases should be genotyped to further 
delineate associations among each transition states. 
6.2.2 A potential follow-up study for SULF1 SNP rs2623047 
SULF1 rs2623047 has been found to be associated with HR-HPV infection in this 
project and the association is independent from previously reported association 
signals within intronic regions of SULF1 (Wang et al., 2010). Since functional assays 
for this SNP could not be done within the timeframe of this project, the in silico tool 
HaploReg v4 (Ward and Kellis, 2011) was used alternatively to generate mechanistic 
hypotheses for future functional analysis. In total, 8 other SNPs have been found in 
strong LD with rs2623047 (see Figure 47). Of the 8 SNPs, two are located upstream 
of the SULF1 gene while the rest all reside in intronic regions. The two upstream 




Figure 47 Regional LD plot of SULF1 rs2623047 
This plot was generated using online tool SNAP 
http://archive.broadinstitute.org/mpg/snap/ldplot.php based on 1000 Genomes pilot 1 
database (CEU).The lead SNP (rs2623047) is represented by the largest diamond in the 
middle of the plot. The 8 SNPs in strong LD with the lead SNP (r2≥0.8) are represented by 
smaller diamonds above the horizontal black dotted line, including rs2704027, rs2244817, 
rs1441201, rs1899276, rs2725090, rs2725089, rs2005370 and rs1545219.  
 
According to the chromatin signals and transcription factor binding profiles provided 
by the HaploReg v4 database, the lead SNP rs2623047 should be prioritized as the 
top candidate SNP in the LD bin for further functional follow-up studies. This SNP 
overlaps with ChromHMM-predicted promoter histone marks in 12 major tissue 
types, including cervical tissue. In the HeLa-S3 cervical carcinoma cell line, the 
rs2623047 locus is classified as an active transcription start site by the 15-state core 
chromatin state model and as a weak enhancer by the 25-state model with imputed 
marks. This SNP has been previously associated with differential SULF1 expression 
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in cerebellum and temporal cortex tissues by a eQTL study (Zou et al., 2012). The 
HaploReg v4 tool also predicted that rs2623047 could change the match to 
transcription factors (TFs) TCF12_disc6 and TEF-1_2. The minor allele G has a 
higher predicted relative affinity for both TFs mentioned than the major allele A 
and the change in log-odds (LOD) score for TCF12_disc6 is large. Based on these 
lines of evidence and the previous study showing higher promoter activity of the G 
allele than the A allele in an ovarian cancer cell line (Han et al., 2011), it is 
reasonable to speculate that the SNP could affect susceptibility to HR-HPV infection 
functionally through regulatory mechanisms. The G allele induced changes in TF 
binding affinity may lead to increased SULF1 expression, altered modulation of 
HSPGs on cervical epithelial cells by sulfatase 1, and finally reduced attachment of 
HR-HPV to HSPGs, which might affect the ability of the virus to enter epithelial 
cells. However, this is just a hypothetical explanation for the observed association in 
this project. Whether the SNP affects the binding affinity of above mentioned TFs in 
cervical epithelial cells, whether SULF1 is differentially expressed in cervical tissue 
of G allele carriers, whether and how the above mentioned TFs affect the expression 
of SULF1 or other functions, need to be answered in future functional assays. SNP 
rs2244817 should also be included in such functional assays since the locus has been 
associated with CTCF and RAD21 protein binding in ChIP-Seq experiments. 
6.2.3 A functional disease related SNP CXCR1 rs2234671  
The association of CXCR1 rs2234671 with disease progression is the key finding of 
this project and will be the main focus for the future work. CXCR1 rs2234671 was 
found to be associated with the progression from high-grade intraepithelial lesion to 
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invasive cancer in the presence of HPV16. The minor allele of this SNP was found to 
be responsible for enhanced cell migration and proliferation in HPV16 positive 
cervical cancer cells in response to exogenous IL-8. These findings provide possible 
explanations for the observed associations, but clearly need to be further 
investigated.  
Firstly, the question “why was the enrichment of the minor allele of the SNP only 
observed in HPV16 positive cervical and vulval cancers, but not in other HR-HPV 
positive cancers” remains unanswered in this project. A possible explanation is the 
interaction between HPV16 and the ligand IL-8. Both HPV16 E6 and E7 have been 
shown to increase IL-8 expression in primary foreskin keratinocytes (Walker et al., 
2011). Abnormal cervical or vulval epithelial cells of the minor allele carriers may 
have higher migratory and proliferative responses to IL-8 induced by HPV16 and 
therefore be more likely to break through the basal membrane and invade adjacent 
organs or tissues. Although increased IL-8 expression in HSIL and cervical cancer 
has been shown in published studies and the previous study in our group, it is still 
unclear whether this increase is HPV type specific. If the increase of IL-8 is universal, 
this hypothesis will be rejected. Another possible explanation is the direct interaction 
between HPV16 and CXCR1. In a previous genetic association study, 
polymorphisms within FGFR2, HSPG2 and SDC2 were found to be associated with 
HPV16 induced cervical lesion progression. All these genes had been shown to 
directly interact with HPV16 (Zou et al., 2016). Similarly, CXCR1 may directly 
interact with HPV16 in a so far unelucidated carcinogenic process. The interaction 
between another chemokine receptor CXCR4 and HPV16 viral proteins has been 
reported (Cheng et al., 2014). However, no study has ever investigated the direct 
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interaction between HPV16 and CXCR1. Thus, CXCR1 and HPV16 interaction 
could also be a focus for further investigations. In this project, stable transduction 
and subsequent functional assays were performed in HPV16 positive cervical cancer 
epithelial cells. It would be interesting to study the functional effects of the SNP in 
HPV16 negative cervical epithelial cells or in HPV18 positive cells in future studies 
since this may give a hint on the processes in which the interaction participates. 
Additionally, the possibility can not be ruled out that the interaction between the 
SNP and other HR-HPV types was missed because of the inadequate number of other 
HR-HPV positive cancer cases in this study. Whether the SNP associate with other 
HR-HPV type related cervical disease still needs to be verified in larger sample set. 
Secondly, the functional effects of the SNP identified in this project add to the 
evidence that IL-8-CXCR1 signalling plays a critical role in the development of 
HR-HPV-related cervical and vulval cancers. Since IL-8 and its receptors have been 
shown to be multifunctional in previous studies on other diseases, undoubtedly they 
will participate in a wide range of biological processes in HR-HPV-related disease. 
However, at the moment, our knowledge about this signalling in HR-HPV-related 
diseases remains limited. It is still not well elucidated how IL-8 and CXCR1 
distribute in different cells and tissues and what processes they get involved in during 
the diseases courses. And according to the results presented here, it is unclear 
whether exogenous IL-8 and endogenous IL-8 have the same effects on target tissues 
and cells. To better understand the functional effect of the CXCR1 rs2234671 SNP, 
especially in different cell types and tissues, a better background knowledge at the 
genetic level is necessarily required.  
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Apart from the results obtained from the functional assays, there was another finding 
that aroused my interest in gene functions. As mentioned previously, an evolutionary 
survey study considered that the serine to threonine change at amino acid position 
276 of CXCR1 was the consequence of accelerated adaptive evolution unique to the 
human lineage (Liu et al., 2005). However, after comparing the nucleotide sequence 
of CXCR1 and CXCR2, I think there might be another explanation.  
 
Figure 48 Nucleotide and amino acid sequence alignments of the E3 loop in 
CXCR1 and CXCR2 
This figure shows the nucleotide sequence and amino acid sequence of the third 
extracellular loop for both CXCR1 and CXCR2. The rs2234671 locus on CXCR1 and its 
homologous locus on CXCR2 are highlighted in bold and underlined. 
As can be seen from Figure 48, the sequences encoding the third extracellular loop of 
CXCR1 and CXCR2 reveal 93.7% nucleotide identity. Although an accession ID 
rs201881186 has been issued to the homologous locus of CXCR1 rs2234671 within 
CXCR2 by dbSNP, it is not considered to be an actual SNP since all subjects (except 
for one Indian subject) in the 1000 Genomes project (phase 3) have the C/C genotype 
at this locus. By contrast, only 3.2% of these subjects have a C/C genotype at the 
CXCR1 rs2234671 locus. Considering that the C allele of rs2234671 has been 
consistently reported as the risk allele in different disease conditions, it is reasonable 
to speculate that the C allele of rs2234671 is the actual ancestral allele, just like the 
E3 loop amino acid sequence
CXCR1:DTLMRTQVIQESCERRNNIGR
CXCR2:DTLMRTQVIQETCERRNHIDR





rs201881186 locus, and that the allele frequency dropped drastically during the 
evolution as a result of negative selection, rather than the other way round as 
mentioned in the published study. If this speculation is true, it will add to the 
evidence that the two alleles are functionally different. Besides, it may indicate that 
the deleterious effects of the minor allele C of rs2234671 will be more pronounced or 
only exist in processes that mediate solely by CXCR1, rather than CXCR2. In order 
to further investigate the functional differences of the two rs2234671 alleles, 
functions exclusively mediated by CXCR1 need to be investigated. Currently, 
however, functional differences between the two IL-8 receptors in HR-HPV-related 
diseases have not been fully understood. The functional roles of CXCR1 and CXCR2 
need to be dissected first to narrow down the list of functions that can be attributed to 
the CXCR1 rs2234671 SNP association with cervical cancer. 
In addition, although this project provides evidence that SNP rs2234671 can affect 
exogenous IL-8 induced cell migration and proliferation, the underlying mechanisms 
of these phenotypic changes remain unknown. It is currently not known whether 
rs2234671 could alter ligand binding activity or cause a conformational change of 
the encoded receptor (or both). Considering that the encoded amino acid of this SNP 
locates next to a previously mentioned disulfide bond Cys30-Cys277 in CXCR1, 
together with the evidence showing the importance of the third extracellular loop of 
CXCR1 in the binding interaction (Barter and Stone, 2012), the role of the SNP in 
IL-8-CXCR1 interaction might well repay detailed investigation. 
Ideally, in follow-up studies, investigations on gene functions and the SNP functions 
could be performed in parallel. As the knowledge about CXCR1 extends, more novel 
insight into the functions of the rs2234671 could be gained, and vice versa. Clearly 
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numerous questions about the rs2234671 and CXCR1 have yet to be answered. Some 
of these questions might be dealt with in near future, such as whether endogenous 
IL-8 causes the baseline change in current wound healing assay, whether the SNP 
affects IL-8 induced angiogenesis in endothelial cells, and what functional impacts 
the missing haplotype (i.e. formed by the minor alleles of rs16858811, rs2234671 
and rs16858808) have. 
Overall, this project has demonstrated the feasibility of using a candidate gene 
approach to identify potentially functional SNPs in HR-HPV-related diseases. It has 
also refined the knowledge of which samples should be included in such a study at 
both discovery and validation phases. Two novel SNPs (SULF1 rs2623047 and 
CXCR1 rs2234671) have been found to be associated with different transition states 
in the pathogenesis of HR-HPV related cervical diseases and both are promising 
targets for further functional follow-up studies. Results from the association study 
and functional assays suggest that CXCR1 rs2234671 may affect cervical cancer 
susceptibility by altering the function of the IL-8-CXCR1 signalling in the presence 
of HPV16. If the genetic association could be further validated in a larger sample set, 
in conjunction with screening programmes, this SNP may be used to improve triage 
of “at risk” patients with HR-HPV infection. As HR-HPV infection is becoming 
increasingly associated with other forms of cancer including penile, anal and head 
and neck cancers, the findings may also be applicable more generally. In addition, 
since CXCR1 rs2234671 has been shown to be associated with many other diseases 
(including, but not exclusively other cancers), the functional effects identified in this 












Appendix-2 The STRING network of known protein-protein 







Appendix-3 Published SNPs within the 83 candidate genes/regions 
 
gene SNPs SNPs location Allele MAF Validation Disease/phenotype PMID published paper #




rs3138031 intron variant A/C C=0.0835/418 YES TB 19057661 1
rs159271 intron variant C/T T=0.0972/486 YES Viseral leishmaniasis 17122780 1
rs159273 upstream variant 2KB G/T T=0.0789/395 YES Viseral leishmaniasis 17122780 1
CCL2 rs2857656 upstream variant 2KB C/G C=0.4209/2108 YES
TB,Carotid atherosclerosis, Non















rs13900 utr variant 3 prime C/T T=0.3632/1819 YES Altered preexercise CK levels 20339010 6








utr variant 3 prime
C/T C=0.1829/915 YES HIV 16773571 1



















rs1065341 utr variant 3 prime A/G C=0.1258/630 YES allergic rhinitis 23663310 1




CCL7 rs991804 NIL A/G T=0.4109/2057 YES Crohn's disease 20570966 7
CCL17 rs223828 intron variant C/T T=0.2308/1156 YES Classical Hodgkin lymphoma 24008079 1
rs223899 intron variant A/C A=0.0509/254 YES Prostate cancer 23920401 1





CCL18 rs712043 intron variant C/T T=0.2033/1018 YES HIV 16773571 1
rs854472 intron variant A/G C=0.2053/1028 YES HIV 16773571 1
rs2015070 intron variant A/G T=0.1058/530 YES HIV 16773571 1
rs2015086 upstream variant 2KB C/T G=0.2548/1275 YES
Higher macrophage expression of
CCL18
19036375 1



















C/T A=0.2001/1002 YES MI 24493450 3
rs11574915
intron variant,
utr variant 5 prime
G/T C=0.1022/511 YES MI 24493450 1
CCL22 rs170359 intron variant A/G G=0.2364/1184 YES Prenatal IgE 19968631 1
rs4359426 missense A/C A=0.0835/417 YES Atopic dermatitis 22125604 1
CCL26 rs2240478 intron variant C/T A=0.2393/1197 YES Asthma 17848170 2




rs6965556 intron variant C/T T=0.2899/1451 YES RA 15784470 2
CCL28 rs11950448 intron variant C/G G=0.3872/1939 YES Family chaos 18360741 1
CXCL1 rs4074 intron variant A/G G=0.4044/2024 YES HCV infection 22173151 3
rs117604 upstream variant 2KB C/T T=0.4728/2367 YES Ischemic stroke 23198952 1
CXCL4 - - - - - - - -

























rs1126647 utr variant 3 prime A/T T=0.2851/1428 YES - - 2











rs2227307 intron variant G/T G=0.4235/2120 YES Periodontitis 21188496 8
rs2227543 intron variant C/T T=0.2885/1444 YES Childhood IgA nephropathy 21214373 3
CXCL9 rs10336
intron variant,
utr variant 3 prime
C/T A=0.2997/1500 YES Chagas cardiomyopathy 23150742 4
rs2276886 intron variant A/G T=0.2065/1034 YES Electrocardiographicvariability 17903306 1
rs3733236
intron variant,
utr variant 3 prime
C/T A=0.1426/714 YES T1DM 19410617 1
CXCL10 rs3921
intron variant,
utr variant 3 prime








rs4859587 intron variant A/C A=0.3087/1545 YES - - 2
rs4859588 intron variant A/G G=0.3087/1545 YES Sepsis in premature neonate 25000179 1
rs35795399
intron variant,
utr variant 3 prime
C/T C=0.0066/33 YES T1DM 19410617 1




CXCL12 rs1804429 utr variant 3 prime G/T C=0.0587/294 YES NSCLC 21514686 1
rs1065297 utr variant 3 prime C/T G=0.0661/330 YES ITP 23078136 1
rs266093 utr variant 3 prime C/G C=0.3480/1742 YES Cervical diseases 19788587 3
rs2839696 utr variant 3 prime C/T A=0.0585/293 YES - - 1
rs1029153 utr variant 3 prime C/T G=0.2504/1253 YES - - 2
rs169097 utr variant 3 prime A/C/G/T A=0.0537/268 YES - - 1
rs1801157 utr variant 3 prime A/G T=0.1855/928 YES
Multiple myeloma, ALL, Breastcancer,
Esophagogastric
cancer,NHL,MI,HIV,Hepatocellular










rs266089 intron variant A/G A=0.1805/903 YES AD 16385451 1




A/G A=0.3678/1842 YES - - 3
rs2297630 intron variant A/G A=0.1839/921 YES - - 4
rs2839693 intron variant A/G T=0.1683/843 YES - - 2
rs2839689 intron variant A/T A=0.1156/578 YES - - 1
rs3780891 intron variant A/G A=0.0675/337 YES - - 1
rs17885289 upstream variant 2KB A/G T=0.1805/903 YES Cervical diseases 19788587 1
rs2839695
intron variant,
utr variant 3 prime
C/T G=0.1148/574 YES - - 1
rs2839685 upstream variant 2KB C/T A=0.1745/874 YES - - 1






IL16 rs859 utr variant 3 prime A/G G=0.3730/1867 YES NHL 19066394 4
rs11325 utr variant 3 prime G/T T=0.2506/1254 YES - - 4
rs1131445
downstream variant
500B,utr variant 3 prime











A/G A=0.1462/731 YES Alopecia areata 24320753 1








rs4128767 intron variant C/T G=0.4347/2176 YES GD 24694201 1
rs4577037 intron variant G/T G=0.1354/677 YES CAD 23195133 1









rs7175701 intron variant C/T C=0.2496/1250 YES Prostate cancer 22923925 1
rs7182786 upstream variant 2KB A/G G=0.4613/2310 YES GD 24694201 1





A/G G=0.4145/2076 YES GD 24694201 1


















rs11638444 intron variant C/T C=0.1873/937 YES - - 1




A/G A=0.2362/1182 YES - - 1












Midkine - - - - - - - -
ALOX5 rs702366 intron variant A/G G=0.4908/2458 YES late-onset Alzheimer disease 16385451 1
rs745986 intron variant A/G G=0.1873/937 YES subclinical atherosclerosis 20592751 1
rs892690 intron variant A/G T=0.3077/1541 YES asthma 19214143 1
rs892691 intron variant A/G A=0.2871/1438 YES atherosclerosis 19130089 4
rs934187 intron variant C/T G=0.2596/1300 YES late-onset Alzheimer disease 16385451 1
rs1059696 intron variant A/G A=0.1510/755 YES subclinical atherosclerosis 20592751 1
rs1369214 intron variant A/G G=0.3992/1998 YES atherosclerosis 19130089 3
rs1487562 intron variant C/T T=0.1661/831 YES atherosclerosis 19130089 2
rs1565096 intron variant A/G G=0.2083/1043 YES rhinosinusitis 18366797 2
rs1864414 intron variant A/C G=0.1793/897 YES Ovarian cancer 22282663 2

















A/G G=0.0867/433 YES - - 1
rs2242332 intron variant C/T T=0.3275/1639 YES atherosclerosis 19130089 1
rs2242334 intron variant G/T G=0.3271/1638 YES atherosclerosis 19130089 2
rs2279435 intron variant A/C C=0.3904/1954 YES rhinosinusitis 18366797 1




rs3740107 intron variant A/G A=0.2780/1391 YES atherosclerosis 19130089 2
rs3780894 intron variant A/G G=0.1751/877 YES rhinosinusitis 18366797 1
rs3780901 intron variant C/T C=0.3612/1808 YES subclinical atherosclerosis 20592751 3
rs3780902 intron variant A/G G=0.0819/409 YES atherosclerosis 19130089 1
rs3780906 intron variant A/G A=0.3359/1682 YES subclinical atherosclerosis 20592751 2
rs3824612 intron variant C/T T=0.3079/1541 YES - - 2
rs3824613 intron variant C/T T=0.1757/880 YES atherosclerosis 19130089 1




ALOX5 rs4948672 intron variant C/G C=0.4217/2111 YES rhinosinusitis 18366797 1
rs4986832 upstream variant 2KB A/G A=0.1791/896 YES montelukast treatment 17460547 2
rs4987105 synonymous codon C/T T=0.1709/856 YES montelukast treatment 17460548 3
rs6593482 upstream variant 2KB G/T T=0.1791/896 YES breast cancer 18843019 1
rs7099684 intron variant A/T A=0.1833/918 YES - - 3
rs7894352 intron variant A/G A=0.1865/934 YES bone mineral density 17909879 1
rs7913948 upstream variant 2KB A/G A=0.1791/896 YES MI 19787205 1
rs7919239 intron variant A/C A=0.2246/1125 YES rhinosinusitis 18366797 1
rs10900213 intron variant G/T T=0.4964/2486 YES bone mineral density 17909879 1
rs10900215 intron variant C/G C=0.1322/661 YES atherosclerosis 19130089 2
rs11239516 intron variant G/T T=0.1010/505 YES bone mineral density 17909879 1
rs11239523 intron variant C/T C=0.0857/428 YES rhinosinusitis 18366797 1
rs11239524 intron variant G/T G=0.0964/483 YES subclinical atherosclerosis 20592751 1
rs12264801 intron variant A/G A=0.4425/2215 YES rhinosinusitis 18366797 1




rs7090328 intron variant A/G A=0.2131/1066 YES - - 1
rs3780905 intron variant C/T T=0.1360/680 YES - - 1
ABCA1 rs363717 utr variant 3 prime A/G C=0.1424/712 YES TrPN 21245421 3
rs1799777
intron variant,
utr variant 5 prime
 /G C=0.1418/709 YES HDLC level 19041386 1
rs1800976 upstream variant 2KB C/G G=0.4940/2474 YES CAD 21840005 2
rs1800977
upstream variant 2KB,








C/G G=0.1418/709 YES HDLC level 21316679 2
rs1883025 intron variant A/G T=0.3075/1540 YES AMD 24970616 13
rs2020927 intron variant C/T G=0.3321/1663 YES Alzheimer's disease 17510949 2
rs2065412 intron variant C/T C=0.1859/931 YES Dementia 19606474 1
rs2066714 missense A/G C=0.3568/1786 YES - - 9
rs2066718 missense A/C/G T=0.0741/371 YES - - 4
rs2230805 synonymous codon A/G T=0.3724/1864 YES Dementia 19606474 3




rs2246298 upstream variant 2KB C/T A=0.2202/1103 YES HDLC level 19041386 1




ABCA1 rs2249891 intron variant A/G G=0.3602/1804 YES CAD 20855565 1 1
rs2275542 intron variant C/T T=0.3053/1529 YES HDLC level 19041386 1 0
rs2275543 intron variant C/T C=0.0747/373 YES TC level 20832063 1 1
rs2275544 intron variant C/T C=0.1258/630 YES Apolipoprotein E levels 17430597 1 0
rs2297398 intron variant G/T G=0.1066/533 YES - - 1 0
rs2297404 intron variant C/G G=0.0940/470 YES Alzheimer's disease 17510949 1 1




rs2472384 intron variant A/G C=0.4441/2223 YES - - 1 0
rs2472386 intron variant C/T G=0.4285/2145 YES Dementia 19606474 1 1
rs2482424 intron variant C/T T=0.1298/649 YES Alzheimer's disease 20061627 1 0
rs2515602 intron variant C/T A=0.4249/2127 YES HDLC level 19041386 1 0
rs2515629 intron variant C/T G=0.1408/705 YES - - 1 0




C/G G=0.3107/1556 YES HDLC level 21216679 1 1
rs2740483 upstream variant 2KB C/G G=0.2129/1065 YES - - 3 0
rs2740491 intron variant C/T G=0.4972/2489 YES - - 1 0
rs2777799 intron variant A/G G=0.1138/570 YES Apolipoprotein E levels 17430597 1 0
rs3758294 intron variant C/T C=0.3003/1503 YES - - 1 0
rs3847303 intron variant A/G T=0.1346/674 YES - - 2 0
rs3858075 intron variant C/T T=0.2242/1122 YES schizophrenia 19721717 1 1
rs3890182 intron variant A/G A=0.0982/491 YES - - 12 0
rs3904999 intron variant A/G T=0.2288/1146 YES Apolipoprotein E levels 17430597 1 0
rs3905000 intron variant A/G A=0.1240/621 YES - - 8 0
rs4149263 intron variant C/T G=0.1627/815 YES atherogenic dyslipidaemia 19538231 2 1
rs4149264 intron variant C/G C=0.1613/808 YES statin responsiveness 21741043 1 1
rs4149268 intron variant A/G T=0.4916/2461 YES - - 8 0
rs4149270 intron variant A/C/G/T A=0.3331/1667 YES - - 1 0
rs4149271 intron variant C/T A=0.2388/1196 YES Dementia 19606474 1 1
rs4149272 intron variant A/G C=0.4896/2452 YES postprandial lipid metabolism 20185793 1 1
rs4149274 intron variant C/T A=0.3341/1672 YES - - 1 0
rs4149310 intron variant A/T T=0.4643/2324 YES - - 2 0




ABCA1 rs4149327 intron variant C/G G=0.2682/1343 YES - - 1
rs4743763 intron variant A/T A=0.4525/2265 YES HDLC level 21347282 1
rs6479283 intron variant C/T T=0.2955/1479 YES Apolipoprotein E levels 17430597 1




rs10512338 intron variant C/T C=0.1406/703 YES - - 2
rs10820738 intron variant C/T C=0.1054/527 YES - - 5
rs12003906 intron variant A/C/G/T T=0.0665/332 YES LDLC level 20031551 1









C/G G=0.0567/284 YES - - 1
rs4149311 intron variant A/G T=0.3397/1701 YES - - 1
rs2066718 missense A/C/G T=0.0741/371 YES Alzheimer's disease 17324514 4
rs12686004 intron variant A/G A=0.1266/633 YES - - 1
rs2575876 intron variant A/G A=0.2632/1318 YES - - 1




A/G A=0.1000/501 YES - - 1




A/G G=0.3423/1713 YES - - 1
rs6799507 intron variant A/G G=0.1292/646 YES - - 1
rs13072552 intron variant G/T T=0.1577/790 YES - - 1
rs17838831 upstream variant 2KB A/G C=0.2039/1021 YES - - 1
C1QA rs2935542 intron variant A/G G=0.1222/611 YES Lupus 19440201 1
rs292001 intron variant A/G G=0.3504/1754 YES RA,T2DM 23607884 4














C1QR1 rs7492 utr variant 3 prime A/G A=0.1234/618 YES renal transplant 22892990 1
rs2749812 utr variant 3 prime A/G A=0.1400/700 YES CAD 21332844 1
rs3746731 missense A/G G=0.4589/2298 YES CAD 18599554 2
C1RL - - - - - - - -
DDX1 rs2302929 synonymous codon C/T C=0.1749/875 YES dyskeratosis congenita 18252230 1
rs3755132 upstream variant 2KB G/T G=0.3149/1576 YES Wilms tumor 22544364 1
rs10221770 utr variant 5 prime A/G A=0.2298/1150 YES dyskeratosis congenita 18252230 1
rs10929378 synonymous codon C/T C=0.2552/1278 YES dyskeratosis congenita 18252230 1
DMC1 rs5757133 intron variant A/C/G/T T=0.2300/1152 YES cervical cancer 20084279 1
DUT rs3784621 intron variant C/T C=0.4589/2298 YES cervical cancer 20084279 1
rs11637235 intron variant C/T T=0.3379/1691 YES - - 3
ENPP1 rs1510 utr variant 3 prime C/G G=0.0521/260 YES - - 1
rs703184 intron variant C/G C=0.1064/533 YES - - 1
rs858338 intron variant G/T T=0.1296/649 YES - - 1
rs858339 intron variant A/T A=0.2809/1406 YES - - 1
rs858341 intron variant A/G G=0.4726/2367 YES - - 3
rs858342 intron variant A/G G=0.2169/1085 YES hand osteoarthritis 1257435 2
rs858345 intron variant A/G T=0.4888/2448 YES - - 1
rs943003 intron variant A/G C=0.2925/1465 YES obesity 18551113 1
rs943004 intron variant A/G T=0.0911/455 YES - - 1
rs1044548 utr variant 3 prime A/G A=0.1162/581 YES - - 1
rs1409181 intron variant C/G G=0.4806/2407 YES - - 1
rs1409182 intron variant A/C/G/T T=0.0889/445 YES - - 1
rs1409184 intron variant C/T A=0.3462/1733 YES T2DM 18678618 1
rs1799774 intron variant /T -=0.4762/2384 YES obesity 18719658 6
rs1800949 upstream variant 2K C/T T=0.1384/693 YES - - 2
rs1830971 intron variant C/T G=0.3702/1854 YES T2DM 18678618 1




rs2021966 intron variant C/T G=0.4661/2333 YES DM 25222839 6
rs4141767 intron variant A/G G=0.1759/881 YES - - 1
rs6569759 intron variant A/G A=0.3880/1942 YES - - 1
rs6916495 intron variant C/T T=0.1244/623 YES - - 1






500B,utr variant 3 prime
A/C C=0.4127/2067 YES T1DM 18184924 1
rs7754859
downstream variant
500B,utr variant 3 prime
C/T C=0.4463/2235 YES T2DM 18678618 1
rs7756163 intron variant C/T C=0.2881/1443 YES - - 1
rs7767111 intron variant A/G A=0.1168/584 YES - - 1
rs7768480 intron variant A/G G=0.2326/1165 YES - - 1
rs7773477 intron variant G/T T=0.1040/521 YES Pseudoxanthoma elasticum 25025693 1
rs7775386 intron variant C/T T=0.2542/1272 YES - - 1
rs9372999 intron variant A/C A=0.1817/909 YES - - 1
rs9375830 intron variant A/G A=0.3606/1805 YES - - 1
rs9402345 intron variant A/G A=0.1112/556 YES - - 1
rs9402346 intron variant C/G G=0.3460/1732 YES T2DM 18678618 1
rs9402348 intron variant G/T G=0.2083/1043 YES - - 1
rs9402349 intron variant A/C C=0.1348/674 YES - - 2
rs9493105 intron variant C/T T=0.1112/556 YES - - 1
rs9493116 intron variant A/G G=0.1396/699 YES - - 1
rs9493120 utr variant 3 prime A/G A=0.1172/586 YES - - 1
rs9493121 utr variant 3 prime A/G G=0.1605/803 YES - - 1
rs11964389 utr variant 3 prime A/G G=0.1605/803 YES obesity 18719658 1
rs12201710 utr variant 3 prime C/G C=0.0789/394 YES - - 1
rs7754561
downstream variant
500B,utr variant 3 prime




EVPL - - - - - - - -
GC rs4752 synonymous codon C/T G=0.1056/529 YES ankylosing spondylitis 21844150 4
rs221999 intron variant C/T G=0.2260/1131 YES - - 1
rs222003 intron variant C/G C=0.1877/940 YES - - 2
rs222011 intron variant G/T A=0.0599/300 YES vitamin D metabolism 16600026 1
rs222014 intron variant A/G T=0.0579/289 YES vitamin D metabolism 23456391 3
rs222016 intron variant A/G G=0.3363/1684 YES





rs222020 intron variant C/T C=0.3377/1691 YES












rs222035 intron variant A/C G=0.3742/1873 YES vitamin D metabolism 22144504 2
rs222040 intron variant C/T A=0.4902/2455 YES vitamin D metabolism 23505139 3
rs705117 intron variant A/G C=0.4217/2111 YES vitamin D metabolism 23505139 5
rs705120 intron variant G/T A=0.4191/2098 YES vitamin D metabolism 23505139 2
rs842999 intron variant A/C/G C=0.3578/1791 YES vitamin D metabolism 23505139 3
rs843006 intron variant G/T T=0.3592/1798 YES vitamin D metabolism 19255064 1




rs1352843 intron variant C/T C=0.0577/289 YES vitamin D metabolism 18593774 2
rs1352844 intron variant C/T T=0.0851/426 YES vitamin D metabolism 19255064 1
rs1491710 intron variant G/T C=0.2218/1110 YES vitamin D metabolism 23505139 1
rs2070741 intron variant A/C G=0.1080/540 YES COPD 21228423 1







rs2298849 intron variant C/T G=0.2947/1475 YES vitamin D metabolism 22583563 4
rs3733359
intron variant,
utr variant 5 prime
C/T A=0.2065/1034 YES ankylosing spondylitis 21844150 3
rs10488854 intron variant A/G T=0.1004/502 YES vitamin D metabolism 23505139 1
rs16846912 intron variant A/G G=0.1062/531 YES vitamin D metabolism 19255064 1




C/T T=0.0701/351 YES colorectal cancer 24562971 1
rs16847036 intron variant A/G G=0.1649/825 YES vitamin D metabolism 19543766 1
rs16847054 intron variant C/T T=0.1250/626 YES T2DM 19956108 1
rs12640179 intron variant C/G G=0.1028/514 YES T2DM 19956108 1
rs1491709 intron variant C/T A=0.1032/517 YES vitamin D metabolism 18593774 2
GDF10 rs3007 utr variant 3 prime A/T A=0.2416/1209 YES  Alzheimer disease 16385451 1
rs1902725 intron variant A/G T=0.2328/1165 YES - - 1
GDF2 rs3781226 intron variant C/T T=0.0845/423 YES - - 1
rs9971293 intron variant C/T C=0.1146/574 YES  Alzheimer disease 16385451 1
GJA1 - - - - - - - -
GSTCD - - - - - - - -
GTF2H4 rs2894054 NIL C/T A=0.0855/428 YES cervical disease 20084279 1











IFNG rs11177074 NIL C/T C=0.1416/708 YES cervical disease 20084279 1
rs1861493 intron variant A/G G=0.2095/1049 YES idiopathic inflammatory myopathy 17405833 6
rs1861494 intron variant C/T C=0.2258/1131 YES imatinib therapy 20959405 11









































rs706779 intron variant A/G C=0.4581/2293 YES - - 3
rs706780 intron variant A/C A=0.1224/612 YES - - 1
rs791587 intron variant A/G A=0.4804/2405 YES - - 1
rs791589 intron variant A/G G=0.3576/1791 YES - - 3
rs791590 intron variant A/T T=0.1108/555 YES - - 1
rs942201 intron variant G/T T=0.1819/911 YES - - 1




IL2RA rs1323658 intron variant A/C/G/T C=0.1498/749 YES - - 1
rs1570538 utr variant 3 prime C/T T=0.3760/1882 YES MS 19125193 2
rs2025345 intron variant A/G T=0.3760/1882 YES - - 2
rs2031229 intron variant A/G A=0.1795/899 YES - - 1
rs2076846 intron variant A/G G=0.2316/1159 YES - - 0
rs2104286 intron variant A/G C=0.1306/653 YES










C/T A=0.0603/301 YES - - 3
rs2228150 synonymous codon A/G T=0.0819/409 YES - - 1
rs2256774 intron variant A/G T=0.0819/409 YES MS 22085902 2
rs2274037 intron variant A/G A=0.0603/301 YES - - 3
rs2386841 intron variant A/C T=0.2446/1225 YES - - 2
rs2476491 intron variant A/T T=0.1909/956 YES - - 1





rs3134883 intron variant C/T A=0.2023/1012 YES T1DM 19956099 3
rs4749924 intron variant A/C C=0.1611/806 YES UC 23972291 2
rs6602391 intron variant A/G A=0.0905/453 YES - - 1
rs6602398 intron variant G/T T=0.1613/808 YES - - 1
rs7072398 intron variant A/G G=0.4768/2387 YES - - 1




rs7093069 intron variant C/T T=0.1679/840 YES T1DM 22211793 2
rs7899538 intron variant A/C A=0.1156/578 YES - - 1
rs7910961 intron variant C/T T=0.2272/1137 YES - - 1
rs9663421 intron variant C/T T=0.1723/862 YES - - 1
rs10905656 intron variant A/C A=0.4397/2201 YES - - 1
rs10905669 intron variant C/T T=0.2129/1065 YES - - 3
rs11256448 intron variant A/G G=0.2252/1128 YES - - 1




IL2RA rs11256497 intron variant A/G A=0.2139/1071 YES - - 2
rs11596355 intron variant C/T C=0.0567/284 YES - - 1
rs12244380 utr variant 3 prime A/G G=0.3548/1776 YES - - 2
rs12722489 intron variant A/G T=0.0911/455 YES MS 243332945 16
rs12722561 intron variant A/G T=0.1266/633 YES - - 2
rs12722574 intron variant C/T A=0.2482/1243 YES - - 1
rs12727588 intron variant A/G T=0.1661/831 YES - - 1
rs12722605 utr variant 3 prime A/T A=0.0747/373 YES - - 3
rs12722608 utr variant 3 prime G/T A=0.0599/300 YES - - 1
ILDR1 rs11718322 intron variant A/G A=0.3936/1970 YES Behçet's disease 20622878 1






rs16938755 intron variant C/T C=0.1997/1000 YES glioma 19423540 1
rs10808798 intron variant C/T C=0.4611/2308 YES wheeze 21389010 1
rs2114169 intron variant A/T T=0.3113/1559 YES major trauma 22266968 1
MBD3L1 - - - - - - - -








A/G A=0.3648/1826 YES SLE 21702010 2





A/G A=0.0645/322 YES T1DM 19143814 1
rs1063635 missense A/G G=0.4167/2086 YES - - 3








utr variant 5 prime















A/G A=0.0761/381 YES RA 19409079 1
rs7756993 intron variant C/T C=0.3433/1719 YES T1DM 19143813 1
rs9266825 utr variant 3 prime A/C A=0.3429/1716 YES NSCLC 24997136 1
rs9380254
missense,
utr variant 5 prime
C/G C=0.0747/373 YES - - 1
rs12660741 intron variant A/G G=0.0521/260 YES leprosy 20617178 1
rs2857281 intron variant A/C C=0.1238/620 YES Behçet's disease 20622878 1
rs12175489 intron variant A/G A=0.1645/824 YES viseral fat 22589738 1
rs2256175 intron variant A/G C=0.4105/2055 YES neuroblastoma 18463370 1
rs2256183 intron variant A/G A=0.2528/1266 YES height 20881960 1
MOCS2 - - - - - - - -
NEIL2 rs804268 intron variant C/G G=0.3730/1867 YES colorectal cancer 17029639 1
rs804269 intron variant A/G T=0.3021/1513 YES colorectal cancer 17029639 1
rs804270
intron variant,
utr variant 5 prime
C/G G=0.4820/2414 YES SCCOOP 18594018 1
rs1534862 utr variant 3 prime C/T T=0.2534/1269 YES colorectal cancer 17029639 1
rs8191518
upstream variant 2KB,
utr variant 5 prime




A/G A=0.0739/370 YES colorectal cancer 17029639 1
rs8191642 synonymous codon A/G G=0.2147/1075 YES breast cancer 18551366 2
rs8191649 intron variant C/T T=0.1464/733 YES breast cancer 18551366 1
rs8191663 intron variant C/T T=0.2604/1303 YES colorectal cancer 17029639 1
rs8191664 missense G/T T=0.0529/264 YES breast cancer 18551366 2
rs6601606 intron variant A/G G=0.0783/392 YES HIV 21507922 1
rs804292 utr variant 3 prime C/T G=0.1729/865 YES - - 1




utr variant 3 prime













utr variant 3 prime




utr variant 3 prime
A/C/G/T G=0.2123/1062 YES - - 5
rs2057778 intron variant A/C G=0.2075/1038 YES West Nile virus infection 19247438 1
rs2158390 upstream variant 2KB C/G C=0.1166/583 YES West Nile virus infection 19247438 1
rs2285934 intron variant A/C T=0.3500/1753 YES West Nile virus infection 19247438 2




A/G A=0.2113/1058 YES West Nile virus infection 19247438 1
rs7956880 intron variant A/C A=0.1110/555 YES West Nile virus infection 19247438 1
rs10744785 intron variant C/G C=0.2813/1409 YES West Nile virus infection 19247438 2
rs12307655 intron variant C/T C=0.1012/506 YES cervical cancer 20084279 1
rs34137742 intron variant C/T T=0.1030/515 YES prostate cancer 21638280 1
rs2660
missense,
utr variant 3 prime




rs10744785 intron variant C/G C=0.2813/1409 YES West Nile virus infection 19247438 2
OAS2 rs15895
stop lost,













rs2072137 intron variant A/G C=0.3235/1619 YES - - 1
rs2072138 synonymous codon C/G G=0.2190/1097 YES - - 1
rs2240185 intron variant C/G C=0.4690/2349 YES - - 1
rs718802 intron variant G/T A=0.1416/708 YES cervical cancer 20084279 1






OAS3 rs2010549 utr variant 3 prime C/G C=0.2127/1065 YES - - 1
rs2010604 utr variant 3 prime C/G G=0.1817/909 YES HCV 18571276 1
rs2072134 utr variant 3 prime C/T A=0.0242/120 YES hypertension 24142389 3
















rs7970983 intron variant C/T T=0.3269/1637 YES RA 20018015 1
rs10774679 upstream variant 2KB C/T C=0.3860/1932 YES - - 1
rs12302655 upstream variant 3KB A/G A=0.1256/628 YES cervical cancer 20084279 1
PGR rs471767
nc transcript variant,
utr variant 3 prime
A/G G=0.2294/1149 YES endometrial cancer 19382201 3
rs480851 intron variant A/G G=0.1488/745 YES - - 1
rs484389
nc transcript variant,
utr variant 3 prime
C/T G=0.2618/1310 YES pelvic organ prolapse 19267271 1
rs485283 intron variant C/T G=0.1542/771 YES - - 1




A/G C=0.2616/1309 YES endometriosis 16126772 4
rs506487 intron variant C/T T=0.1522/762 YES - - 1




utr variant 5 prime
A/G A=0.1328/665 YES - - 3
rs547378 intron variant A/G A=0.2454/1228 YES endometrial cancer 19382201 1
rs550778 intron variant A/C G=0.1542/771 YES - - 1
rs560291 intron variant G/T T=0.1464/733 YES - - 1
rs561650 intron variant C/T C=0.0865/433 YES female reproductive cancer 22121098 1
rs566351 intron variant C/T T=0.4339/2173 YES breast cancer 16614108 2




A/C A=0.2610/1306 YES - - 1
rs578029 intron variant A/T A=0.2262/1132 YES preterm birth 20308837 1












utr variant 3 prime




rs613120 intron variant C/T G=0.3900/1952 YES bladder cancer 19252927 1
rs619487 intron variant G/T G=0.1484/743 YES - - 1



































C/G G=0.0721/361 YES - - 1
rs7116336 intron variant A/T A=0.3351/1678 YES breast cancer 16614108 1
rs10895054 intron variant A/T T=0.0699/350 YES breast cancer 23764995 1
rs11224561
nc transcript variant,
utr variant 3 prime
C/T T=0.3013/1509 YES endometrial cancer 21148628 2
rs11224579 intron variant C/T T=0.3181/1592 YES endometrial cancer 19382201 1
rs11224592 intron variant C/T C=0.2827/1416 YES RPL 21086036 1
rs11224598 intron variant C/T C=0.2849/1426 YES endometrial cancer 19382201 1
rs11571171 intron variant C/T G=0.2246/1125 YES breast cancer 16614108 1
rs493220 intron variant A/G C=0.1486/743 YES - - 1
PIK3CA rs1607237 intron variant C/T C=0.3714/1860 YES breast cancer 22033276 3















A/T T=0.0763/382 YES ovarian cancer 19240718 1
rs4855094 intron variant A/G A=0.0863/432 YES esophageal adenocarcinoma 21212151 1






rs7621329 intron variant C/T T=0.2702/1353 YES esophageal squamous cell carcinoma 24945674 3
rs7640662 intron variant C/G G=0.0635/317 YES - - 3
rs7641889 intron variant C/T T=0.1012/506 YES ovarian cancer 19240718 1
rs7644648 intron variant A/G G=0.2702/1353 YES - - 3






rs9838411 intron variant A/G A=0.2368/1185 YES endometrial cancer 22146979 1
rs17849071 intron variant G/T G=0.1026/514 YES breast cancer 24908061 1
POLN rs1923775 intron variant C/T C=0.4439/2223 YES AD 22159054 1
rs482519 intron variant C/T A=0.1967/984 YES - - 1
HAUS3 rs17132382 intron variant C/T T=0.2440/1222 YES cervical cancer 20084279 1
PRDX3 rs2271362 intron variant C/T T=0.3159/1582 YES AD 16385451 1
rs7082598 - C/T T=0.1102/552 YES cervical cancer 22496757 1
PRLH - - - - - - - -
RPS19 rs873282 intron variant A/G T=0.4433/2220 YES Diamond-Blackfan Anemia 19587786 1
SULF1 rs437999 intron variant A/G A=0.1963/983 YES cervical cancer 20084279 1
rs4284050 intron variant A/C A=0.4028/2017 YES cervical cancer 20084279 1
rs3802278
missense,
utr variant 3 prime
A/G A=0.3317/1660 YES ovarian cancer 21214932 1
rs6990375
missense,
utr variant 3 prime
A/G A=0.3125/1565 YES ovarian cancer 21214932 1




rs3087714 utr variant 3 prime C/T A=0.3025/1515 YES ovarian cancer 21214932 1
rs10108002 intron variant C/T T=0.2065/1034 YES cervical cancer 20084279 1
rs13264163 utr variant 5 prime A/G G=0.1697/849 YES ovarian cancer 21214932 1
TELO2?
RBFOX1













A/G G=0.4597/2302 YES Squamous cell skin cancer 24913986 1




A/G A=0.1430/715 YES cervical disease 21387291 1
rs454138 utr variant 3 prime C/G C=0.3431/1717 YES schizophrenia 19223858 1
TYMS rs2790
intron variant,
utr variant 3 prime







C/T T=0.3998/2001 YES renal cancer 18098291 5
rs699517
nc transcript variant,
utr variant 3 prime








utr variant 3 prime
A/G T=0.4978/2493 YES gastric cancer 24756984 3




utr variant 3 prime
A/G G=0.4714/2361 YES AML 22964418 1
rs2847149 intron variant A/G G=0.3878/1942 YES - - 1
rs2847153 intron variant A/G A=0.2901/1453 YES Neural tube defects 22903727 2
rs2853532
intron variant,
utr variant 3 prime




C/G C=0.3391/1698 YES colorectal cancer 23893618 3
rs2853536
intron variant,
utr variant 3 prime











C/T C=0.2222/1112 YES lung cancer 18221821 1
rs3786362 synonymous codon C/T G=0.0623/311 YES endometrial cancer 19190136 1
rs16948305 intron variant C/T T=0.0797/398 YES colorectal cancer 23893618 3
WIF1 rs10506532 intron variant A/G T=0.0401/201 YES - - 2
CADM1 rs220840 intron variant C/T A=0.0891/446 YES - 17903299 1
rs314474 intron variant A/G T=0.0739/370 YES - 17903299 1
rs3802858 intron variant A/G C=0.4253/2129 YES venous thrombosis 19643986 1
rs4445669 utr variant 3 prime C/T C=0.3542/1773 YES - - 2
rs7122693 intron variant A/G G=0.2334/1169 YES - - 1
rs7125361 intron variant C/G G=0.4954/2480 YES Alzheimer disease rs19361613 1
rs7927241 intron variant C/G G=0.4407/2207 YES venous thrombosis 19643986 1








A/G A=0.3187/1595 YES venous thrombosis 19643986 1
rs11215406 intron variant C/T C=0.1941/971 YES - - 1
rs11215437 intron variant C/T C=0.4203/2104 YES - - 1
rs11215474 intron variant A/G G=0.4321/2164 YES venous thrombosis 19643986 1
rs220836 intron variant A/G C=0.2173/1087 YES childhood obesity 23251661 1
rs7950069 intron variant A/G A=0.3874/1939 YES - - 1
CD83 rs9230 utr variant 3 prime C/T T=0.2175/1088 YES cervical disease 18056445 2
rs853360 intron variant C/T T=0.2354/1178 YES cervical disease 22134374 3
rs9296925 intron variant C/T C=0.4325/2166 YES cervical disease 19446866 2
rs750749 NIL C/T C=0.2470/1237 YES cervical disease 19446866 2
rs9370729 NIL C/T T=0.3187/1595 YES cervical disease 19446866 2
CDKN2B rs1063192
intron variant,
utr variant 3 prime
















C/G G=0.1991/996 YES - - 4
rs2069422 intron variant A/C G=0.0639/320 YES glaucoma 24875940 1
rs2069426 intron variant A/C T=0.0607/304 YES - - 2
rs3217986
intron variant,
utr variant 3 prime
A/C G=0.1168/584 YES ovatian cancer 19258477 1
rs3217989
intron variant,
utr variant 3 prime
A/G C=0.0747/373 YES CAD 21270820 1
rs3217992
intron variant,
utr variant 3 prime











CDKN2A rs3731201 intron variant A/G C=0.0988/495 YES impaired glucose metabolism 20384434 1
DCLRE1A rs3750898 missense C/G C=0.3423/1713 YES Alzheimer's disease 16385451 1
FANCD2 rs9849434 intron variant A/G A=0.2412/1207 YES Alzheimer's disease 24755620 1




A/C G=0.2422/1212 YES breast cancer 16679306 1
FASLG rs6700734 intron variant A/G G=0.2576/1290 YES - - 1
rs5030772 intron variant A/G G=0.0555/278 YES - - 2
FLJ35220 - - - - - - - -
ITGA4 rs12988934 intron variant C/T T=0.1206/603 YES - - 1
rs3770138 intron variant A/G T=0.1394/698 YES RA 25147926 1
rs2124440 intron variant C/T G=0.4692/2349 YES - - 3
rs3770132 intron variant C/T G=0.1074/537 YES - - 2
rs155095 intron variant C/T A=0.3107/1556 YES RA 25147926 1
rs155100 intron variant A/T T=0.4497/2252 YES - - 3
rs155101 intron variant A/G G=0.3063/1534 YES - - 1
rs155102 intron variant C/T A=0.4505/2255 YES - - 1
rs155103 intron variant C/T A=0.3059/1532 YES - - 1
rs1038034 intron variant C/T G=0.1246/624 YES - - 1
rs2305586 intron variant A/G C=0.1406/703 YES - - 1
rs1143674 synonymous codon A/G A=0.3385/1694 YES RA 25147926 2
rs3770112 intron variant C/T A=0.1637/819 YES - - 2
rs1143676 missense A/G G=0.2095/1049 YES MS 19604093 2




ITGA7 - - - - - - - -
ILDR1 rs11718322 intron variant A/G A=0.3936/1970 YES Behçet's disease 20622878 1












































rs1800610 intron variant C/T A=0.1004/502 YES - - 11
















































rs3093661 intron variant A/G A=0.0521/260 YES Graves' disease 19732761 4
rs3093662 intron variant A/G G=0.0799/399 YES TB 21463712 14




C/G C=0.0511/255 YES T1DM 19167443 4





rs1800389 synonymous codon C/T C=0.3127/1566 YES - - 1
rs1800392 synonymous codon G/T T=0.4712/2359 YES - - 3
rs1801195 missense G/T T=0.4960/2483 YES - - 7
rs2230009 missense A/G A=0.0743/372 YES breast cancer 17764108 5
rs3024239 intron variant C/T T=0.3750/1878 YES - - 1
rs2553268 intron variant A/C G=0.3117/1560 YES - - 1
rs2725338 intron variant A/G A=0.1168/584 YES cataract 22322570 1
rs2725383 intron variant C/G C=0.2400/1202 YES cataract 22322570 1
rs3213199 intron variant A/T A=0.1004/502 YES - - 1
rs4733220 intron variant A/G G=0.4732/2370 YES cataract 22322570 1
rs4733225 intron variant C/T C=0.1713/858 YES - - 1
rs4987036 intron variant C/T T=0.2614/1309 YES - - 1
rs1574311 intron variant C/T C=0.1552/777 YES cataract 22322570 1
rs13269094 intron variant G/T G=0.1585/793 YES - - 1
rs2015230 intron variant A/G C=0.3427/1716 YES - - 1
rs2725385 intron variant A/G T=0.3081/1542 YES - - 1
rs2725361 intron variant A/G G=0.3718/1861 YES - - 1
rs1801195 missense G/T T=0.4960/2483 YES - - 7
rs6994361 intron variant C/T C=0.4395/2201 YES - - 1




CXCR2 rs1126579 utr variant 3 prime C/T T=0.3968/1986 YES
bile duct cancer& biliary












rs1126580 utr variant 3 prime A/G A=0.3672/1838 YES
bile duct cancer& biliary









C/T T=0.4714/2361 YES MI 24462138 3
rs4674259
intron variant,
utr variant 5 prime
A/G G=0.4115/2061 YES IgA nephropathy 21214373 3
rs6723449 intron variant C/T T=0.3978/1992 YES MI 24462138 1
rs11574750 synonymous codon C/T T=0.0549/274 YES UTI 20016852 2
rs17844697 intron variant A/G A=0.3666/1835 YES HIV 17360650 1




C/T A=0.4385/2195 YES childhood obesity 23251661 1
CXCR1 rs2234671 missense C/G G=0.1442/721 YES HBV 23396733 10




C/G G=0.1753/877 YES cutaneous leishmaniasis 20089160 2




LIG3 rs3135974 intron variant A/G A=0.1012/507 YES
 posthematopoietic cell transplant
(HCT) outcomes
20226869 2
rs3135989 intron variant G/T G=0.0559/280 YES  -  - 2
rs2074518 intron variant A/G T=0.3105/1555 YES QT interval 19305408 9
rs2074517 intron variant A/G C=0.0645/323 YES nasopharyngeal carcinoma 25124928 1
rs2074516 intron variant C/G G=0.2835/1420 YES  -  - 1















500B,utr variant 3 prime
C/T T=0.3041/1523 YES











500B,utr variant 3 prime
















A/C T=0.3041/1523 YES  -  - 1




A/G T=0.1322/662 YES  -  - 1
rs3181080 upstream variant 2KB A/T T=0.0923/462 YES  -  - 1
XCR1 - - - - - - - -
CCR2 rs3918357 upstream variant 2KB A/C A=0.1659/831 YES  -  - 1




rs3918359 upstream variant 2KB A/T A=0.1947/975 YES  prediabetic condition 18096169 1
rs3749461
upstream variant 2KB
utr variant 5 prime
A/G G=0.0683/342 YES  -  - 2
rs3092964
upstream variant 2KB
utr variant 5 prime
A/G G=0.1947/975 YES  -  - 1


































utr variant 3 prime
A/G G=0.3287/1646 YES  -  - 1
rs743660 utr variant 3 prime A/G A=0.1949/976 YES IgE levels 19520154 2
DARC rs13962 missense A/G A=0.0689/345 YES  - 22075330 1
rs2814778
upstream variant 2KB,
utr variant 5 prime
A/G C=0.2664/1334 YES neutrophil count - 20
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Appendix-4 Kaplan Meier survival plots generated for each gene based on TCGA-CESC database using GEPIA software  




   
To analyze the impact of a specific gene on overall survival of cervical cancer, patient samples in TCGA-CESC were split into two groups according to the median 
expression of the proposed gene. High expression group (red line) and low expression group (blue line) were compared by a Kaplan-Meier survival plot by both simple 
log-rank analysis and Cox regression analysis using GEPIA software. Hazard ratio was calculated for each gene based on Cox's proportional hazards Model. 95% confidence 
intervals were shown as dotted lines. Since the results were only served as supplementary reference standards, raw p values without multiple testing corrections were used.  
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